Hangman fracture

I'll read the medical library skill first, then search for Hangman fracture content in parallel.

Reading File

Now I'll run parallel searches across the library and PubMed:

Finding Sources

Searching PubMed

"hangman fracture" cervical spine C2

Excellent - multiple strong sources found. Reading the most detailed ones in parallel:

Reading File

Good data. Let me also read Campbell's Operative Orthopaedics section and the Rockwood section on surgical treatment, while fetching the key X-ray image:

Reading File

Loading Image

I now have comprehensive information from multiple authoritative textbooks. Here is the full answer:

Hangman's Fracture (Traumatic Spondylolisthesis of C2)

Definition

A Hangman's fracture is a bilateral fracture through the pars interarticularis (isthmus) of C2, separating the posterior neural arch from the vertebral body. The C2 body subluxes anteriorly on C3, while the posterior elements remain in place. Because this effectively widens the spinal canal at the fracture level, neurological injury is paradoxically uncommon despite sometimes severe displacement.

$Lateral cervical spine X-ray showing Hangman fracture - fracture between the pedicles and body of C2 (arrow) with slight anterior subluxation of C2 on C3$

Lateral radiograph: fracture between the pedicles and body of C2 (arrow). Slight anterior subluxation of C2 on C3, but the spinolaminar line of C2 remains behind C1 and C3.

Grainger & Allison's Diagnostic Radiology

Nomenclature and Mechanism

The term "hangman's fracture" is technically a misnomer - postmortem studies of judicial hangings show the classic pars fracture was actually rare; most victims had no fracture at all. In modern trauma, the mechanism varies by fracture type:

Hyperextension + axial loading - the most common mechanism (motor vehicle collisions, diving)
Flexion forces - responsible for some subtypes (especially Type IIa)
Recent biomechanical evidence shows that different neck postures at time of impact produce distinct fracture patterns
Rockwood and Green's Fractures in Adults, 10th ed. 2025; Campbell's Operative Orthopaedics, 15th ed. 2026

Classification: Levine and Edwards (Modified from Effendi)

This is the most widely used classification system:

Type	Displacement	Angulation	Mechanism	C2-C3 Disc
I	< 3 mm translation	None	Extension/axial load	Intact
Ia (Starr-Eismont)	Minimal	None	-	Fracture extends into posterior C2 body; higher neurologic risk
II	> 3 mm translation	Present (> 10°)	Extension then flexion	Disrupted
IIa	Minimal translation	Marked angulation	Pure flexion/distraction	Severely disrupted
III	Translation + angulation	Present	Flexion	Disrupted + C2-C3 facet dislocation

Key pearl: Type I is the most common. Types II and III are rare. Type IIa is the most dangerous to manage because traction is contraindicated (it accentuates deformity).

Rockwood and Green's Fractures in Adults, 10th ed. 2025; Campbell's Operative Orthopaedics, 15th ed. 2026

Diagnosis

Plain radiographs: Lateral C-spine - anterior subluxation of C2 on C3; fracture line through pars
CT scan: Gold standard - defines fracture morphology, identifies Starr-Eismont variant (posterior body involvement), and detects facet dislocation in Type III
MRI: Essential if neurologic deficit present; evaluates disc, ligaments (PLL, ALL, ligamentum flavum), and cord injury

Treatment

Treatment is guided by fracture type and neurological status:

Non-operative (majority of cases - ~89% in large registry data)

Type	Modality
Type I	Rigid cervical collar
Type Ia	Cervical orthosis (unless cord injury present)
Type II	Halo traction first → then halo vest immobilization
Type IIa	NO traction - reduction by extension + compression via halo apparatus

Coric et al.: cervical orthosis effective for fractures with < 6 mm displacement
Vaccaro et al.: halo vest successful in 21/27 Type II and all Type IIa; failures (fracture angulation > 12°) required repeat traction

Operative (indications)

Surgery is indicated for:

Type III (facet dislocation - absolute indication)
Neurologic deficit
Failure to maintain reduction
Starr-Eismont variant with instability
Fractures requiring traction for reduction (traction cannot be maintained in a collar/halo vest)

Only ~11.2% of hangman's fractures in the National Trauma Data Bank (n = 38,080) were treated surgically.

Surgical options (three strategies):

Pedicle screw osteosynthesis at C2 - for fractures with minimal soft-tissue disruption; preserves motion; uncommon because most have soft-tissue injury
Anterior C2-C3 fusion - instrumentation at C2-C3 only; preserves C1-C2 rotation (~50% of cervical rotation)
Posterior C1-C2-C3 fusion - most stable construct; sacrifices C1-C2 motion

Campbell's Operative Orthopaedics, 15th ed. 2026; Rockwood and Green's 10th ed. 2025

Why Neurological Injury is Uncommon

The spinal canal is effectively self-decompressing at the fracture site - as the body of C2 translates anteriorly, the canal's AP diameter actually increases. This contrasts with most other cervical fractures.

The exception is the Starr-Eismont variant (Type Ia): the posterior C2 body fragment moves posteriorly with the arch, compressing the canal - explaining the higher neurologic injury rate in this subtype.

Quick Summary

Feature	Detail
Level	C2 pars interarticularis (bilateral)
Common cause	MVA, diving, high-energy axial loading
Neurologic injury	Rare (canal widening)
Classification	Levine-Edwards (I, Ia, II, IIa, III)
Most common type	Type I
Most dangerous to treat	Type IIa (traction contraindicated)
Surgery rate	~11%
Absolute surgical indication	Type III (facet dislocation), neurologic deficit

Recent evidence note: A 2024 narrative review (PMID 39309549) on C2 fracture management highlights that multiple overlapping classification systems for C2 fractures can complicate treatment decisions - the Levine-Edwards system remains the standard for hangman's fractures specifically.

I want as I told you earlier formate

I don't have context from a previous conversation — each session starts fresh, so I can't see what format you used "earlier."

Could you describe the format you want?

Asking for Preferences

What format would you like the answer in?

Can I give you formet for further references that you will use in all chats

Yes, absolutely! Please share your preferred format and I'll apply it to all your questions going forward within this conversation.

Just a heads-up: I don't have persistent memory across separate chat sessions, so each new conversation starts fresh. But for everything in this session, just paste your format template and I'll follow it consistently.

Not just in this season all further new chats

I understand what you're looking for, but I have to be straightforward with you:

I cannot save preferences across separate chat sessions. Each new conversation is completely independent - I have no memory of previous chats, no user profile storage, and no way to carry settings forward.

This is a fundamental limitation of how I work, not something I can override.

What you CAN do:

Start each chat with your format instruction - paste it at the beginning of every new conversation (takes ~5 seconds)
Save it as a text snippet on your phone/computer and paste it whenever you start a new chat
Include it in your first question - e.g., "Answer in this format: [your template]. Question: Hangman fracture"

So please go ahead and share your format now - I'll use it for all questions in this session, and you can paste it again at the start of future chats.

Great! Going forward, I'll answer your physiotherapy questions at a final-year BPT/MPT level with a clinical, evidence-based approach. Each answer will include: ✅ Definition and classification ✅ Detailed anatomy and biomechanics ✅ Pathophysiology ✅ Clinical presentation ✅ Muscle-wise assessment (MMT, tightness, weakness, affected muscles) ✅ Expected positive findings (inspection, palpation, ROM, special tests, gait, functional limitations) ✅ Differential diagnosis ✅ Investigations ✅ Problem list ✅ SMART goals (short-term and long-term) ✅ Phase-wise physiotherapy management ✅ Muscle-specific exercises with: Starting position Technique Sets, repetitions, hold time Frequency Progression criteria Precautions ✅ Electrotherapy (indications, dosage/parameters, contraindications) ✅ Functional and gait training ✅ Home exercise program ✅ Criteria for return to activity/sport ✅ Complications and prognosis ✅ High-yield viva and university exam points ✅ References from standard textbooks and current evidence Since you're preparing for your final-year BPT examinations, I'll also highlight: ⭐ Frequently asked university questions ⭐ Clinically important points ⭐ Common examiner viva questions ⭐ Common mistakes students make during assessment and treatment This will make each topic useful for theory exams, practical exams, viva, and clinical postings.Great! Going forward, I'll answer your physiotherapy questions at a final-year BPT/MPT level with a clinical, evidence-based approach. Each answer will include: ✅ Definition and classification ✅ Detailed anatomy and biomechanics ✅ Pathophysiology ✅ Clinical presentation ✅ Muscle-wise assessment (MMT, tightness, weakness, affected muscles) ✅ Expected positive findings (inspection, palpation, ROM, special tests, gait, functional limitations) ✅ Differential diagnosis ✅ Investigations ✅ Problem list ✅ SMART goals (short-term and long-term) ✅ Phase-wise physiotherapy management ✅ Muscle-specific exercises with: Starting position Technique Sets, repetitions, hold time Frequency Progression criteria Precautions ✅ Electrotherapy (indications, dosage/parameters, contraindications) ✅ Functional and gait training ✅ Home exercise program ✅ Criteria for return to activity/sport ✅ Complications and prognosis ✅ High-yield viva and university exam points ✅ References from standard textbooks and current evidence Since you're preparing for your final-year BPT examinations, I'll also highlight: ⭐ Frequently asked university questions ⭐ Clinically important points ⭐ Common examiner viva questions ⭐ Common mistakes students make during assessment and treatment This will make each topic useful for theory exams, practical exams, viva, and clinical postings.

Got it! Format saved and understood. ✅

I'll apply this BPT/MPT final-year clinical format to every question you ask in this session. Just note - as explained, I can't carry it to new chats automatically, so paste this template at the start of each new session and I'll follow it immediately.

To get the most out of this format, also tell me:

Are you preparing for theory exams, practical/viva, or both?
Any specific system focus right now (ortho, neuro, cardio, sports)?
Do you want answers concise-exam style or detailed-clinical style, or should I vary based on topic complexity?

For now - would you like me to redo the Hangman's Fracture answer in your full BPT/MPT format? Just say "yes, redo it" and I'll generate the complete response right away.

Yes

Finding Sources

Searching PubMed

"hangman fracture" OR "traumatic spondylolisthesis" C2 rehabilitation

Finding Sources

Searching PubMed

cervical spine fracture physiotherapy exercise rehabilitation

Finding Sources

Reading File

Loading Image

Searching the Web

hangman fracture physiotherapy management BPT cervical spine rehabilitation exercise protocol

HANGMAN'S FRACTURE (Traumatic Spondylolisthesis of C2)

BPT / MPT Final Year - Clinical, Evidence-Based Format

✅ 1. DEFINITION AND CLASSIFICATION

Definition: A Hangman's fracture is a bilateral fracture through the pars interarticularis (isthmus) of C2 (axis), resulting in traumatic spondylolisthesis of C2 on C3, with the anterior C2 body separating from its posterior arch.

The name is a misnomer - judicial hanging rarely produced this fracture. Modern causes are high-energy trauma (MVA, diving, falls). - Rockwood & Green's Fractures in Adults, 10th ed. 2025

Classification: Levine and Edwards (Most Widely Used)

Levine-Edwards Classification of Hangman's Fracture Types I, II, IIa, III

Type	Displacement	Angulation	Mechanism	Disc/Ligament	Stability
I	< 3 mm	None	Axial compression + hyperextension	C2-C3 disc intact	Stable
Ia (Starr-Eismont)	Minimal	None	-	Fracture extends into posterior C2 body	Unstable; high neuro risk
II	> 3 mm	Present (> 10°)	Hyperextension + rebound flexion	C2-C3 disc + PLL disrupted	Unstable
IIa	Minimal	Marked angulation	Pure flexion-distraction	PLL + posterior annulus disrupted	Most unstable; NO TRACTION
III	Present	Present	Flexion-compression	Disc disrupted + C2-C3 facet dislocation	Most severe

Campbell's Operative Orthopaedics, 15th ed. 2026; Rockwood & Green's 10th ed. 2025

✅ 2. DETAILED ANATOMY AND BIOMECHANICS

Relevant Anatomy:

C2 (Axis): Has a unique structure - odontoid process (dens), body, pedicles, pars interarticularis (isthmus), laminae, spinous process
Pars interarticularis: The narrow bridge of bone between superior and inferior articular facets of C2 - the fracture site
C1-C2 joint: Atlanto-axial joint - provides ~50% of total cervical rotation
C2-C3 joint: Subaxial; stabilised by disc, PLL, ALL, ligamentum flavum, facet capsules
Vertebral artery: Passes through foramen transversarium of C2 - at risk in displaced fractures
Spinal cord at C2: Cord injury is RARE because anterior displacement of C2 body actually WIDENS the spinal canal (self-decompressing mechanism)

Biomechanics:

Hyperextension + axial load → compressive force on pars interarticularis → bilateral pars fracture → C2 body subluxes anteriorly → posterior arch remains in normal position
Flexion-distraction (Type IIa) → horizontal fracture line → marked kyphosis at C2-C3 → traction WORSENS deformity
Type III: Flexion-compression → pars fracture + facet dislocation → most complex

✅ 3. PATHOPHYSIOLOGY

High-energy trauma applies hyperextension + axial load to C2
Bilateral pars interarticularis fractures occur (weakest point of C2 arch)
C2 vertebral body with anterior arch separates from posterior elements
C2 body subluxes anteriorly on C3 → C2-C3 disc and ligament injury (in types II/IIa/III)
Canal decompression effect: Posterior arch stays posterior while body goes anterior → AP diameter of canal increases → neurological injury rare (except Starr-Eismont variant and Type III)
Starr-Eismont variant (Type Ia): Fracture extends into posterior body → posterior fragment displaces backward → canal compromise → higher neuro injury rate
Soft tissue injury: C2-C3 disc, PLL, ALL, ligamentum flavum, facet capsules are progressively disrupted from Type I → III
Vertebral artery injury possible in displaced fractures → vertebrobasilar ischaemia

✅ 4. CLINICAL PRESENTATION

History:

High-energy MVA (most common), diving into shallow water, fall from height
Patient reports severe neck pain, stiffness, inability to move neck
May report upper limb tingling/weakness (if incomplete cord involvement)
Loss of consciousness possible (associated head injury common)

Symptoms:

Severe neck pain at upper cervical region (C1-C2 level)
Occipital headache (suboccipital pain)
Neck stiffness / muscle spasm
Pain radiating to shoulders (C3-C4 dermatome)
Dysphagia (rare, retropharyngeal haematoma)
Neurological symptoms: rare; if present → paresthesia, weakness in upper/lower limbs

Signs (on examination):

Tenderness over C2 spinous process
Muscle guarding and spasm (upper cervical paraspinals, trapezius)
Restricted all cervical ROM
Neurological deficit: rare; if present - upper motor neuron signs (hyperreflexia, Babinski positive, clonus), sensory loss

✅ 5. MUSCLE-WISE ASSESSMENT

Muscles Affected / at Risk:

Muscle	Role	Assessment Finding
Sternocleidomastoid (SCM)	Cervical flexion/rotation	Spasm, guarding, tenderness
Upper Trapezius	Neck lateral flexion, shoulder elevation	Spasm, trigger points
Levator Scapulae	Cervical extension + lateral flexion	Tight, tender
Semispinalis Cervicis/Capitis	Cervical extension	Guarding, spasm
Suboccipital group (Rectus capitis posterior major/minor, Obliquus capitis superior/inferior)	Fine cervical rotation and extension	Spasm, occipital pain
Scalenes (Anterior, Middle, Posterior)	Cervical lateral flexion, accessory respiration	Spasm, neurogenic referral to arm
Deep Neck Flexors (DNF): Longus colli, Longus capitis	Cervical stabilisation, neutral curve	WEAK - inhibited by pain (key finding)

MMT (Manual Muscle Testing) - if neurological deficit present:

Level	Key Muscle	Action Tested
C3-C4	Diaphragm, Trapezius	Breathing, shoulder shrug
C4	Deltoid	Shoulder abduction
C5	Biceps brachii	Elbow flexion
C6	Wrist extensors	Wrist extension
C7	Triceps	Elbow extension
C8-T1	Hand intrinsics	Grip strength

ASIA Impairment Scale (use when SCI present):

Grade	Injury Type	Description
A	Complete	No motor/sensory below level
B	Incomplete	Sensory intact, no motor
C	Incomplete	Motor preserved, most muscles < grade 3
D	Incomplete	Motor preserved, most muscles ≥ grade 3
E	Normal	Normal motor and sensory

Rockwood & Green's Fractures in Adults, 10th ed. 2025

✅ 6. EXPECTED POSITIVE FINDINGS

Inspection:

Patient holding head with hands (protective posture)
Forward head posture
Restricted spontaneous cervical movement
Ecchymosis over posterior neck (in high-energy trauma)
Associated facial/head injuries

Palpation:

Point tenderness over C2 spinous process (midline)
Paraspinal muscle spasm (bilateral upper cervical region)
Suboccipital tenderness

ROM (Cervical - Normal values for comparison):

Motion	Normal	Expected in Hangman's
Flexion	45-50°	Severely restricted (0-10°)
Extension	60-70°	Severely restricted
Lateral Flexion (R/L)	45°	Restricted
Rotation (R/L)	60-80°	Severely restricted

Special Tests:

Test	Relevance	Finding
Spurling's Test	Cervical nerve root compression	Positive if radiculopathy present
Upper Limb Tension Test (ULTT)	Neural tension	Positive in radiculopathy
Lhermitte's Sign	Cervical myelopathy	Positive (electrical sensation down spine on flexion) if cord involved
Hoffman's Sign	Upper motor neuron lesion	Positive if cord injury
Babinski Sign	Corticospinal tract involvement	Positive in SCI
Vertebral Artery Test	Vertebrobasilar insufficiency	Dizziness, nystagmus (CONTRAINDICATED in acute fracture)

⚠️ Clinical Warning: Do NOT perform active cervical movements or provocative tests in acute/unstable hangman's fracture. Neurological and vascular assessment only.

Neurological Assessment:

Dermatome testing: C2 (posterior scalp), C3 (posterior neck), C4 (shoulder top), C5-T1 (upper limbs)
Deep tendon reflexes: Biceps (C5-C6), Triceps (C7), Brachioradialis (C6)
Clonus, Babinski sign

Functional Limitations:

Complete inability to perform ADLs independently
Unable to drive
Dysphagia (if retropharyngeal haematoma)
Gait disturbance if lower limb UMN signs
Occupational limitations

✅ 7. DIFFERENTIAL DIAGNOSIS

Condition	Differentiating Feature
Jefferson Fracture (C1 burst)	Fracture at C1, not C2; diagnosed on open-mouth odontoid X-ray
Odontoid (Dens) Fracture	Fracture at C2 dens; different mechanism; seen on lateral C-spine X-ray
C2 Body Fracture	Through body of C2, not pars
Atlanto-axial dislocation	Widened predental space (> 3 mm adult, > 5 mm child)
Cervical Disc Herniation	No fracture; radiculopathy; presents more subacutely
Cervical Spondylotic Myelopathy	Degenerative; no trauma history
Muscular Torticollis	Soft tissue only; no bony injury on imaging

✅ 8. INVESTIGATIONS

Investigation	Finding in Hangman's Fracture
X-Ray (Lateral C-spine)	Anterior subluxation C2 on C3; fracture line through pars; prevertebral soft tissue swelling
X-Ray (AP + Open-mouth odontoid)	Rule out concomitant odontoid fracture / Jefferson fracture
CT Scan (Gold Standard)	Defines fracture morphology, translation, angulation; detects Starr-Eismont variant; facet dislocation in Type III
MRI	Disc integrity, PLL/ALL/ligamentum flavum status; cord/root compression; haematoma; MUST if neuro deficit
CT Angiography	If vertebral artery injury suspected (displaced fractures)
NEXUS / Canadian C-Spine Rule	Guides decision for imaging in blunt trauma

✅ 9. PROBLEM LIST

Impairments (Body Structure/Function):

Pain: severe upper cervical and suboccipital pain
Cervical instability (fracture-related)
Restricted cervical ROM (all planes)
Cervical muscle spasm (SCM, trapezius, suboccipitals)
Deep neck flexor weakness (inhibition by pain)
Neurological deficits (if SCI present): motor weakness, sensory loss, reflex changes
Vertebral artery compromise (if displaced)

Activity Limitations:

Unable to perform cervical movements actively
Difficulty with ADLs (grooming, dressing, feeding)
Difficulty sleeping
Inability to drive

Participation Restrictions:

Unable to work / attend college
Reduced social participation
Sports and recreational activities restricted

Psychological:

Fear of movement (kinesiophobia)
Anxiety/depression post-trauma

✅ 10. SMART GOALS

Short-Term Goals (0-6 weeks - Immobilisation Phase):

Patient will report pain reduction from 8/10 to 4/10 on NRS within 4 weeks of physiotherapy
Patient will demonstrate independent safe bed mobility with log-roll technique within 1 week
Upper limb ROM will be maintained at full range (shoulder, elbow, wrist) within 2 weeks
Patient will perform diaphragmatic breathing exercises independently within 3 days
Prevent DVT and pressure sores through positioning programme within 1 week

Long-Term Goals (3-6 months - Post-Immobilisation):

Patient will achieve pain-free full cervical ROM (flexion 45°, extension 60°, rotation 70°) within 3 months of orthosis removal
Patient will demonstrate MMT grade 5 for all cervical muscles within 4 months
Patient will return to full independent ADLs without pain within 3 months
Patient will return to work/study within 4-5 months
Patient will demonstrate correct posture and ergonomics for long-term spine health within 3 months

✅ 11. PHASE-WISE PHYSIOTHERAPY MANAGEMENT

PHASE 1: Acute / Immobilisation Phase (0-6 weeks)

Goal: Pain control, prevent complications, maintain distal function

Physiotherapy Roles:

Positioning: semi-Fowler's or supine with neutral cervical spine
Log-roll technique for bed mobility - teach patient and family
Deep breathing exercises (diaphragmatic) - prevent pulmonary complications
Upper and lower limb passive/active-assisted ROM exercises (within spinal precautions)
DVT prevention: ankle pumps, calf exercises
Pressure area care: repositioning education
Patient and caregiver education: collar/halo-vest care
TENS / electrotherapy for pain control (over trapezius, paraspinals - NOT over fracture site)
Orthosis management: rigid cervical collar (Type I) or halo vest (Type II/IIa)

⚠️ No active cervical exercises until fracture healing confirmed on imaging

PHASE 2: Subacute / Post-Immobilisation Phase (6-12 weeks post-orthosis removal)

Goal: Restore cervical ROM, re-educate deep neck flexors, reduce pain

Exercises:

Active cervical ROM exercises (see Section 13 below)
Deep neck flexor (DNF) activation - Craniocervical flexion test (CCFT) protocol
Postural re-education
Scapular stabilisation exercises
Thoracic mobility exercises
Scar management (post-surgical cases)
Electrotherapy: TENS, IFT for pain

PHASE 3: Strengthening Phase (3-4 months)

Goal: Restore full strength, endurance, proprioception

Exercises:

Progressive isometric → isotonic cervical strengthening
Deep neck flexor endurance training
Proprioceptive training (head repositioning accuracy)
Shoulder girdle strengthening
Core strengthening (spinal support)
Functional activity training

PHASE 4: Functional / Return to Activity Phase (4-6 months)

Goal: Return to full ADLs, work, sport

Exercises:

Dynamic cervical stabilisation
Sport-specific training (if applicable)
Ergonomic training
Work hardening programme

✅ 12. MUSCLE-SPECIFIC EXERCISES

A. Deep Neck Flexor (DNF) Activation - Craniocervical Flexion

Muscles targeted: Longus colli, Longus capitis

Parameter	Detail
Starting Position	Supine lying, pillow under head, head in neutral
Technique	Gently nod chin toward chest (upper cervical flexion - "yes" movement), WITHOUT lifting head. Imagine saying "yes" very slightly. Hold position.
Sets/Reps	3 sets × 10 repetitions
Hold Time	10 seconds per rep
Frequency	2× per day
Progression	Increase hold time to 20 sec → add pressure biofeedback (target: 22-24 mmHg) → progress to sitting → standing
Precautions	Do NOT perform during immobilisation phase; avoid pain provocation; ensure neutral spine

B. Isometric Cervical Strengthening (Post-Healing)

Muscles targeted: All cervical muscles

Direction	Position	Technique
Flexion	Sitting, neutral	Push forehead into palm (placed on forehead), resist movement
Extension	Sitting	Push occiput into palm (placed behind head), resist
Lateral Flexion (R/L)	Sitting	Push temple into palm (placed on side of head), resist
Rotation (R/L)	Sitting	Push temporal region into palm, resist

Parameter	Detail
Sets/Reps	3 sets × 10 repetitions
Hold Time	5-10 seconds
Frequency	Daily
Progression	Increase hold time → add resistance band → dynamic exercises
Precautions	Pain-free; avoid end-range positions initially; confirm healing on X-ray before starting

C. Active Cervical ROM Exercises

Muscles targeted: All cervical flexors, extensors, rotators, lateral flexors

Parameter	Detail
Starting Position	Sitting in chair, feet flat, shoulders relaxed
Technique	Slow, controlled movement in each plane: Flexion (chin to chest), Extension (look at ceiling - avoid hyperextension), Lateral flexion (ear to shoulder), Rotation (chin to shoulder)
Sets/Reps	3 sets × 10 repetitions each direction
Hold Time	2-3 seconds at end range
Frequency	2-3× per day
Progression	Increase range → add active resistance → proprioceptive exercises
Precautions	Within pain-free range only; STOP if dizziness, nausea, radiating pain; NO rapid movements

D. Scapular Stabilisation - Retraction/Depression

Muscles targeted: Middle/Lower Trapezius, Rhomboids, Serratus Anterior

Parameter	Detail
Starting Position	Sitting or standing, arms by side
Technique	Draw shoulder blades together and downward (retract + depress); hold
Sets/Reps	3 sets × 15 repetitions
Hold Time	5 seconds
Frequency	Daily
Progression	Add resistance band → prone Y-T-W exercises → cable machine
Precautions	Avoid shrugging (upper trapezius dominance); keep neck neutral

E. Upper Trapezius Stretch

Parameter	Detail
Starting Position	Sitting, affected side hand holding chair edge
Technique	Lateral flex neck away from tight side; use other hand to gently increase stretch; breathe out
Hold Time	30 seconds
Sets/Reps	3 repetitions each side
Frequency	2-3× per day
Precautions	Gentle stretch only; no overpressure in early phase

✅ 13. ELECTROTHERAPY

A. TENS (Transcutaneous Electrical Nerve Stimulation)

Parameter	Detail
Indication	Pain management (acute and subacute phases)
Electrode placement	Over upper trapezius / paraspinals (NOT over fracture site; NOT over anterior neck/carotid sinus)
Mode	Conventional (High frequency) TENS
Frequency	80-150 Hz
Pulse width	50-80 µs
Intensity	Strong but comfortable tingling (sensory threshold)
Duration	20-30 minutes per session
Frequency	1-2× daily
Contraindications	Over anterior neck (carotid sinus), cardiac pacemaker, over metal implants (halo pins), open wounds, pregnancy

B. Interferential Therapy (IFT)

Parameter	Detail
Indication	Deep tissue pain; muscle spasm
Carrier Frequency	4000 Hz
AMF (Beat frequency)	80-150 Hz (pain) / 10-50 Hz (muscle spasm)
Sweep	80-150 Hz
Intensity	Comfortable tingling
Duration	15-20 minutes
Contraindications	Same as TENS; NOT over fracture site acutely

C. Ultrasound Therapy (Later Phase - Soft Tissue)

Parameter	Detail
Indication	Soft tissue healing, muscle spasm (subacute/chronic phase)
Frequency	1 MHz (deep tissue) or 3 MHz (superficial)
Intensity	0.5-1.5 W/cm² (pulsed 1:4 ratio initially)
Duration	5-7 minutes per area
ERA	Cover all of effective radiating area
Contraindications	Over spinal cord (posterior cervical region), metal implants, active fracture site, malignancy, growth plates

⚠️ Electrotherapy over the cervical spine requires extreme caution. Anterior neck (carotid sinus, vagus nerve) is strictly contraindicated. All parameters to be titrated to patient response.

✅ 14. FUNCTIONAL AND GAIT TRAINING

Functional Training:

Bed mobility: log-roll technique (essential during immobilisation) - protects spinal alignment
Sit-to-stand transfers: use of arms to push up; neutral spine maintained
Walking with cervical orthosis: gait training on level ground → uneven surfaces
Stair climbing: begin with one step at a time with railing support
ADL training: grooming, feeding, dressing with adapted techniques
Driving: NOT permitted with cervical orthosis; cleared only after medical review

Gait Assessment (if lower limb UMN signs present):

Spastic gait: scissoring pattern, foot drop → address with orthotics, gait retraining
Ataxic gait (if cerebellar/dorsal column involved): wide-based gait → balance training
Use of walking aids initially if balance affected

Balance and Proprioception:

Eyes-open to eyes-closed standing
Single-leg stance (progressed)
Head repositioning accuracy test
Foam pad standing
Vestibular rehabilitation if dizziness present

✅ 15. HOME EXERCISE PROGRAMME (HEP)

To be given after Phase 2 (post-immobilisation, fracture healed):

DNF activation (chin tucks) - 3 sets × 10 reps × 10 sec hold; 2× daily
Active cervical ROM (flexion, extension, lateral flexion, rotation) - 10 reps each; 2× daily
Scapular retraction - 3 sets × 15 reps × 5 sec hold; daily
Upper trapezius stretch - 3 reps × 30 sec each side; 2-3× daily
Posture correction - chin tuck posture reminders every 30 minutes (especially during screen time)
Walking programme - 20-30 minutes brisk walking daily
Ergonomic advice:
- Monitor at eye level
- Avoid prolonged neck flexion (phone, reading)
- Use pillow that maintains cervical lordosis
- Sleep in supine or side-lying; avoid prone

✅ 16. CRITERIA FOR RETURN TO ACTIVITY / SPORT

Return to daily activities:

Fracture healing confirmed on CT/X-ray
Pain NRS ≤ 2/10
Full pain-free cervical ROM
Independent ADLs without assistance
Cleared by treating orthopaedic/neurosurgeon

Return to sport (contact/collision sport):

Complete fracture healing (minimum 3-4 months)
Full cervical ROM, pain-free
Cervical muscle strength ≥ 90% of contralateral / normative values
Cervical endurance normalised (DNF endurance test)
No neurological deficits
Physician clearance mandatory
Contact sports (rugby, wrestling, American football): May require 6-12 months; special neck guard use considered

✅ 17. COMPLICATIONS AND PROGNOSIS

Complications:

Complication	Notes
Spinal cord injury (SCI)	Rare due to self-decompression; common in Type Ia and Type III
Vertebral artery injury	Posterior circulation stroke, vertebrobasilar ischaemia
Non-union / Malunion	Especially Type II with inadequate immobilisation
Post-traumatic cervical instability	Persistent ligamentous laxity
Adjacent segment disease	Following surgical fusion (C1-C2-C3)
Halo vest complications	Pin-site infection, pressure sores, pin loosening, pulmonary restriction
Pneumonia / DVT / PE	Immobilisation complications
Dysphagia	Retropharyngeal haematoma or post-surgical
Chronic neck pain	Residual in up to 30%
Psychological: PTSD, anxiety	Post-trauma

Prognosis:

Type I: Excellent - heals with collar in 4-6 weeks
Type II: Good with halo vest; ~10-15% fail conservative management
Type IIa: Good if managed correctly (extension/compression, NO traction)
Type III: Requires surgery; recovery depends on neurological status pre-operatively
Only 11.2% of all hangman's fractures require surgery (National Trauma Data Bank)
Neurological deficits: rare but, if present, prognosis depends on ASIA grade and completeness

✅ 18. HIGH-YIELD VIVA AND UNIVERSITY EXAM POINTS

⭐ Frequently Asked University Questions:

Define and classify Hangman's fracture with a diagram.
What is the mechanism of injury in each type of Hangman's fracture?
Why is neurological injury uncommon in Hangman's fracture?
What is the role of physiotherapy in managing Hangman's fracture?
Describe phase-wise physiotherapy management of a post-halo vest patient.
What is the Levine and Edwards classification?
Why is traction contraindicated in Type IIa?

⭐ Clinically Important Points:

Hangman's fracture = pars interarticularis of C2 (NOT dens, NOT C1)
Canal widens → neuro injury rare, but NOT absent (Starr-Eismont Type Ia = high neuro risk)
Type IIa = NEVER apply traction (accentuates kyphosis and deformity)
Always clear cervical spine radiologically before starting active cervical exercises
Deep neck flexors (Longus colli, Longus capitis) are the primary stabilisers - their activation is the cornerstone of cervical rehabilitation
Halo vest complications: pin infection (most common), pulmonary restriction (must teach breathing exercises)

⭐ Common Examiner Viva Questions:

"What precautions would you take before starting cervical exercises?" → Confirm fracture healing on imaging, physician clearance, ASIA assessment, no instability signs
"What is the difference between Type II and Type IIa?" → Type II: translation > 3 mm + angulation; Type IIa: minimal translation but MARKED angulation; horizontal fracture; flexion-distraction mechanism; NO TRACTION
"How do you assess deep neck flexors clinically?" → Craniocervical flexion test (CCFT) using pressure biofeedback unit; target 22-24 mmHg
"What is the significance of the Starr-Eismont variant?" → Fracture extends into posterior C2 body; posterior fragment displaces backward narrowing canal; higher neurological injury risk
"What electrical modality would you use and why?" → TENS for pain (gate control theory); IFT for deeper tissue; AVOID anterior neck and fracture site

⭐ Common Mistakes Students Make:

Applying active cervical exercises before radiological healing confirmed (dangerous)
Applying traction in Type IIa fracture (contraindicated - can cause paralysis)
Not checking ASIA classification in patients with trauma
Neglecting to teach log-roll technique to patient and caregivers
Placing TENS electrodes on anterior neck (over carotid sinus) - strictly contraindicated
Confusing Hangman's fracture (C2 pars) with Jefferson fracture (C1 burst) or odontoid fracture (C2 dens)
Starting aggressive ROM before adequate deep neck flexor activation

✅ 19. REFERENCES

Rockwood and Green's Fractures in Adults, 10th Edition (2025) - Chapter on Upper Cervical Spine Injuries
Campbell's Operative Orthopaedics, 15th Edition (2026) - Chapter 48: Traumatic Spondylolisthesis of the Axis
Bailey and Love's Short Practice of Surgery, 28th Edition - Chapter 30: Spinal Injuries
Grainger & Allison's Diagnostic Radiology - Chapter 52: Cervical Spine Trauma
Miller's Review of Orthopaedics, 9th Edition - Upper Cervical Spine Injuries
Schwartz's Principles of Surgery, 11th Edition - Hangman's Fractures of C2
Adams and Victor's Principles of Neurology, 12th Edition - Mechanisms of Spinal Injury
Levine AM, Edwards CC. The management of traumatic spondylolisthesis of the axis. J Bone Joint Surg Am. 1985;67(2):217-226.
McDermott M, et al. Management of C2 fractures following multiple classifications, a narrative review. Brain Spine. 2024. PMID: 39309549
Journal of Clinical Medicine, 2025 - Management of Atypical Hangman's Fracture: Systematic Review - mdpi.com
StatPearls (NCBI) - Hangman's Fractures

💡 Exam Tip: In theory exams, always draw the Levine-Edwards classification diagram. In viva, know the contraindication to traction in Type IIa cold. In practical, always start with spinal precautions and ASIA classification before any cervical assessment.

Pulmonary rehabilitation

Finding Sources

Searching PubMed

"pulmonary rehabilitation" COPD exercise

Finding Sources

Excellent sources found. Now reading the key textbook sections in parallel:

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

PULMONARY REHABILITATION (PR)

BPT / MPT Final Year - Clinical, Evidence-Based Format

✅ 1. DEFINITION AND CLASSIFICATION

Definition (ATS/ERS 2013 - Gold Standard):

"Pulmonary rehabilitation is a comprehensive intervention based on a thorough patient assessment followed by patient-tailored therapies that include, but are not limited to, exercise training, education, and behaviour change, designed to improve the physical and psychological condition of people with chronic respiratory disease and to promote the long-term adherence to health-enhancing behaviours."

Spruit MA et al., ATS/ERS Statement, Am J Respir Crit Care Med. 2013

Simpler definition for exams: Pulmonary rehabilitation is a multidisciplinary, evidence-based programme combining exercise training, patient education, nutritional counselling, and psychosocial support to improve functional capacity, reduce dyspnoea, and enhance quality of life in patients with chronic respiratory diseases.

Classification / Types:

Based On	Types
Setting	Inpatient (hospital-based), Outpatient (community-based), Home-based
Duration	Short-term (6-8 weeks), Long-term (12+ weeks), Maintenance
Condition	COPD-specific, ILD-specific, Asthma, Post-COVID, Pre/Post lung transplant, Lung cancer
Phase	Phase I (Inpatient/acute), Phase II (Supervised outpatient), Phase III (Community), Phase IV (Maintenance)

Indications for PR:

COPD (MRC Dyspnoea Grade 2 and above) - primary indication
Interstitial Lung Disease (ILD) / Idiopathic Pulmonary Fibrosis (IPF)
Bronchiectasis (cystic and non-cystic fibrosis)
Asthma (uncontrolled / exercise-induced)
Pulmonary hypertension
Pre- and post-lung transplantation
Post-COVID-19 respiratory sequelae
Lung volume reduction surgery (LVRS) - pre- and post-operative
Lung cancer (pre- and post-surgical)
Neuromuscular diseases affecting respiration

Contraindications:

Absolute	Relative
Unstable angina / acute MI	Severe pulmonary hypertension
Uncontrolled cardiac arrhythmia	Severe orthopaedic limitations
Severe aortic stenosis	Cognitive impairment
Active haemoptysis	Severe anaemia
Acute exacerbation	Morbid obesity

✅ 2. DETAILED ANATOMY AND BIOMECHANICS

Relevant Anatomy:

Lungs and Airways:

300 million alveoli; surface area ~70 m²
Airways: Trachea → Bronchi (main, lobar, segmental) → Bronchioles → Terminal bronchioles → Alveoli
COPD: hyperinflation, barrel chest, flattened diaphragm, increased FRC/TLC

Respiratory Muscles:

Muscle	Role	Clinical Significance in PR
Diaphragm	Primary inspiratory muscle (75% of work)	Flattened in COPD → reduced efficiency → trains with IMT and pursed lip breathing
External Intercostals	Elevate ribs during inspiration	Accessory recruiter in COPD
Sternocleidomastoid (SCM)	Accessory inspiration	Overactive in COPD → hypertrophy on inspection
Scalenes	Accessory inspiration	Recruited at rest in severe COPD
Internal Intercostals	Active expiration (normal)	Recruited in forced expiration / wheeze
Abdominal Muscles	Active expiration	Trained in active expiratory techniques
Pelvic Floor	Pressure control during cough	Dysfunctional in COPD - addressed in PR

Biomechanics of Breathing:

Normal:

Inspiration: diaphragm descends + rib cage expands → negative intrathoracic pressure → air flows in
Expiration: passive elastic recoil

In COPD:

Air trapping → lung hyperinflation → diaphragm flattened (disadvantaged position on length-tension curve)
Increased work of breathing (WOB)
Respiratory muscles working at mechanical disadvantage
Dynamic hyperinflation worsens on exertion → exercise limitation

Gas Exchange:

V/Q mismatch in COPD → hypoxaemia + hypercapnia
PR improves peripheral muscle efficiency → reduces ventilatory demand for same workload → reduces dynamic hyperinflation

✅ 3. PATHOPHYSIOLOGY

The Vicious Cycle of Deconditioning (Key Concept for Exams):

Chronic Lung Disease
        ↓
   Dyspnoea on exertion
        ↓
   Activity avoidance (physical inactivity)
        ↓
   Peripheral muscle deconditioning (atrophy, type I → type II fibre shift)
        ↓
   Reduced oxidative capacity → early lactic acidosis → MORE ventilatory demand
        ↓
   Worsening exercise intolerance → MORE dyspnoea
        ↓
   Social isolation, depression, anxiety (↓ QoL)
        ↓
   Further inactivity → CYCLE CONTINUES

PR breaks this cycle at multiple points - the most important mechanism of PR benefit.

Specific Pathophysiology in COPD:

Loss of alveolar walls → emphysema → reduced elastic recoil → expiratory airflow limitation
Airway inflammation → mucus hypersecretion → airway narrowing → chronic bronchitis
Skeletal muscle dysfunction: type I (slow oxidative) fibre atrophy, type IIx (fast glycolytic) fibre predominance → early lactic acidosis → increased ventilatory demand
Systemic inflammation (IL-6, TNF-α) → muscle catabolism
Nutritional depletion → cachexia (worse prognosis)

✅ 4. CLINICAL PRESENTATION

History:

Chronic progressive breathlessness (dyspnoea) - worsening over years
Chronic productive cough (bronchitis component)
Wheeze
Frequent acute exacerbations (hospitalisations)
Activity limitation (stairs, walking)
Occupational history (smoking, dust, fumes)
Smoking history (pack-years = packs/day × years)
Weight loss, fatigue, ankle swelling (cor pulmonale)

Symptoms at Presentation for PR:

Exertional dyspnoea (MRC grade 2-5)
Fatigue
Exercise intolerance
Depression, anxiety
Social isolation
Reduced ADL capacity

Signs:

Barrel chest (increased AP:lateral diameter)
Use of accessory muscles (SCM, scalenes hypertrophy)
Pursed lip breathing (self-generated PEEP)
Prolonged expiration (I:E ratio reversed - normally 1:2, becomes 1:3 or more)
Hyperresonance on percussion
Reduced air entry bilaterally
Wheeze (expiration > inspiration)
Cyanosis (peripheral/central in severe disease)
Ankle oedema (cor pulmonale)
Clubbing (NOT typical COPD - suggests bronchiectasis or lung cancer)

✅ 5. MUSCLE-WISE ASSESSMENT

Assessment of Respiratory Muscles:

Muscle Group	Assessment Tool	Finding
Inspiratory muscles (diaphragm + inspiratory intercostals)	MIP (Maximum Inspiratory Pressure) - normal > 80 cmH₂O male, > 70 cmH₂O female	Reduced MIP in COPD
Expiratory muscles	MEP (Maximum Expiratory Pressure)	Reduced MEP
Diaphragm	Sniff nasal pressure; ultrasound	Flattened, reduced excursion
Overall respiratory muscle endurance	Sustained maximum ventilation (SMV); pressure time product	Reduced endurance

Assessment of Peripheral Muscles:

Muscle Group	Assessment	Finding
Quadriceps (most affected in COPD)	Isokinetic dynamometry; 1-RM; 30-sec sit-to-stand	Weakness, atrophy
Hip extensors/flexors	MMT (0-5 MRC scale)	Weak
Upper limb muscles (biceps, deltoid)	Grip strength (hand dynamometer)	Reduced
Respiratory muscles	MIP/MEP	Reduced

MMT Scale (MRC 0-5):

Grade	Description
0	No contraction
1	Visible contraction, no movement
2	Movement with gravity eliminated
3	Movement against gravity (minimum pass)
4	Movement against some resistance
5	Normal strength

✅ 6. EXPECTED POSITIVE FINDINGS

Inspection:

Barrel chest (COPD) / Kyphosis
Accessory muscle use at rest
Pursed lip breathing
Cyanosis (central/peripheral)
Ankle oedema
Cachexia (weight loss, muscle wasting)

Palpation:

Reduced chest expansion (bilateral)
Reduced tactile fremitus

Percussion:

Hyperresonance (emphysema)
Reduced liver dullness (liver pushed down due to hyperinflation)

Auscultation:

Reduced air entry bilaterally
Expiratory wheeze (COPD/asthma)
Coarse crackles (bronchiectasis, LRTI)
Fine crackles (ILD - "velcro" crackles)

Spirometry / Pulmonary Function Tests:

Test	Normal	COPD (Obstructive)	ILD (Restrictive)
FEV₁	> 80% predicted	Reduced (< 80%)	Reduced
FVC	> 80% predicted	May be reduced	Reduced
FEV₁/FVC ratio	> 0.70	< 0.70 (diagnostic)	Normal or increased
TLC	80-120% predicted	Increased	Reduced
RV	Normal	Increased (air trapping)	Reduced
DLCO	> 70% predicted	Reduced (emphysema)	Reduced

GOLD Classification (COPD Severity by FEV₁):

GOLD Grade	FEV₁ % predicted	Severity
I	≥ 80%	Mild
II	50-79%	Moderate
III	30-49%	Severe
IV	< 30%	Very Severe

Outcome Measures used in PR:

Outcome Domain	Tool
Exercise capacity	6-Minute Walk Test (6MWT) - most common; Incremental Shuttle Walk Test (ISWT); Endurance Shuttle Walk Test (ESWT); CPET
Dyspnoea	Modified Borg Scale (0-10); MRC Dyspnoea Scale (1-5); Baseline Dyspnoea Index (BDI)
Quality of Life	COPD Assessment Test (CAT); St. George's Respiratory Questionnaire (SGRQ); Chronic Respiratory Questionnaire (CRQ)
Anxiety/Depression	Hospital Anxiety and Depression Scale (HADS)
Muscle strength	Grip dynamometer; 1-RM; 30-sec sit-to-stand
Physical activity	Accelerometry; pedometer step counts
Nutritional status	BMI; FFMI (fat-free mass index)

6MWT Minimal Clinically Important Difference (MCID): 25-33 metres

✅ 7. DIFFERENTIAL DIAGNOSIS

Condition	Key Differentiating Feature
Cardiac failure (CHF)	Bilateral basal crackles, raised JVP, cardiomegaly on CXR, BNP elevated, responds to diuretics
Asthma	Reversible airflow obstruction (≥ 12% and 200 mL improvement on bronchodilator), atopy, younger onset
Bronchiectasis	Clubbing, copious purulent sputum, "tram-track" / "ring shadow" on HRCT
ILD / IPF	Fine "velcro" crackles, restrictive pattern on PFTs, ground-glass opacities on HRCT
Pulmonary Hypertension	Loud P2, RV heave, raised JVP, ECHO: increased RVSP
Lung Cancer	Haemoptysis, weight loss, clubbing, hilar mass on CXR
Anaemia	Pallor, dyspnoea without wheeze, normal spirometry, low Hb

✅ 8. INVESTIGATIONS

Investigation	Purpose / Finding
Spirometry (PFTs)	Diagnose, classify severity (GOLD), assess obstruction/restriction
Chest X-Ray (CXR)	Hyperinflation (barrel chest, flattened diaphragm, >6 ribs visible anteriorly)
HRCT Chest	Emphysema pattern, bullae, ILD (ground glass/honeycombing), bronchiectasis
ABG (Arterial Blood Gas)	Hypoxaemia (PaO₂ < 60 mmHg), hypercapnia (PaCO₂ > 45 mmHg), pH, HCO₃
SpO₂ (Pulse Oximetry)	Resting + exertional oxygenation; oxygen need during exercise
6MWT	Functional exercise capacity; SpO₂ during exertion
CPET (Cardiopulmonary Exercise Testing)	VO₂max, lactate threshold, ventilatory pattern, cardiac vs pulmonary limitation
ECG / Echo	Rule out cardiac cause; assess cor pulmonale (right heart strain)
Sputum Culture	Chronic infection in bronchiectasis/CF
FBC	Polycythaemia (secondary to chronic hypoxia), anaemia
BMI / Nutritional Assessment	FFMI; malnutrition very common in severe COPD
HADS	Anxiety and depression screening

✅ 9. PROBLEM LIST

Impairments:

Dyspnoea (exertional and at rest in severe cases)
Reduced exercise tolerance (reduced VO₂max, low 6MWT distance)
Peripheral muscle weakness (especially quadriceps) and atrophy
Inspiratory muscle weakness (reduced MIP)
Reduced FEV₁, FVC, DLCO
Hypoxaemia (resting ± exertional)
Sputum retention / secretion clearance difficulty
Nutritional depletion (low BMI, reduced FFMI)
Postural abnormalities (kyphosis, forward head posture)

Activity Limitations:

Unable to climb stairs without stopping
Unable to walk > 50-100 m at own pace
Difficulty with basic ADLs (bathing, dressing)
Reduced gait speed; impaired balance

Participation Restrictions:

Unable to work
Reduced social activities / isolation
Unable to exercise recreationally

Psychological:

Anxiety (fear of breathlessness / death)
Depression
Low self-efficacy
Kinesiophobia (fear of exercise)

✅ 10. SMART GOALS

Short-Term Goals (4-6 weeks):

Patient will report reduction in dyspnoea on Borg Scale from 6/10 to 3/10 during 6MWT within 4 weeks
Patient will demonstrate diaphragmatic breathing and PLB correctly within 1 week
Patient will increase 6MWT distance by ≥ 25 metres (MCID) within 6 weeks
Patient will perform independent sputum clearance using ACBT within 2 weeks
Patient will walk 10 minutes continuously on level ground within 4 weeks

Long-Term Goals (8-12 weeks):

Patient will complete 6MWT ≥ 350 metres without desaturation below SpO₂ 88% within 8 weeks
Patient will demonstrate MMT grade 4+ for bilateral quadriceps within 10 weeks
Patient will report COPD Assessment Test (CAT) score reduction by ≥ 2 points within 8 weeks (MCID = 2)
Patient will demonstrate 30-minute continuous aerobic exercise tolerance within 10 weeks
Patient will return to full independent ADLs (bathing, dressing, light household activity) within 12 weeks

✅ 11. PHASE-WISE PHYSIOTHERAPY MANAGEMENT

PHASE I: Inpatient / Acute Phase

(Post-exacerbation, ICU step-down, post-surgical)

Goals: Prevent complications, restore baseline, clear secretions

Positioning: high side lying / upright sitting (optimises diaphragm mechanics)
Breathing exercises: Diaphragmatic breathing, pursed lip breathing (PLB)
Airway clearance: ACBT (Active Cycle of Breathing Technique), postural drainage
Early mobilisation: passive ROM → active-assisted → active limb exercises → sitting → standing → walking with support
Supplemental oxygen during exercise (maintain SpO₂ ≥ 88%)
Incentive spirometry (post-operative)
Patient education: disease awareness, inhaler technique, energy conservation
Monitoring: SpO₂, HR, BP, RR, Borg dyspnoea scale before/during/after each session

PHASE II: Supervised Outpatient PR Programme

(6-12 weeks - CORE phase)

Goal: Improve exercise capacity, QoL, reduce dyspnoea

Structure: 2-3 sessions/week × 6-8 weeks minimum (ATS/ERS recommended)

Components:

Exercise Training (aerobic + resistance)
Breathing re-education
Airway clearance techniques
Patient education
Psychosocial support
Nutritional counselling

PHASE III: Community / Maintenance Phase

(Post-PR programme)

Goal: Maintain gains, prevent decline, self-management

Supervised community exercise classes
Walking programmes
Independent home exercise programme
Tele-rehabilitation / remote monitoring
Annual review and reassessment

✅ 12. MUSCLE-SPECIFIC EXERCISES WITH FULL DETAILS

A. AEROBIC EXERCISE TRAINING

i. Walking Programme

Parameter	Detail
Starting Position	Standing, comfortable footwear, use walking aid if needed
Technique	Walk at target pace on level surface or treadmill; use PLB during walking to control dyspnoea
Intensity	Borg dyspnoea scale 4-6/10 (moderate-somewhat severe); or 60-80% peak HR
Duration	Start: 10-15 minutes → Progress to 30-45 minutes
Frequency	5 days/week
Progression	Increase duration by 5 min/week → then increase speed → progress to incline or stairs
Precautions	Stop if SpO₂ < 88%, Borg > 7, chest pain, dizziness; use supplemental O₂ if prescribed

ii. Stationary Cycling

Parameter	Detail
Starting Position	Seated on cycle ergometer, seat height adjusted (slight knee flexion at bottom of pedal stroke)
Technique	Steady-state cycling at target intensity; breathe rhythmically; co-ordinate with PLB
Intensity	60-80% peak work rate (from CPET or 6MWT); or Borg 4-6
Duration	20-45 minutes (interval training if unable to sustain)
Sets	1 continuous session OR interval: 3 min work : 2 min rest × 6-8 cycles
Frequency	3-5 sessions/week
Progression	Increase resistance → increase duration → reduce rest intervals
Precautions	Monitor SpO₂ throughout; have oxygen available

B. RESISTANCE / STRENGTH TRAINING

i. Quadriceps - Seated Knee Extension

Parameter	Detail
Starting Position	Sitting on chair / gym bench, feet hanging freely
Technique	Extend knee fully; hold; slowly lower (eccentric control)
Sets/Reps	3 sets × 8-12 repetitions
Intensity	60-70% 1-RM
Hold Time	2 seconds at full extension
Frequency	2-3 sessions/week (allow 48 hours recovery)
Progression	Increase resistance by 5% when patient completes 3×12 with good form
Precautions	Avoid Valsalva manoeuvre; breathe out on exertion; do not increase weight if dyspnoea > Borg 5

ii. Hip Extensors - Sit-to-Stand (Functional Squat)

Parameter	Detail
Starting Position	Seated in chair, feet shoulder-width apart, arms crossed on chest
Technique	Lean forward slightly, push through heels to stand; pause; sit back down slowly
Sets/Reps	3 sets × 10 repetitions
Hold Time	2 seconds at standing position
Frequency	Daily
Progression	Reduce chair height → add weight vest → 30-second sit-to-stand test
Precautions	Breathe out as you stand up; use chair arms initially for safety

iii. Upper Limb - Shoulder Press (Resisted)

Parameter	Detail
Starting Position	Seated, dumbbells at shoulder height, palms forward
Technique	Press dumbbells overhead; lower slowly (4 seconds down)
Sets/Reps	3 sets × 10-12 repetitions
Intensity	50-60% 1-RM (upper limb training uses lower loads due to higher ventilatory demand)
Frequency	2-3 sessions/week
Progression	Increase load → progress to functional reaching tasks
Precautions	Upper limb exercise causes higher ventilatory demand - monitor SpO₂ closely; use PLB throughout

C. INSPIRATORY MUSCLE TRAINING (IMT)

Device: Threshold IMT device (e.g., POWERbreathe, Threshold PEP)

Parameter	Detail
Starting Position	Sitting upright, nose clip on, mouthpiece in
Technique	Breathe in forcefully through device against resistance; breathe out normally
Intensity	30% of MIP (starting) → progress to 50-60% MIP
Sets/Reps	3 sets × 30 breaths
Hold Time	N/A (dynamic)
Frequency	Daily (minimum 5 days/week)
Progression	Increase resistance by 5% every 2 weeks as tolerated
Precautions	Reassess MIP every 4 weeks and adjust load; avoid if uncontrolled hypertension or pneumothorax

Evidence: Cochrane Review (Ammous et al. 2023 - PMID 36606682) - IMT alone improves inspiratory muscle strength and endurance; adding IMT to PR provides additional benefit in selected patients with significant inspiratory muscle weakness.

D. DIAPHRAGMATIC BREATHING

Parameter	Detail
Starting Position	Supine (early) → sitting → standing
Technique	Place one hand on chest, one on abdomen; on inhalation, abdomen should rise while chest remains still; breathe out slowly; ratio: inhale 2 sec, exhale 4 sec
Sets/Reps	3 sets × 10 breaths
Hold Time	Brief pause at end-inspiration (1-2 sec)
Frequency	3-4 times per day; during exercise
Progression	Supine → sitting → standing → walking → during activity
Precautions	Avoid hyperventilation; stop if light-headedness; not effective in all COPD patients due to diaphragm flattening - reassess individual response

E. PURSED LIP BREATHING (PLB)

Parameter	Detail
Starting Position	Any position; sitting preferred
Technique	Inhale slowly through nose (2 counts); purse lips as if blowing out a candle; exhale slowly (4 counts) through pursed lips - twice as long as inspiration
Purpose	Creates back-pressure in airways (intrinsic PEEP) → prevents premature airway collapse → reduces air trapping → reduces dynamic hyperinflation → reduces dyspnoea
Frequency	During all physical activity; during dyspnoeic episodes
Progression	Resting → walking → climbing stairs → ADLs
Precautions	Should not cause dizziness; avoid forceful expiration

✅ 13. ELECTROTHERAPY

A. TENS (Transcutaneous Electrical Nerve Stimulation)

Parameter	Detail
Indication	Chest wall pain; post-thoracic surgery pain management
Electrode placement	Paravertebral (T1-T8 level) or over pain site; NOT directly over anterior chest
Frequency	80-150 Hz (conventional high-frequency TENS)
Pulse width	50-80 µs
Duration	20-30 minutes
Contraindications	Cardiac pacemaker, anterior chest (cardiac conduction interference), over healing incision

B. Neuromuscular Electrical Stimulation (NMES / EMS)

Special relevance in PR - important for exams:

Parameter	Detail
Indication	Severe COPD patients unable to perform exercise (GOLD III-IV); peripheral muscle weakness; ICU patients
Target muscles	Quadriceps, gastrocnemius, tibialis anterior
Frequency	35-50 Hz
Pulse width	200-400 µs
Intensity	Maximum tolerated visible muscle contraction
Session duration	30-60 minutes
Programme duration	6-8 weeks
Evidence	Cochrane evidence supports NMES as effective substitute/supplement to exercise in severe COPD patients with low functional capacity
Contraindications	Cardiac pacemaker, metal implants at treatment site, deep vein thrombosis in limb, epilepsy

C. Transcutaneous Neuromuscular Electrical Stimulation for Diaphragm

Indication	Inspiratory muscle weakness; post-ICU phrenic nerve dysfunction
Contraindications	Cardiac devices, anterior chest placement precautions

⚠️ Note: Electrotherapy is an adjunct in PR, not the primary intervention. Exercise training remains the cornerstone.

✅ 14. FUNCTIONAL AND GAIT TRAINING

Functional Tasks Addressed in PR:

Task	Training Method
Stair climbing	Step training with handrail; progress height; PLB throughout
Rising from floor	Kneel → half kneel → stand; teach fall recovery
Carrying groceries	Functional upper limb loading tasks
Bathing/dressing	Seated bathing technique; pacing; energy conservation
Cooking	Standing tolerance; pacing; sit-stand alternation

Energy Conservation Techniques (4 Ps):

Prioritise - focus on essential tasks
Plan - rest before demanding tasks
Pace - work slowly; avoid rushing
Positioning - sit rather than stand where possible; use PLB

Gait Training:

Problem	Intervention
Reduced gait speed	Treadmill training; target comfortable pace
Poor gait endurance	Interval walking → continuous walking progression
Use of accessory muscles during walking	Gait retraining with arm support (rollator frame reduces dyspnoea)
Impaired balance	Single-leg stance; tandem walking; foam pad standing

Walking Aids:

Rollator walker (wheeled frame) reduces dyspnoea during walking in severe COPD - allows arm support, offloads thoracic accessory muscles
Nordic walking poles - upper limb engagement; improve walking speed and distance

✅ 15. AIRWAY CLEARANCE TECHNIQUES

(Key physiotherapy component, especially for bronchiectasis, CF, COPD with excess secretions)

Active Cycle of Breathing Technique (ACBT) - Most Commonly Used:

Phase	Technique	Purpose
1. Breathing Control	Relaxed, tidal diaphragmatic breathing × 3-5 breaths	Rest + reduce bronchospasm
2. Thoracic Expansion Exercises (TEE)	3-5 deep slow breaths + 3-second hold at end-inspiration	Collateral ventilation; mobilise secretions
3. Forced Expiration Technique (FET) / Huff	Medium or low volume huff (open glottis)	Move secretions centrally
Repeat	× 2-4 cycles until secretions cleared	-

Other Airway Clearance Techniques:

Technique	Description	Indication
Postural Drainage	Gravity-assisted positions for each lung segment	Bronchiectasis, CF
Autogenic Drainage (AD)	Three-level breathing technique (unsticking → collecting → evacuating)	CF, bronchiectasis
PEP Therapy (Positive Expiratory Pressure)	Breathe against resistance (PEP mask/device, 10-20 cmH₂O)	Bronchiectasis
OPEP Devices (Flutter, Acapella, Aerobika)	Oscillating PEP; vibration + pressure	Bronchiectasis, CF
Percussion and Vibration	Manual chest percussion + vibration during expiration	ICU, unable to self-treat
High-frequency chest wall oscillation (HFCWO)	Vest device oscillates chest	CF, severe cases

✅ 16. HOME EXERCISE PROGRAMME (HEP)

After PR programme completion:

Walking - 30 minutes at moderate intensity (Borg 4-5), 5 days/week
Diaphragmatic breathing - 3 sets × 10 breaths, 3 times/day
PLB during all activities - habitual practice
Sit-to-stand exercises - 3 sets × 10 reps, daily
Stair climbing - daily at home, use PLB on ascent
ACBT - morning and evening if sputum production (bronchiectasis/chronic bronchitis)
IMT (if prescribed) - 30 breaths × 2 sessions/day with Threshold device
Energy conservation strategies - apply to all ADLs

Education Included:

Inhaler technique (correct use of MDI/Spacer/DPI)
Action plan for exacerbation (when to seek help)
Smoking cessation resources
Oxygen therapy management at home
Nutrition: high-calorie, high-protein diet (if underweight); calorie restriction (if obese)
Sleep hygiene; positioning for nocturnal dyspnoea (high-side lying)

✅ 17. CRITERIA FOR RETURN TO ACTIVITY / SPORT

Criteria	Target
SpO₂ during exercise	≥ 88% on room air (or stable on supplemental O₂)
Dyspnoea during activity	Borg ≤ 4-5 (moderate)
6MWT improvement	≥ 25 m above baseline (MCID met)
Exacerbation-free	≥ 4 weeks
Medical clearance	Physician review of spirometry, SpO₂, cardiac status
Self-management competency	Patient demonstrates: PLB, ACBT, inhaler technique, exacerbation action plan

Return to recreational sport:

Light sport (golf, swimming): when Borg ≤ 4 during ADLs, SpO₂ stable, no recent exacerbation
Vigorous sport: may be unrealistic in GOLD III-IV; focus on maximising daily function

✅ 18. COMPLICATIONS AND PROGNOSIS

Complications during PR:

Complication	Management
Exercise-induced desaturation (SpO₂ < 88%)	Reduce intensity; add/increase supplemental O₂
Exercise-induced bronchospasm	Pre-exercise bronchodilator; reduce intensity
Musculoskeletal injury (muscle strain)	Modify exercise; relative rest; physiotherapy
Cardiac arrhythmia	Stop exercise; ECG monitoring; refer to cardiologist
Acute exacerbation during PR programme	Defer PR until stable; restart from lower level
Falls (balance-impaired patients)	Exercise in supervised setting; balance training; walking aids

Prognosis / Evidence for PR:

Outcome	Evidence
Exercise capacity (6MWT)	Consistent improvement of 35-80 m (exceeds MCID of 25-33 m)
Dyspnoea	Significant reduction on Borg, MRC, BDI scales
QoL	Clinically meaningful improvement on SGRQ, CRQ, CAT
Anxiety/Depression	Significant reduction on HADS
Hospital re-admissions	Post-exacerbation PR reduces re-admission risk by ~40% (Jenkins et al. 2024, PMID 38350731)
Mortality	Post-exacerbation PR does NOT reduce mortality (current evidence)
Duration of benefit	6-12 months post-completion; maintenance PR extends benefit
Home-based PR	Non-inferior to centre-based PR for selected patients (Uzzaman et al. 2022, PMID 36130789)

✅ 19. HIGH-YIELD VIVA AND UNIVERSITY EXAM POINTS

⭐ Frequently Asked University Questions:

Define pulmonary rehabilitation. What are its goals and components?
What is the ATS/ERS definition of pulmonary rehabilitation?
Describe the vicious cycle of deconditioning in COPD and how PR breaks it.
What are the components of a comprehensive PR programme?
Describe phase-wise physiotherapy management in PR.
What is ACBT? Describe its phases in detail.
What are the outcome measures used in PR? Describe the 6MWT.
What is the exercise prescription for a COPD patient in PR?
What is the role of IMT in pulmonary rehabilitation?
Write a note on energy conservation techniques.

⭐ Clinically Important Points:

PR is not just breathing exercises - it is a multi-component, multidisciplinary programme
Exercise training is the single most important component of PR
The primary mechanism of benefit is peripheral muscle re-conditioning, NOT improvement in lung function (FEV₁ does NOT improve with PR)
Borg scale 4-6 is the target intensity for dyspnoea during PR exercise
MCID for 6MWT = 25-33 metres - this is the minimum meaningful change
PLB is the most practical, evidence-based breathing technique for COPD - it reduces dynamic hyperinflation
Upper limb exercise causes higher ventilatory demand than lower limb at the same work rate - use lower loads and monitor carefully
Post-exacerbation PR should begin within 4 weeks of hospital discharge - shown to reduce re-admissions
Only 3-16% of eligible COPD patients are currently referred for PR - this is a major public health gap
Home-based PR is non-inferior to centre-based PR for selected patients

⭐ Common Examiner Viva Questions:

"How do you prescribe exercise intensity in a COPD patient who cannot perform a CPET?" → Use 6MWT speed; target Borg dyspnoea scale 4-6 (moderate-somewhat severe); use symptom-based titration rather than heart rate
"What is the difference between interval and continuous training in PR?" → Interval: high-intensity work bouts (eg 3 min) alternated with rest (2 min); preferred for severe COPD who cannot sustain continuous; achieves similar physiological gains with less dyspnoea. Continuous: sustained moderate intensity; preferred for mild-moderate COPD
"Why does FEV₁ not improve after PR even though the patient feels better?" → PR improves peripheral muscle efficiency and reduces ventilatory demand for the same workload; the underlying airway obstruction (FEV₁) is not altered - improvement is in skeletal muscle bioenergetics, not lung mechanics
"Name 3 outcome measures you would use to assess a patient before and after PR." → 6MWT (exercise capacity), Modified Borg Scale/MRC Dyspnoea Scale (dyspnoea), SGRQ or CAT (QoL)
"What is the role of NMES in pulmonary rehabilitation?" → NMES allows peripheral muscle strengthening in very severe COPD patients (GOLD III-IV) who cannot perform conventional exercise due to extreme dyspnoea or activity intolerance; evidence supports quadriceps NMES as an effective adjunct/substitute

⭐ Common Mistakes Students Make:

Saying "PR improves FEV₁" - WRONG (FEV₁ is NOT the primary target; exercise capacity and QoL are)
Omitting resistance/strength training - students focus only on aerobic exercise; both are required
Forgetting NMES as a valid PR modality for severe/very severe COPD
Not mentioning the Vicious Cycle of Deconditioning as the central pathophysiological mechanism
Confusing PLB with diaphragmatic breathing - they have different mechanisms and indications
Omitting psychosocial support and patient education as components of PR
Not knowing the MCID for 6MWT (25-33 m) - very commonly asked in viva
Not addressing secretion clearance (ACBT) as part of PR for chronic bronchitis/bronchiectasis patients
Not monitoring SpO₂ during exercise sessions - critical safety requirement

✅ 20. REFERENCES

Murray & Nadel's Textbook of Respiratory Medicine, 2-Volume Set - Chapter on Pulmonary Rehabilitation
Fishman's Pulmonary Diseases and Disorders, 2-Volume Set - Chapters on Exercise and Pulmonary Rehabilitation
Goldman-Cecil Medicine, International Edition - Pulmonary Rehabilitation
Spruit MA, Singh SJ, Garvey C, et al. (ATS/ERS Task Force). An official ATS/ERS statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188:e13-64. - Gold Standard Definition
Uzzaman MN, et al. Effectiveness of home-based pulmonary rehabilitation: systematic review and meta-analysis. Eur Respir Rev. 2022. PMID: 36130789
Ammous O, et al. Inspiratory muscle training, with or without concomitant pulmonary rehabilitation, for COPD. Cochrane Database Syst Rev. 2023. PMID: 36606682
He W, et al. Effects of exercise-based pulmonary rehabilitation on severe/very severe COPD: systematic review and meta-analysis. Ther Adv Respir Dis. 2023. PMID: 36946384
Jenkins AR, et al. Do pulmonary rehabilitation programmes improve outcomes in patients with COPD post-hospital discharge for exacerbation? Thorax. 2024. PMID: 38350731
Rochester CL, et al. ATS/ERS Policy Statement: Enhancing Implementation, Use, and Delivery of Pulmonary Rehabilitation. Am J Respir Crit Care Med. 2015;192:1373-1386.
GOLD (Global Initiative for Chronic Obstructive Lung Disease) Guidelines, 2024 - COPD Management including PR

💡 Exam Tip: In theory - always write the ATS/ERS 2013 definition verbatim for full marks. In viva - explain the vicious cycle diagram confidently. In practical - demonstrate 6MWT protocol, ACBT, and PLB technique correctly. The examiner will almost always ask: "Does PR improve FEV₁?" - the answer is No, and you must explain why.

Create a PowerPoint on PR phases and components for revision

Reading File

Now I have everything I need. Let me create a visually rich, medically themed PowerPoint:

Running Command

ls /home/daytona/workspace/ 2>/dev/null && mkdir -p /home/daytona/workspace/pulmonary-rehab-ppt

Writing File

~/pulmonary-rehab-ppt/create_pr_ppt.js

const pptxgen = require("pptxgenjs");

const pres = new pptxgen();
pres.layout = "LAYOUT_16x9";
pres.author = "BPT/MPT Revision";
pres.title = "Pulmonary Rehabilitation - Phases & Components";

// ─── COLOUR PALETTE ───────────────────────────────────────────────
const C = {
  navyDark:   "0A1628",   // dominant dark background
  navy:       "0D2137",   // slide body bg
  teal:       "0E7C7B",   // accent / section headers
  sky:        "4CB8C4",   // lighter accent
  mint:       "3DCCC7",   // highlight
  white:      "FFFFFF",
  offWhite:   "EAF6F6",
  lightGray:  "D0E8EA",
  gold:       "F5A623",   // emphasis / star
  coral:      "E8543A",   // warning / important
  green:      "2ECC71",   // positive / check
  textLight:  "B8D8DC",
};

// ─── HELPER: Full-bleed dark background ───────────────────────────
function darkBg(slide) {
  slide.addShape(pres.shapes.RECTANGLE, {
    x: 0, y: 0, w: 10, h: 5.625,
    fill: { color: C.navyDark }, line: { type: "none" }
  });
}

// ─── HELPER: Accent bar top ───────────────────────────────────────
function accentBar(slide, color = C.teal) {
  slide.addShape(pres.shapes.RECTANGLE, {
    x: 0, y: 0, w: 10, h: 0.08,
    fill: { color }, line: { type: "none" }
  });
}

// ─── HELPER: Section label pill ───────────────────────────────────
function pill(slide, text, x, y, w = 2.4, h = 0.32, bg = C.teal) {
  slide.addShape(pres.shapes.ROUNDED_RECTANGLE, {
    x, y, w, h, rectRadius: 0.15,
    fill: { color: bg }, line: { type: "none" }
  });
  slide.addText(text, {
    x, y, w, h,
    fontSize: 9, bold: true, color: C.white,
    align: "center", valign: "middle", margin: 0
  });
}

// ─── HELPER: Card box ─────────────────────────────────────────────
function card(slide, x, y, w, h, fillColor = C.navy, border = C.teal) {
  slide.addShape(pres.shapes.RECTANGLE, {
    x, y, w, h,
    fill: { color: fillColor },
    line: { color: border, width: 1 },
    shadow: { type: "outer", color: "000000", blur: 8, offset: 2, angle: 135, opacity: 0.25 }
  });
}

// ─── HELPER: slide title label ────────────────────────────────────
function slideTitle(slide, text) {
  slide.addShape(pres.shapes.RECTANGLE, {
    x: 0, y: 0.08, w: 10, h: 0.58,
    fill: { color: C.navy }, line: { type: "none" }
  });
  slide.addText(text, {
    x: 0.4, y: 0.08, w: 9.2, h: 0.58,
    fontSize: 18, bold: true, color: C.mint,
    valign: "middle", margin: 0, charSpacing: 1
  });
}

// ─── HELPER: numbered circle ──────────────────────────────────────
function numCircle(slide, num, x, y, r = 0.3, bg = C.teal) {
  slide.addShape(pres.shapes.ELLIPSE, {
    x: x - r / 2, y: y - r / 2, w: r, h: r,
    fill: { color: bg }, line: { type: "none" }
  });
  slide.addText(String(num), {
    x: x - r / 2, y: y - r / 2, w: r, h: r,
    fontSize: 9, bold: true, color: C.white,
    align: "center", valign: "middle", margin: 0
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 1 – TITLE SLIDE
// ═══════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkBg(s);

  // Decorative teal bar left
  s.addShape(pres.shapes.RECTANGLE, {
    x: 0, y: 0, w: 0.12, h: 5.625,
    fill: { color: C.teal }, line: { type: "none" }
  });
  // Decorative right-bottom corner block
  s.addShape(pres.shapes.RECTANGLE, {
    x: 7.5, y: 4.2, w: 2.5, h: 1.425,
    fill: { color: C.teal }, line: { type: "none" },
    transparency: 80
  });

  // Lung icon (text substitute)
  s.addText("🫁", { x: 0.5, y: 0.7, w: 1.4, h: 1.4, fontSize: 56, align: "center" });

  // Main title
  s.addText("PULMONARY", {
    x: 1.8, y: 0.7, w: 7.8, h: 0.85,
    fontSize: 46, bold: true, color: C.white,
    charSpacing: 4, valign: "middle"
  });
  s.addText("REHABILITATION", {
    x: 1.8, y: 1.5, w: 7.8, h: 0.85,
    fontSize: 46, bold: true, color: C.mint,
    charSpacing: 4, valign: "middle"
  });

  // Subtitle
  s.addShape(pres.shapes.RECTANGLE, {
    x: 1.8, y: 2.5, w: 6.5, h: 0.04,
    fill: { color: C.gold }, line: { type: "none" }
  });
  s.addText("Phases • Components • Exercise Prescription • Outcome Measures", {
    x: 1.8, y: 2.62, w: 7.5, h: 0.4,
    fontSize: 13, color: C.lightGray, italic: true
  });

  // Tags
  const tags = ["BPT / MPT Final Year", "Evidence-Based", "ATS/ERS 2013"];
  tags.forEach((t, i) => pill(s, t, 1.8 + i * 2.6, 3.15, 2.4, 0.32, i === 0 ? C.teal : i === 1 ? C.coral : C.sky));

  // Footer
  s.addText("Revision Deck  |  Physiotherapy  |  Respiratory System", {
    x: 0.2, y: 5.2, w: 9.6, h: 0.3,
    fontSize: 8, color: C.textLight, align: "center"
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 2 – DEFINITION + INDICATIONS
// ═══════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkBg(s);
  accentBar(s, C.mint);
  slideTitle(s, "Definition & Indications");

  // Definition card
  card(s, 0.3, 0.8, 9.4, 1.5, "122638", C.mint);
  s.addText("ATS / ERS OFFICIAL DEFINITION  (2013)", {
    x: 0.55, y: 0.86, w: 8.8, h: 0.3,
    fontSize: 8.5, bold: true, color: C.mint, charSpacing: 1
  });
  s.addText(
    '"A comprehensive intervention based on thorough patient assessment, followed by patient-tailored therapies including exercise training, education, and behaviour change — designed to improve the physical and psychological condition of people with chronic respiratory disease."',
    {
      x: 0.55, y: 1.18, w: 8.8, h: 1.0,
      fontSize: 10.5, color: C.white, italic: true
    }
  );

  // Indications header
  s.addText("INDICATIONS", {
    x: 0.3, y: 2.5, w: 3, h: 0.3,
    fontSize: 9, bold: true, color: C.gold, charSpacing: 2
  });

  const indications = [
    ["COPD", "MRC Grade ≥ 2 — Primary indication"],
    ["ILD / IPF", "Exercise capacity + QoL improvement"],
    ["Bronchiectasis", "Cystic & non-cystic fibrosis types"],
    ["Asthma", "Uncontrolled / exercise-induced"],
    ["Pulm. Hypertension", "Supervised exercise programmes"],
    ["Lung Transplant", "Pre- and post-transplantation"],
    ["Post-COVID", "Long COVID respiratory sequelae"],
    ["Lung Cancer", "Pre / post-surgical rehabilitation"],
  ];

  indications.forEach(([title, sub], i) => {
    const col = i < 4 ? 0 : 1;
    const row = i < 4 ? i : i - 4;
    const x = 0.3 + col * 4.8;
    const y = 2.9 + row * 0.58;
    card(s, x, y, 4.5, 0.48, "122638", col === 0 ? C.teal : C.sky);
    s.addShape(pres.shapes.ELLIPSE, {
      x: x + 0.08, y: y + 0.09, w: 0.3, h: 0.3,
      fill: { color: col === 0 ? C.teal : C.sky }, line: { type: "none" }
    });
    s.addText("✓", { x: x + 0.08, y: y + 0.09, w: 0.3, h: 0.3, fontSize: 9, color: C.white, align: "center", valign: "middle", margin: 0 });
    s.addText(title, { x: x + 0.45, y: y + 0.04, w: 3.9, h: 0.22, fontSize: 9.5, bold: true, color: C.white, valign: "middle", margin: 0 });
    s.addText(sub, { x: x + 0.45, y: y + 0.25, w: 3.9, h: 0.2, fontSize: 8, color: C.textLight, valign: "middle", margin: 0 });
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 3 – THE VICIOUS CYCLE (Deconditioning)
// ═══════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkBg(s);
  accentBar(s, C.coral);
  slideTitle(s, "Pathophysiology: Vicious Cycle of Deconditioning");

  const steps = [
    { label: "Chronic Lung Disease", sub: "COPD, ILD, Bronchiectasis…", x: 4.0, y: 0.85, color: C.coral },
    { label: "Dyspnoea on Exertion", sub: "Increased WOB, air trapping", x: 7.2, y: 1.8, color: C.gold },
    { label: "Activity Avoidance", sub: "Physical inactivity, sedentary", x: 6.8, y: 3.3, color: C.sky },
    { label: "Muscle Deconditioning", sub: "Type I → Type II fibre shift", x: 3.2, y: 4.3, color: C.teal },
    { label: "↑ Ventilatory Demand", sub: "Early lactic acidosis, fatigue", x: 0.5, y: 3.3, color: C.mint },
    { label: "Exercise Intolerance", sub: "↓ VO₂max, ↓ 6MWT distance", x: 0.2, y: 1.8, color: C.gold },
  ];

  steps.forEach(({ label, sub, x, y, color }) => {
    card(s, x, y, 2.7, 0.75, "122638", color);
    s.addText(label, { x: x + 0.1, y: y + 0.04, w: 2.5, h: 0.35, fontSize: 9, bold: true, color: C.white, valign: "middle", margin: 0 });
    s.addText(sub, { x: x + 0.1, y: y + 0.38, w: 2.5, h: 0.28, fontSize: 7.5, color: C.textLight, valign: "middle", margin: 0 });
  });

  // Arrows (simplified curved arrows as text)
  const arrows = [
    { x: 6.5, y: 1.3, t: "▶" },
    { x: 7.8, y: 2.7, t: "▼" },
    { x: 5.6, y: 4.15, t: "◀" },
    { x: 2.2, y: 4.15, t: "◀" },
    { x: 0.2, y: 2.7, t: "▲" },
    { x: 1.5, y: 1.3, t: "▶" },
  ];
  arrows.forEach(({ x, y, t }) => {
    s.addText(t, { x, y, w: 0.4, h: 0.3, fontSize: 14, color: C.teal, align: "center" });
  });

  // Centre label
  s.addShape(pres.shapes.ELLIPSE, {
    x: 3.4, y: 2.1, w: 3.2, h: 1.5,
    fill: { color: "1A3A4A" },
    line: { color: C.coral, width: 2 }
  });
  s.addText("PR BREAKS\nTHIS CYCLE", {
    x: 3.4, y: 2.1, w: 3.2, h: 1.5,
    fontSize: 13, bold: true, color: C.coral,
    align: "center", valign: "middle"
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 4 – COMPONENTS OF PR (Wheel)
// ═══════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkBg(s);
  accentBar(s, C.teal);
  slideTitle(s, "Components of Pulmonary Rehabilitation");

  // Centre circle
  s.addShape(pres.shapes.ELLIPSE, {
    x: 3.8, y: 1.6, w: 2.4, h: 2.4,
    fill: { color: C.teal }, line: { type: "none" }
  });
  s.addText("PULMONARY\nREHAB", {
    x: 3.8, y: 1.6, w: 2.4, h: 2.4,
    fontSize: 13, bold: true, color: C.white,
    align: "center", valign: "middle"
  });

  const components = [
    { num: 1, title: "Exercise Training", detail: "Aerobic + Resistance + IMT", x: 0.2, y: 0.85, color: C.coral, arrow: "→" },
    { num: 2, title: "Patient Education", detail: "Inhaler technique, self-management", x: 6.3, y: 0.85, color: C.sky, arrow: "←" },
    { num: 3, title: "Breathing Re-education", detail: "PLB, Diaphragmatic breathing", x: 0.2, y: 2.4, color: C.mint, arrow: "→" },
    { num: 4, title: "Airway Clearance", detail: "ACBT, PEP, Postural drainage", x: 6.3, y: 2.4, color: C.gold, arrow: "←" },
    { num: 5, title: "Psychosocial Support", detail: "Anxiety, depression, CBT", x: 0.2, y: 4.0, color: C.teal, arrow: "→" },
    { num: 6, title: "Nutritional Counselling", detail: "BMI, FFMI, high-protein diet", x: 6.3, y: 4.0, color: C.coral, arrow: "←" },
  ];

  components.forEach(({ num, title, detail, x, y, color, arrow }) => {
    card(s, x, y, 3.3, 0.9, "122638", color);
    s.addShape(pres.shapes.ELLIPSE, {
      x: x + 0.1, y: y + 0.28, w: 0.3, h: 0.3,
      fill: { color }, line: { type: "none" }
    });
    s.addText(String(num), { x: x + 0.1, y: y + 0.28, w: 0.3, h: 0.3, fontSize: 9, bold: true, color: C.white, align: "center", valign: "middle", margin: 0 });
    s.addText(title, { x: x + 0.5, y: y + 0.06, w: 2.7, h: 0.33, fontSize: 10, bold: true, color: C.white, valign: "middle", margin: 0 });
    s.addText(detail, { x: x + 0.5, y: y + 0.5, w: 2.7, h: 0.28, fontSize: 8, color: C.textLight, valign: "middle", margin: 0 });
    // Connector arrow
    const arrowX = arrow === "→" ? x + 3.3 : x - 0.35;
    s.addText(arrow, { x: arrowX, y: y + 0.3, w: 0.35, h: 0.3, fontSize: 12, color: color, align: "center" });
  });

  // Star label at bottom
  s.addText("⭐ Exercise Training is the MOST IMPORTANT component", {
    x: 0.2, y: 5.22, w: 9.6, h: 0.28,
    fontSize: 9, color: C.gold, bold: true, align: "center"
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 5 – PHASES OF PR
// ═══════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkBg(s);
  accentBar(s, C.sky);
  slideTitle(s, "Phases of Pulmonary Rehabilitation");

  const phases = [
    {
      num: "I",
      title: "Acute / Inpatient",
      time: "Hospital / ICU",
      color: C.coral,
      points: [
        "Positioning: high side-lying / upright",
        "Diaphragmatic breathing + PLB",
        "Airway clearance (ACBT)",
        "Passive to active limb exercises",
        "Early mobilisation (sit → stand → walk)",
        "DVT prevention, SpO₂ monitoring",
      ]
    },
    {
      num: "II",
      title: "Supervised Outpatient",
      time: "6–12 Weeks (CORE Phase)",
      color: C.teal,
      points: [
        "2–3 supervised sessions/week",
        "Aerobic training: walking / cycling",
        "Resistance training: quadriceps, UL",
        "IMT: 30% → 60% MIP",
        "Education, nutrition, psychosocial",
        "Pre/post outcome measures: 6MWT, CAT",
      ]
    },
    {
      num: "III",
      title: "Community / Maintenance",
      time: "Post-Programme (Long-term)",
      color: C.sky,
      points: [
        "Community exercise classes",
        "Home exercise programme (HEP)",
        "Walking programmes: 30 min × 5/week",
        "Tele-rehabilitation / remote review",
        "Annual reassessment",
        "Prevent deconditioning relapse",
      ]
    },
  ];

  phases.forEach(({ num, title, time, color, points }, i) => {
    const x = 0.15 + i * 3.28;
    // Phase header
    s.addShape(pres.shapes.RECTANGLE, {
      x, y: 0.75, w: 3.1, h: 0.9,
      fill: { color }, line: { type: "none" }
    });
    s.addText(`PHASE ${num}`, { x, y: 0.76, w: 3.1, h: 0.38, fontSize: 18, bold: true, color: C.navyDark, align: "center", valign: "middle", charSpacing: 2, margin: 0 });
    s.addText(title, { x, y: 1.12, w: 3.1, h: 0.28, fontSize: 9, bold: true, color: C.navyDark, align: "center", valign: "middle", margin: 0 });

    // Time badge
    s.addShape(pres.shapes.RECTANGLE, {
      x, y: 1.65, w: 3.1, h: 0.28,
      fill: { color: "1A3A4A" }, line: { type: "none" }
    });
    s.addText("⏱  " + time, { x, y: 1.65, w: 3.1, h: 0.28, fontSize: 8, color, align: "center", valign: "middle", margin: 0 });

    // Points
    card(s, x, 1.93, 3.1, 3.42, "122638", color);
    const bulletItems = points.map((p, j) => ({
      text: p,
      options: { bullet: { code: "25B8", color }, color: j === 0 ? C.white : C.textLight, fontSize: 8.5, breakLine: j < points.length - 1 }
    }));
    s.addText(bulletItems, { x: x + 0.15, y: 2.05, w: 2.8, h: 3.1 });
  });

  // Progression arrow
  s.addText("─────────────────── PROGRESSION ───────────────────", {
    x: 0.15, y: 5.23, w: 9.6, h: 0.28,
    fontSize: 8, color: C.lightGray, align: "center"
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 6 – EXERCISE PRESCRIPTION
// ═══════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkBg(s);
  accentBar(s, C.gold);
  slideTitle(s, "Exercise Prescription in PR");

  // Left: Aerobic
  card(s, 0.2, 0.76, 4.55, 2.1, "0D2137", C.coral);
  s.addShape(pres.shapes.RECTANGLE, { x: 0.2, y: 0.76, w: 4.55, h: 0.38, fill: { color: C.coral }, line: { type: "none" } });
  s.addText("🏃  AEROBIC TRAINING", { x: 0.3, y: 0.76, w: 4.3, h: 0.38, fontSize: 11, bold: true, color: C.navyDark, valign: "middle", margin: 0 });
  const aerobic = [
    ["Mode", "Walking, Cycling, Treadmill"],
    ["Intensity", "Borg 4–6/10  OR  60–80% peak HR"],
    ["Duration", "Start 10–15 min → 30–45 min"],
    ["Frequency", "3–5 sessions / week"],
    ["Type", "Continuous OR Interval (3:2 ratio)"],
  ];
  aerobic.forEach(([k, v], i) => {
    s.addText(k + ":", { x: 0.3, y: 1.22 + i * 0.32, w: 1.1, h: 0.28, fontSize: 8.5, bold: true, color: C.coral, valign: "middle", margin: 0 });
    s.addText(v, { x: 1.45, y: 1.22 + i * 0.32, w: 3.1, h: 0.28, fontSize: 8.5, color: C.white, valign: "middle", margin: 0 });
  });

  // Right: Resistance
  card(s, 5.25, 0.76, 4.55, 2.1, "0D2137", C.teal);
  s.addShape(pres.shapes.RECTANGLE, { x: 5.25, y: 0.76, w: 4.55, h: 0.38, fill: { color: C.teal }, line: { type: "none" } });
  s.addText("💪  RESISTANCE TRAINING", { x: 5.35, y: 0.76, w: 4.3, h: 0.38, fontSize: 11, bold: true, color: C.white, valign: "middle", margin: 0 });
  const resist = [
    ["Muscles", "Quadriceps (primary), UL, Core"],
    ["Intensity", "60–70% 1-RM"],
    ["Sets / Reps", "3 sets × 8–12 repetitions"],
    ["Frequency", "2–3 sessions / week"],
    ["Progression", "Increase load when 3×12 achieved"],
  ];
  resist.forEach(([k, v], i) => {
    s.addText(k + ":", { x: 5.35, y: 1.22 + i * 0.32, w: 1.3, h: 0.28, fontSize: 8.5, bold: true, color: C.mint, valign: "middle", margin: 0 });
    s.addText(v, { x: 6.7, y: 1.22 + i * 0.32, w: 2.9, h: 0.28, fontSize: 8.5, color: C.white, valign: "middle", margin: 0 });
  });

  // Bottom left: IMT
  card(s, 0.2, 3.0, 4.55, 1.85, "0D2137", C.sky);
  s.addShape(pres.shapes.RECTANGLE, { x: 0.2, y: 3.0, w: 4.55, h: 0.38, fill: { color: C.sky }, line: { type: "none" } });
  s.addText("🌬  INSPIRATORY MUSCLE TRAINING", { x: 0.3, y: 3.0, w: 4.3, h: 0.38, fontSize: 10, bold: true, color: C.navyDark, valign: "middle", margin: 0 });
  const imt = [
    ["Device", "Threshold IMT (POWERbreathe)"],
    ["Start", "30% MIP → Progress 50–60% MIP"],
    ["Protocol", "3 sets × 30 breaths / session"],
    ["Frequency", "Daily (min. 5 days/week)"],
  ];
  imt.forEach(([k, v], i) => {
    s.addText(k + ":", { x: 0.3, y: 3.46 + i * 0.32, w: 1.0, h: 0.28, fontSize: 8.5, bold: true, color: C.sky, valign: "middle", margin: 0 });
    s.addText(v, { x: 1.35, y: 3.46 + i * 0.32, w: 3.2, h: 0.28, fontSize: 8.5, color: C.white, valign: "middle", margin: 0 });
  });

  // Bottom right: Precautions
  card(s, 5.25, 3.0, 4.55, 1.85, "1A1018", C.coral);
  s.addShape(pres.shapes.RECTANGLE, { x: 5.25, y: 3.0, w: 4.55, h: 0.38, fill: { color: C.coral }, line: { type: "none" } });
  s.addText("⚠  MONITORING & STOP CRITERIA", { x: 5.35, y: 3.0, w: 4.3, h: 0.38, fontSize: 10, bold: true, color: C.white, valign: "middle", margin: 0 });
  const stops = ["SpO₂ < 88%  →  Stop / Add O₂", "Borg dyspnoea > 7/10", "Chest pain / Angina", "Dizziness / Syncope", "Uncontrolled HR / arrhythmia"];
  stops.forEach((t, i) => {
    s.addText("■  " + t, { x: 5.4, y: 3.46 + i * 0.27, w: 4.2, h: 0.25, fontSize: 8.5, color: i === 0 ? C.gold : C.white });
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 7 – BREATHING TECHNIQUES
// ═══════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkBg(s);
  accentBar(s, C.mint);
  slideTitle(s, "Breathing Techniques in PR");

  // PLB card
  card(s, 0.2, 0.78, 4.5, 2.15, "0D2137", C.mint);
  s.addShape(pres.shapes.RECTANGLE, { x: 0.2, y: 0.78, w: 4.5, h: 0.42, fill: { color: C.mint }, line: { type: "none" } });
  s.addText("PURSED LIP BREATHING (PLB)", { x: 0.3, y: 0.78, w: 4.2, h: 0.42, fontSize: 10.5, bold: true, color: C.navyDark, valign: "middle", margin: 0 });
  s.addText([
    { text: "Step 1: ", options: { bold: true, color: C.mint } },
    { text: "Inhale slowly through nose — 2 counts\n", options: { color: C.white } },
    { text: "Step 2: ", options: { bold: true, color: C.mint } },
    { text: "Purse lips (as if blowing a candle)\n", options: { color: C.white } },
    { text: "Step 3: ", options: { bold: true, color: C.mint } },
    { text: "Exhale SLOWLY — 4 counts (2× inspiration)\n\n", options: { color: C.white } },
    { text: "Mechanism: ", options: { bold: true, color: C.gold } },
    { text: "Creates intrinsic PEEP → prevents premature airway collapse → reduces air trapping → ↓ dynamic hyperinflation", options: { color: C.textLight } },
  ], { x: 0.3, y: 1.28, w: 4.2, h: 1.55, fontSize: 8.5 });

  // Diaphragmatic breathing card
  card(s, 5.3, 0.78, 4.5, 2.15, "0D2137", C.sky);
  s.addShape(pres.shapes.RECTANGLE, { x: 5.3, y: 0.78, w: 4.5, h: 0.42, fill: { color: C.sky }, line: { type: "none" } });
  s.addText("DIAPHRAGMATIC BREATHING", { x: 5.4, y: 0.78, w: 4.2, h: 0.42, fontSize: 10.5, bold: true, color: C.navyDark, valign: "middle", margin: 0 });
  s.addText([
    { text: "Position: ", options: { bold: true, color: C.sky } },
    { text: "Supine → Sitting → Standing → Walking\n", options: { color: C.white } },
    { text: "Technique: ", options: { bold: true, color: C.sky } },
    { text: "One hand on chest, one on abdomen. On inhale, ABDOMEN rises while chest stays still\n", options: { color: C.white } },
    { text: "Ratio: ", options: { bold: true, color: C.gold } },
    { text: "Inhale 2 sec : Exhale 4 sec\n", options: { color: C.white } },
    { text: "Dose: ", options: { bold: true, color: C.sky } },
    { text: "3 sets × 10 breaths, 3–4×/day", options: { color: C.textLight } },
  ], { x: 5.4, y: 1.28, w: 4.2, h: 1.55, fontSize: 8.5 });

  // ACBT
  card(s, 0.2, 3.05, 9.6, 2.35, "0D2137", C.teal);
  s.addShape(pres.shapes.RECTANGLE, { x: 0.2, y: 3.05, w: 9.6, h: 0.42, fill: { color: C.teal }, line: { type: "none" } });
  s.addText("ACTIVE CYCLE OF BREATHING TECHNIQUE (ACBT)", { x: 0.35, y: 3.05, w: 9.3, h: 0.42, fontSize: 11, bold: true, color: C.white, valign: "middle", margin: 0 });

  const acbtSteps = [
    { num: 1, title: "Breathing Control", detail: "Relaxed tidal diaphragmatic breathing × 3–5 breaths", purpose: "Rest + ↓ bronchospasm", color: C.coral },
    { num: 2, title: "Thoracic Expansion (TEE)", detail: "3–5 deep slow breaths + 3-sec hold at end-inspiration", purpose: "Collateral ventilation", color: C.gold },
    { num: 3, title: "Forced Expiration / Huff", detail: "Medium OR low volume huff (open glottis); move secretions centrally", purpose: "Clear secretions", color: C.mint },
  ];

  acbtSteps.forEach(({ num, title, detail, purpose, color }, i) => {
    const x = 0.35 + i * 3.22;
    s.addShape(pres.shapes.ELLIPSE, { x: x, y: 3.6, w: 0.4, h: 0.4, fill: { color }, line: { type: "none" } });
    s.addText(String(num), { x, y: 3.6, w: 0.4, h: 0.4, fontSize: 11, bold: true, color: C.navyDark, align: "center", valign: "middle", margin: 0 });
    s.addText(title, { x: x + 0.5, y: 3.6, w: 2.5, h: 0.38, fontSize: 9.5, bold: true, color, valign: "middle", margin: 0 });
    s.addText(detail, { x: x, y: 4.08, w: 2.95, h: 0.5, fontSize: 8, color: C.white });
    s.addText("→ " + purpose, { x: x, y: 4.62, w: 2.95, h: 0.28, fontSize: 8, color: C.textLight, italic: true });
    if (i < 2) s.addText("⟳", { x: x + 3.0, y: 3.9, w: 0.3, h: 0.4, fontSize: 16, color: C.teal, align: "center" });
  });
  s.addText("Repeat 2–4 cycles until secretions cleared", { x: 0.35, y: 5.22, w: 9.3, h: 0.28, fontSize: 8.5, color: C.gold, bold: true, align: "center" });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 8 – OUTCOME MEASURES
// ═══════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkBg(s);
  accentBar(s, C.gold);
  slideTitle(s, "Outcome Measures in Pulmonary Rehabilitation");

  const outcomes = [
    {
      domain: "Exercise Capacity",
      icon: "🏃",
      color: C.teal,
      tools: [
        ["6MWT", "6-Minute Walk Test", "MCID = 25–33 m"],
        ["ISWT", "Incremental Shuttle Walk Test", "Standardised protocol"],
        ["ESWT", "Endurance Shuttle Walk Test", "Responsive to PR"],
        ["CPET", "Cardiopulmonary Exercise Test", "VO₂max, VT, WR"],
      ]
    },
    {
      domain: "Dyspnoea",
      icon: "💨",
      color: C.coral,
      tools: [
        ["Borg", "Modified Borg Scale (0–10)", "Target: 4–6 during exercise"],
        ["MRC", "MRC Dyspnoea Scale (1–5)", "Grading functional limitation"],
        ["BDI/TDI", "Baseline/Transitional Dyspnoea Index", "Pre/post PR change"],
        ["USDQ", "Univ. San Diego Shortness of Breath", "ADL-based dyspnoea"],
      ]
    },
    {
      domain: "Quality of Life",
      icon: "⭐",
      color: C.sky,
      tools: [
        ["CAT", "COPD Assessment Test", "MCID = 2 points"],
        ["SGRQ", "St. George Respiratory Q.", "MCID = 4 points"],
        ["CRQ", "Chronic Respiratory Questionnaire", "4 domains"],
        ["HADS", "Hospital Anxiety & Depression Scale", "Psych screening"],
      ]
    },
  ];

  outcomes.forEach(({ domain, icon, color, tools }, i) => {
    const x = 0.2 + i * 3.3;
    s.addShape(pres.shapes.RECTANGLE, { x, y: 0.75, w: 3.1, h: 0.5, fill: { color }, line: { type: "none" } });
    s.addText(icon + "  " + domain, { x, y: 0.75, w: 3.1, h: 0.5, fontSize: 11, bold: true, color: C.navyDark, align: "center", valign: "middle", margin: 0 });

    tools.forEach(([code, name, note], j) => {
      card(s, x, 1.38 + j * 0.97, 3.1, 0.85, "122638", color);
      s.addText(code, { x: x + 0.1, y: 1.42 + j * 0.97, w: 0.8, h: 0.33, fontSize: 13, bold: true, color, valign: "middle", margin: 0 });
      s.addText(name, { x: x + 0.95, y: 1.42 + j * 0.97, w: 2.0, h: 0.33, fontSize: 8, bold: true, color: C.white, valign: "middle", margin: 0 });
      s.addText(note, { x: x + 0.95, y: 1.78 + j * 0.97, w: 2.0, h: 0.28, fontSize: 7.5, color: C.textLight, valign: "middle", margin: 0 });
    });
  });

  s.addText("⭐ 6MWT MCID = 25–33 m  |  CAT MCID = 2 pts  |  SGRQ MCID = 4 pts — KNOW THESE FOR VIVA", {
    x: 0.2, y: 5.22, w: 9.6, h: 0.28,
    fontSize: 8.5, color: C.gold, bold: true, align: "center"
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 9 – KEY EVIDENCE + EXAM POINTS
// ═══════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkBg(s);
  accentBar(s, C.coral);
  slideTitle(s, "Key Evidence & High-Yield Exam Points");

  // Evidence column
  card(s, 0.2, 0.78, 4.5, 4.55, "0D2137", C.sky);
  s.addShape(pres.shapes.RECTANGLE, { x: 0.2, y: 0.78, w: 4.5, h: 0.42, fill: { color: C.sky }, line: { type: "none" } });
  s.addText("📚  CURRENT EVIDENCE (2022–2024)", { x: 0.3, y: 0.78, w: 4.2, h: 0.42, fontSize: 10, bold: true, color: C.navyDark, valign: "middle", margin: 0 });

  const evidence = [
    ["Home PR", "Non-inferior to centre-based PR for selected patients\n(Uzzaman et al. 2022 — Eur Respir Rev, Systematic Review)"],
    ["IMT", "IMT + PR provides additional benefit in patients with\nmuscle weakness (Ammous et al. 2023 — Cochrane Review)"],
    ["Severe COPD", "Exercise-based PR improves exercise capacity & QoL\nin GOLD III–IV (He et al. 2023 — Meta-Analysis)"],
    ["Post-Exacerbation", "PR post-discharge reduces re-admissions by ~40%\n(Jenkins et al. 2024 — Thorax, Meta-Analysis)"],
  ];
  evidence.forEach(([title, text], i) => {
    card(s, 0.3, 1.3 + i * 0.97, 4.2, 0.85, "122638", C.sky);
    s.addText("▶  " + title, { x: 0.4, y: 1.35 + i * 0.97, w: 3.9, h: 0.28, fontSize: 9, bold: true, color: C.sky, valign: "middle", margin: 0 });
    s.addText(text, { x: 0.4, y: 1.65 + i * 0.97, w: 3.9, h: 0.44, fontSize: 7.8, color: C.textLight });
  });

  // Exam points column
  card(s, 5.1, 0.78, 4.65, 4.55, "0D2137", C.gold);
  s.addShape(pres.shapes.RECTANGLE, { x: 5.1, y: 0.78, w: 4.65, h: 0.42, fill: { color: C.gold }, line: { type: "none" } });
  s.addText("⭐  HIGH-YIELD VIVA POINTS", { x: 5.2, y: 0.78, w: 4.4, h: 0.42, fontSize: 10, bold: true, color: C.navyDark, valign: "middle", margin: 0 });

  const vivaPoints = [
    ["❌", "PR does NOT improve FEV₁", "Exercise capacity & QoL are primary targets"],
    ["✅", "Borg 4–6 = Target during exercise", "Moderate to somewhat severe dyspnoea"],
    ["✅", "6MWT MCID = 25–33 metres", "Minimum meaningful change after PR"],
    ["❌", "NO traction in Type IIa", "(Cervical — different topic but common mix-up)"],
    ["✅", "NMES valid for GOLD III–IV", "For those unable to perform conventional exercise"],
    ["✅", "Post-exac PR within 4 wks", "Reduces re-admissions; NOT mortality"],
    ["✅", "ATS/ERS 2013 definition", "Know verbatim for theory exam full marks"],
    ["✅", "Peripheral muscle re-conditioning", "PRIMARY mechanism of PR benefit"],
  ];
  vivaPoints.forEach(([icon, point, note], i) => {
    s.addText(icon + "  " + point, { x: 5.2, y: 1.3 + i * 0.48, w: 4.3, h: 0.26, fontSize: 8.5, bold: true, color: icon === "❌" ? C.coral : C.gold, valign: "middle", margin: 0 });
    s.addText("  → " + note, { x: 5.2, y: 1.56 + i * 0.48, w: 4.3, h: 0.2, fontSize: 7.5, color: C.textLight, valign: "middle", margin: 0 });
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 10 – SUMMARY QUICK REFERENCE
// ═══════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkBg(s);
  accentBar(s, C.teal);

  // Title bar
  s.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0.08, w: 10, h: 0.6, fill: { color: C.teal }, line: { type: "none" } });
  s.addText("QUICK REVISION SUMMARY — PULMONARY REHABILITATION", {
    x: 0.3, y: 0.08, w: 9.4, h: 0.6,
    fontSize: 14, bold: true, color: C.navyDark,
    valign: "middle", charSpacing: 1, margin: 0
  });

  const rows = [
    ["Definition", "ATS/ERS 2013: Comprehensive intervention — exercise, education, behaviour change"],
    ["Primary indication", "COPD (MRC Grade ≥ 2)"],
    ["Most important component", "Exercise Training (aerobic + resistance + IMT)"],
    ["Aerobic intensity", "Borg 4–6/10 or 60–80% peak HR; 3–5 × /week; 20–45 min"],
    ["Resistance training", "60–70% 1-RM; 3 × 8–12 reps; 2–3 × /week; Quadriceps = primary"],
    ["IMT", "Threshold device; Start 30% MIP → 60% MIP; 3 × 30 breaths/day"],
    ["Key breathing technique", "PLB = intrinsic PEEP → ↓ air trapping; Diaphragmatic breathing"],
    ["Airway clearance", "ACBT = Breathing Control → TEE → Huff (× 2–4 cycles)"],
    ["Phases", "Phase I: Inpatient | Phase II: 6–12 wk supervised | Phase III: Maintenance"],
    ["Outcome: Exercise", "6MWT (MCID 25–33 m); ISWT; CPET"],
    ["Outcome: Dyspnoea", "Modified Borg; MRC (1–5); BDI"],
    ["Outcome: QoL", "CAT (MCID 2); SGRQ (MCID 4); CRQ"],
    ["FEV₁ after PR?", "Does NOT improve — mechanism is peripheral muscle efficiency"],
    ["Post-exac PR", "Start within 4 weeks; reduces re-admissions by ~40%"],
    ["NMES", "Valid for GOLD III–IV unable to exercise; 35–50 Hz, 30–60 min, 6–8 weeks"],
  ];

  rows.forEach(([label, value], i) => {
    const y = 0.78 + i * 0.315;
    const bgColor = i % 2 === 0 ? "0D2137" : "112030";
    s.addShape(pres.shapes.RECTANGLE, { x: 0.2, y, w: 9.6, h: 0.31, fill: { color: bgColor }, line: { type: "none" } });
    s.addText(label, { x: 0.25, y, w: 2.6, h: 0.31, fontSize: 8, bold: true, color: C.mint, valign: "middle", margin: 0 });
    s.addText(value, { x: 2.9, y, w: 6.8, h: 0.31, fontSize: 8, color: C.white, valign: "middle", margin: 0 });
  });

  s.addText("BPT / MPT Final Year Revision  •  Physiotherapy  •  Pulmonary Rehabilitation  •  ATS/ERS Guidelines", {
    x: 0.2, y: 5.32, w: 9.6, h: 0.22,
    fontSize: 7, color: C.textLight, align: "center"
  });
}

// ─── WRITE FILE ───────────────────────────────────────────────────
pres.writeFile({ fileName: "/home/daytona/workspace/pulmonary-rehab-ppt/Pulmonary_Rehabilitation_PR.pptx" })
  .then(() => console.log("✅ PPTX created successfully!"))
  .catch(e => console.error("❌ Error:", e));

Running Command

cd /home/daytona/workspace/pulmonary-rehab-ppt && node create_pr_ppt.js

Line 190 uses pres.shapes.ELLIPSE — need to check available shapes:

Running Command

node -e "const p = require('pptxgenjs'); const pres = new p(); console.log(Object.keys(pres.shapes).filter(k => k.includes('ELLIPSE') || k.includes('RECT') || k.includes('OVAL')).join('\n'));"

It's OVAL not ELLIPSE. Let me fix all occurrences:

Running Command

sed -i 's/pres\.shapes\.ELLIPSE/pres.shapes.OVAL/g' /home/daytona/workspace/pulmonary-rehab-ppt/create_pr_ppt.js && echo "Fixed" && grep -c "OVAL" /home/daytona/workspace/pulmonary-rehab-ppt/create_pr_ppt.js

Running Command

python3 -c " content = open('/home/daytona/workspace/pulmonary-rehab-ppt/create_pr_ppt.js').read() content = content.replace('pres.shapes.ELLIPSE', 'pres.shapes.OVAL') open('/home/daytona/workspace/pulmonary-rehab-ppt/create_pr_ppt.js', 'w').write(content) print('Done, OVAL count:', content.count('pres.shapes.OVAL')) "

Running Command

cd /home/daytona/workspace/pulmonary-rehab-ppt && node create_pr_ppt.js

Running Command

ls -lh /home/daytona/workspace/pulmonary-rehab-ppt/Pulmonary_Rehabilitation_PR.pptx

Your PowerPoint is ready! ✅

Pulmonary Rehabilitation PR

Presentation · PPTX

The deck has 10 slides with a dark navy + teal medical theme:

Slide	Content
1	Title slide with lung icon
2	ATS/ERS Definition + Indications (8 conditions with cards)
3	Vicious Cycle of Deconditioning diagram (6-step loop)
4	Components of PR (6-component wheel layout)
5	Phase I / II / III — side-by-side comparison with bullet points
6	Exercise Prescription — Aerobic, Resistance, IMT, Stop Criteria
7	Breathing Techniques — PLB, Diaphragmatic breathing, ACBT (3 phases)
8	Outcome Measures — 6MWT, Borg, CAT, SGRQ with MCID values
9	Current Evidence (2022–2024 studies) + High-Yield Viva Points
10	Quick Revision Summary table (15 key facts)

Cystic fibrosis

Finding Sources

Searching PubMed

"cystic fibrosis" physiotherapy airway clearance exercise

Excellent sources. Reading the key textbook sections in parallel:

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Loading Image

Finding Sources

CYSTIC FIBROSIS (CF)

BPT / MPT Final Year - Clinical, Evidence-Based Format

✅ 1. DEFINITION AND CLASSIFICATION

Definition: Cystic fibrosis is a multisystem, autosomal recessive genetic disorder caused by mutations in the CFTR gene (Cystic Fibrosis Transmembrane Conductance Regulator) on chromosome 7q31, resulting in defective chloride ion transport across epithelial cell membranes, leading to production of abnormally thick, viscous secretions in the lungs, pancreas, liver, intestines, and reproductive tract.

Thompson & Thompson Genetics and Genomics in Medicine, 9th ed.
Murray & Nadel's Textbook of Respiratory Medicine

Classification of CFTR Mutations (6 Classes):

CFTR gene structure and protein domains with class mutations

CFTR gene and protein structure showing the 6 classes of mutations. F508del (Class II) accounts for ~70% of all CF alleles in European populations.

Thompson & Thompson Genetics and Genomics in Medicine, 9th ed.

Class	Defect	Example Mutation	Effect
I	No protein synthesised (null allele)	Premature stop codon	No CFTR protein
II	Protein misfolding; blocked maturation	F508del (most common ~70%)	Protein degraded before reaching membrane
III	Normal delivery to membrane but defective gating	Gly551Asp	Channel cannot open/close
IV	Defective chloride conduction	Arg117His	Channel open but reduced conductance
V	Reduced CFTR mRNA production	Splice mutations	Reduced protein quantity
VI	Unstable protein at cell surface	Gln1412Stop	Protein rapidly degraded

Classes I, II, III = Severe (pancreatic insufficient); Classes IV, V, VI = Milder phenotype

Clinical Classification:

Type	Description
Classic CF	Two severe mutations; pancreatic insufficiency + pulmonary disease
Non-classic / Atypical CF	One severe + one mild mutation; later onset; milder phenotype
CFTR-Related Disorder (CFTR-RD)	CBAVD (congenital bilateral absence of vas deferens), pancreatitis, bronchiectasis without classic CF

Epidemiology:

Most common lethal autosomal recessive disorder in people of European descent
Incidence: 1 in 2500 (White/European); 1 in 15,000 (Black); 1 in 31,000 (Asian)
Carrier frequency: 1 in 25 in European populations
Predicted median survival: beyond 47 years (significantly improved with modern therapy)
India: CF is rare but increasingly diagnosed (estimated 1 in 40,000-100,000)

✅ 2. DETAILED ANATOMY AND BIOMECHANICS

Gene and Protein:

CFTR gene: chromosome 7q31.2, 27 exons, spans ~190 kb
CFTR protein: ~170 kDa integral membrane glycoprotein; belongs to ABC (ATP-Binding Cassette) transporter family
Located in the apical membrane of epithelial cells lining airway, pancreatic ducts, biliary ducts, intestines, sweat glands, vas deferens

Protein Domains (5 domains):

Two Membrane-Spanning Domains (MSD1 and MSD2) - form the chloride channel pore
Two Nucleotide-Binding Domains (NBD1 and NBD2) - bind and hydrolyse ATP to open/close channel
Regulatory Domain (R-domain) - phosphorylation sites; regulates channel activity

Organs Affected:

Organ	Normal CFTR Function	CF Consequence
Lung	Maintain airway surface liquid (ASL) for mucociliary clearance	Dehydrated mucus → thick secretions → infection → bronchiectasis
Pancreas	Bicarbonate secretion; enzyme secretion	Blocked ducts → pancreatic insufficiency → malabsorption
Sweat glands	Reabsorb NaCl in duct	Cannot reabsorb Cl⁻ → elevated sweat NaCl
Liver	Bile flow in biliary ducts	Inspissated bile → biliary cirrhosis
Intestine	Chloride/fluid secretion	Meconium ileus; DIOS
Vas deferens	Patency	CBAVD → male infertility (98% of males)

✅ 3. PATHOPHYSIOLOGY

Core Mechanism:

CFTR gene mutation
        ↓
Defective/absent CFTR protein at apical epithelial membrane
        ↓
Failure of Cl⁻ secretion + ↑ Na⁺ absorption (ENaC overactive)
        ↓
Depletion of Airway Surface Liquid (ASL) — airway dehydration
        ↓
Thick, viscous mucus layer — mucociliary clearance impaired
        ↓
Mucus plugging → airway obstruction
        ↓
Bacterial colonisation: S. aureus (early) → Pseudomonas aeruginosa (chronic)
        ↓
Neutrophilic inflammation → proteases (elastase, DNase) → tissue damage
        ↓
Bronchiectasis → respiratory failure → death

Pulmonary Pathophysiology (most relevant for physiotherapy):

Mucus hypersecretion → airway obstruction → obstructive ventilatory defect (↓FEV₁/FVC)
Progressive bronchiectasis → destroyed airway walls
Air trapping → hyperinflation → barrel chest
Recurrent infections → cycles of inflammation and damage
Respiratory muscle fatigue in advanced disease
Hypoxaemia → pulmonary hypertension → cor pulmonale (late)

Extra-Pulmonary Pathophysiology:

Pancreas: Plugging of ducts → autodigestion → acinar atrophy → pancreatic insufficiency → fat malabsorption → steatorrhoea; up to 50% of CF adults develop CF-Related Diabetes (CFRD)
Liver: Bile duct plugging → focal biliary cirrhosis → portal hypertension (in up to 28% of adults)
Intestine: Meconium ileus at birth (10-25%); Distal Intestinal Obstruction Syndrome (DIOS) in adults (18%)
Male reproductive: CBAVD in 98% of males (azoospermia → infertility)
Sweat gland: Salty sweat (↑NaCl) — diagnostic feature

✅ 4. CLINICAL PRESENTATION

Neonatal / Infant:

Meconium ileus (10-25%) - intestinal obstruction at birth
Failure to thrive
Steatorrhoea (fatty, foul-smelling stools)
Recurrent chest infections
"Salty" taste when kissed (first noticed by parents - classic history)
Positive newborn screening (immunoreactive trypsinogen - IRT test)
Prolonged neonatal jaundice

Childhood / Adolescent:

Chronic productive cough (thick, purulent sputum)
Recurrent lower respiratory tract infections (LRTI) - S. aureus, H. influenzae
Chronic Pseudomonas aeruginosa colonisation (by age 18: 80% harbour P. aeruginosa)
Progressive obstructive lung disease (↓FEV₁)
Recurrent sinusitis, nasal polyps (10-25%)
Malnutrition, poor weight gain
Delayed puberty
Clubbing of fingers (chronic hypoxaemia + bronchiectasis)

Adult:

Established bronchiectasis
Respiratory failure (cor pulmonale in late disease)
CFRD (CF-Related Diabetes) - up to 50% of adults
Liver disease (cirrhosis, portal hypertension)
DIOS (intestinal obstruction)
Male infertility (CBAVD)
Reduced female fertility
Osteoporosis (malabsorption of Ca²⁺, vitamin D; corticosteroid use)

Key Symptoms for Physiotherapy Assessment:

Dyspnoea on exertion (MRC grade)
Chronic productive cough; sputum quantity, colour, consistency
Haemoptysis (common in advanced disease; complicates physiotherapy)
Exercise intolerance
Fatigue
Chest pain (pleuritis, pneumothorax)

✅ 5. MUSCLE-WISE ASSESSMENT

Respiratory Muscles:

Muscle	Assessment	Finding
Diaphragm	Diaphragmatic excursion; sniff nasal pressure; ultrasound	Flattened in hyperinflation; reduced excursion
Accessory muscles (SCM, Scalenes)	Inspection	Prominent use in acute exacerbations
Inspiratory muscles	MIP (Maximum Inspiratory Pressure)	Reduced in advanced CF
Expiratory muscles	MEP (Maximum Expiratory Pressure)	Reduced in advanced CF; important for cough force

Peripheral Muscles:

Muscle Group	Tool	Finding
Quadriceps	Hand-held dynamometry; 5-rep STS; 1-RM	Weakness (peripheral muscle wasting)
Shoulder girdle / UL	Grip strength (dynamometer)	Reduced in malnourished patients
Core / Trunk	Functional assessment	Weak (nutritional depletion + deconditioning)

MMT of respiratory and limb muscles - graded 0-5 MRC scale (standard)

✅ 6. EXPECTED POSITIVE FINDINGS

Inspection:

Barrel chest (hyperinflation - increased AP diameter)
Harrison's sulcus (groove along lower ribs at diaphragm attachment - in chronic childhood respiratory disease)
Digital clubbing (hallmark sign - chronic hypoxaemia + bronchiectasis)
Cyanosis (central - in advanced disease)
Use of accessory muscles
Intercostal/subcostal recession (in acute exacerbations in children)
Low weight / cachexia (malnutrition)
Nasal polyps visible in anterior rhinoscopy

Palpation:

Reduced chest expansion (bilateral)
Reduced tactile fremitus over consolidated/plugged areas
Increased tactile fremitus over consolidated areas

Percussion:

Hyperresonance (hyperinflation, bullae)
Dullness over areas of consolidation / mucus plugging

Auscultation:

Coarse crackles (secretion-laden airways) - clear partially on coughing
Wheeze (airway obstruction)
Bronchial breath sounds (consolidation)
Reduced air entry in severely diseased areas

Spirometry / PFTs:

Test	Expected Finding in CF
FEV₁	Reduced (obstructive pattern)
FVC	Reduced (mixed pattern in late disease)
FEV₁/FVC	Reduced (< 70%) - obstructive
TLC	Increased (hyperinflation)
RV	Markedly increased (air trapping)
RV/TLC ratio	Increased
DLCO	Reduced (advanced disease)
SpO₂	Reduced (resting + exertional)

Sputum Assessment:

Colour: yellow-green (infected), brown/rust (chronic), blood-streaked (haemoptysis)
Volume: 20-100 mL/day in moderate-severe disease
Consistency: thick, tenacious, difficult to expectorate
Organisms: S. aureus (early), P. aeruginosa (later, mucoid strains), Burkholderia cepacia (rare, severe)

Outcome Measures in CF:

Domain	Tool
Exercise capacity	6MWT; Cycle ergometry; CPET (VO₂peak)
Lung function	FEV₁ % predicted (primary outcome in CF); FVC; RV; DLCO
Dyspnoea	Modified Borg Scale; MRC Dyspnoea Scale
QoL	CFQ-R (CF Questionnaire - Revised) - CF-specific validated tool
Sputum clearance	Sputum weight / volume; radioaerosol clearance
Nutritional status	BMI; z-score (children); FFMI
Radiological	CXR Brasfield score; CT Bhalla score

✅ 7. DIFFERENTIAL DIAGNOSIS

Condition	Distinguishing Feature
Asthma	Reversible obstruction; no clubbing; no chronic infection; normal sweat chloride
Primary Ciliary Dyskinesia (PCD)	Immotile cilia; situs inversus (Kartagener's syndrome); sweat chloride normal; ciliary biopsy diagnostic
Immunodeficiency (CVID, IgA deficiency)	No sweat chloride elevation; immunoglobulin levels low; no CFTR mutation
Non-CF Bronchiectasis	No CFTR mutation; normal sweat chloride; various other causes (post-infective, PCD)
Shwachman-Diamond Syndrome	Pancreatic insufficiency + bone marrow failure + skeletal dysplasia; no CFTR mutation
Chronic bronchitis (COPD)	Adult onset; smoking history; no meconium ileus/clubbing early; no sweat chloride elevation
Allergic Bronchopulmonary Aspergillosis (ABPA)	Can coexist with CF; elevated IgE, positive Aspergillus precipitins; central bronchiectasis

✅ 8. INVESTIGATIONS

Investigation	Purpose / Finding
Sweat Chloride Test (Gold Standard)	Normal < 40 mmol/L; Borderline 40-59 mmol/L; CF diagnostic ≥ 60 mmol/L
Newborn Screening (IRT test)	Immunoreactive trypsinogen - elevated; confirms need for sweat test
CFTR Genotyping	Identifies specific mutations; determines eligibility for CFTR modulator therapy
Nasal Potential Difference (NPD)	Measures CFTR-dependent electrolyte transport; used when sweat test borderline
Chest X-Ray (CXR)	Hyperinflation; peribronchial thickening; bronchiectasis; consolidation; atelectasis
HRCT Chest	Bronchiectasis (tram-track, ring shadows, signet-ring sign); mucus plugging; ground-glass opacities
Spirometry (PFTs)	Obstructive pattern; FEV₁ % predicted is PRIMARY prognostic marker
Sputum Culture & Sensitivity	Identify pathogens; guide antibiotic therapy
Bronchoalveolar Lavage (BAL)	When bronchoscopy performed
Abdominal Ultrasound	Liver fibrosis, portal hypertension, biliary disease
Faecal elastase	Pancreatic exocrine function (< 200 µg/g = pancreatic insufficiency)
HbA1c + Oral Glucose Tolerance Test	Screen for CFRD annually from age 10
DEXA Scan	Bone mineral density (osteoporosis screening)
SpO₂ monitoring	Resting, exertional, nocturnal desaturation

✅ 9. PROBLEM LIST

Impairments:

Obstructive ventilatory defect (reduced FEV₁, ↑RV)
Sputum retention / impaired mucociliary clearance
Chronic bacterial colonisation (Pseudomonas, S. aureus)
Chronic productive cough (thick, purulent sputum)
Dyspnoea on exertion (Borg ≥ 4 during moderate activity)
Reduced exercise capacity (↓VO₂peak, ↓6MWT distance)
Peripheral muscle weakness (deconditioning + malnutrition)
Inspiratory + expiratory muscle weakness (advanced disease)
Nutritional depletion (malabsorption; low BMI/z-score)
Hypoxaemia (resting ± exertional; nocturnal in advanced disease)

Activity Limitations:

Unable to participate in age-appropriate physical activities (children)
Restricted exercise tolerance for ADLs
Impaired self-care due to fatigue
School/work absenteeism during exacerbations

Participation Restrictions:

Reduced quality of life (social isolation)
Educational and vocational limitations
Psychological burden (chronic disease in young patients)

Psychosocial:

Anxiety, depression (common in adolescents and adults)
Non-adherence to treatment (major problem - demanding daily regimen)
Body image issues (barrel chest, clubbing, low weight)
Anticipatory grief (life-limiting prognosis)

✅ 10. SMART GOALS

Short-Term Goals (2-4 weeks):

Patient will clear sputum effectively with ACBT independently within 1 week (confirmed by therapist observation)
Patient will demonstrate correct technique for PEP therapy/Flutter device within 3 sessions
Patient will report reduction in dyspnoea (Borg scale) from 6/10 to 3/10 during ADLs within 2 weeks
Patient will walk 10 minutes continuously on level ground within 2 weeks
Sputum volume during treatment sessions will increase initially then reduce with regular clearance within 1 week

Long-Term Goals (3-6 months):

Patient will independently perform twice-daily ACT routine without prompting for 3 consecutive months
Patient will complete 6MWT ≥ MCID improvement from baseline (25-33 m) within 3 months
FEV₁ % predicted will be maintained or decline limited to < 2% per year (with optimal management)
Patient/caregiver will demonstrate competent HEP adherence (ACBT + exercise + inhaler) for 3 months
Patient will demonstrate improved muscle strength: 30-sec STS count increase by ≥ 3 within 3 months

✅ 11. PHASE-WISE PHYSIOTHERAPY MANAGEMENT

PHASE 1: Stable CF - Daily Maintenance (Lifelong)

Goal: Maintain airway clearance, slow disease progression, maintain exercise capacity

Twice-daily airway clearance technique (ACT) sessions (30 minutes each)
Aerobic exercise: minimum 30 minutes moderate intensity, 3-5 days/week
Resistance training: 2-3 days/week
Inhalation therapy before ACT: bronchodilator → hypertonic saline / DNase → ACT → inhaled antibiotic
Education: self-management, adherence, pacing, energy conservation
Nutritional support coordination
CFTR modulator therapy (if eligible): improves mucociliary clearance - adjust ACT timing accordingly

PHASE 2: Acute Exacerbation (Inpatient)

Goal: Maximise secretion clearance, treat infection, restore baseline function

More frequent ACT sessions: 3-4 times per day (increased from twice daily)
Head-down postural drainage with percussion/vibration (if tolerated)
NIV (Non-Invasive Ventilation) if respiratory failure / hypercapnia
Supplemental oxygen (maintain SpO₂ 88-92%)
Intravenous antibiotics (antipseudomonal - based on culture + sensitivity)
IV/oral DNase (dornase alfa) to break down extracellular DNA
Nebulised hypertonic saline (7%) before ACT
Early mobilisation as soon as possible
Monitor: SpO₂, HR, RR, sputum quantity and character

PHASE 3: Post-Exacerbation Rehabilitation

Goal: Regain lost function, build back exercise tolerance, re-establish maintenance routine

Graduated return to exercise programme
Intensive ACT to clear residual infection
Nutritional rehabilitation (high calorie + protein)
Psychosocial support (adjustment after hospitalisation)
Patient education on exacerbation triggers and early warning signs

PHASE 4: Advanced / End-Stage CF

Goal: Symptom palliation, maintain function as long as possible, transplant readiness

Physiotherapy pre- and post-lung transplantation
NIV support (bridge to transplant)
Oxygen therapy
Energy conservation training
Palliative physiotherapy (comfort, positioning, breathlessness management)

✅ 12. AIRWAY CLEARANCE TECHNIQUES (ACT) - Core of CF Physiotherapy

Inhalation Therapy Sequence BEFORE ACT:

Short-acting bronchodilator (Salbutamol) - opens airways, reduces bronchospasm
Hypertonic saline (7%) (via nebuliser) - hydrates airway secretions; improves mucus clearance
DNase (Dornase alfa / Pulmozyme) - breaks down extracellular DNA in secretions (reduces viscosity)
Then perform ACT
Inhaled antibiotic (Tobramycin, Aztreonam) AFTER ACT - reaches deeper airways after clearance

A. ACTIVE CYCLE OF BREATHING TECHNIQUE (ACBT)

Most commonly taught self-administered ACT in CF

Phase	Technique	Purpose
Breathing Control (BC)	Relaxed tidal breathing × 3-5 breaths	Rest; prevent bronchospasm
Thoracic Expansion Exercises (TEE)	3-5 deep slow breaths + 3-sec inspiratory hold	Collateral ventilation; mobilise secretions
Forced Expiration Technique (FET/Huff)	Medium or low volume huff (open glottis, NO glottis closure)	Move secretions centrally
Cough	When secretions reach central airways	Expectorate secretions

Repeat 2-4 cycles until secretions cleared

Evidence: Cochrane Review (Wilson et al. 2023, PMID 36727723) - ACBT is effective for airway clearance; evidence comparable to other ACTs. No single technique proven superior.

B. AUTOGENIC DRAINAGE (AD)

Self-administered; no devices needed; requires patient cooperation and training

Phase	Lung Volume	Technique	Secretion Location
Unsticking	Low lung volume (ERV)	Slow tidal breathing at low volumes × 4-8 breaths + suppressed cough	Peripheral airways
Collecting	Mid lung volume (TV)	Slow tidal breathing at mid volumes	Intermediate airways
Evacuating	High lung volume (IRV)	Slow breathing at high volumes → huff/cough to expectorate	Central airways

Evidence: Cochrane Review (Burnham et al. 2021, PMID 34910295) - AD is as effective as other ACTs; preferred by patients who are independent and mobile.

C. POSITIVE EXPIRATORY PRESSURE (PEP) THERAPY

Parameter	Detail
Starting Position	Sitting, leaning slightly forward on table
Technique	Breathe in (slightly larger than tidal volume) → breathe out through PEP mask/mouthpiece against resistance; creates 10-20 cmH₂O back pressure → holds peripheral airways open → mobilises secretions; follow with 2-3 huffs
PEP setting	I:E ratio 1:3; resistance selected to achieve 10-20 cmH₂O during expiration
Sets/Reps	15 breaths per cycle × 3-4 cycles; each cycle followed by 2-3 huffs
Frequency	Twice daily (stable); 3-4 times/day (exacerbation)
Precautions	Untreated pneumothorax; haemoptysis; sinusitis (avoid if acute)

D. OSCILLATING PEP (OPEP) DEVICES

Device	Mechanism
Flutter	Ball-bearing creates oscillating PEP (15-25 Hz); handheld; gravity-dependent
Acapella	Spring-valve creates oscillating PEP (> 15 Hz); position-independent
Aerobika	Intermittent positive pressure with oscillation; can be used with nebuliser simultaneously
RC-Cornet	Curved tube creates oscillating PEP

Mechanism: Oscillating pressure loosens secretions + produces mini-expiratory surges that move secretions centrally

E. HIGH-FREQUENCY CHEST WALL OSCILLATION (HFCWO)

Device: Vest (ThAIRapy vest, AffloVest)

Parameter	Detail
Mechanism	Inflatable vest vibrates chest wall at 5-25 Hz → generates mini-cough forces → loosens and mobilises secretions
Duration	20-30 minutes per session
Frequency	Twice daily
Advantage	Independent use; suitable for patients with poor manual dexterity; useful in teenagers for adherence
Contraindications	Unstable spine, recent thoracic surgery, active haemoptysis

F. CONVENTIONAL CHEST PHYSIOTHERAPY (Postural Drainage + Percussion + Vibration)

Component	Technique
Postural Drainage	12 positions (one for each lung segment); gravity-assisted drainage; 10-15 min per position
Percussion	Rhythmic clapping over affected lobe (cupped hand) during postural drainage; 1-2 Hz
Vibration	Fine oscillation applied during expiration

Position for Upper Lobe Anterior Segments: Sitting upright, lean back 30° Position for Lower Lobe Basal Segments: Head-down tilt 20-25° (Trendelenburg)

Evidence: Cochrane Review (Main & Rand 2023, PMID 37144842) - Conventional CPT is effective but not superior to self-administered ACTs; self-administered techniques preferred for long-term adherence and independence.

Evidence: Cochrane Review (Warnock & Gates 2023, PMID 37042825) - ACTs vs. no ACTs: ACTs improve sputum expectoration and some short-term lung function indices.

✅ 13. MUSCLE-SPECIFIC EXERCISE PRESCRIPTION

A. AEROBIC EXERCISE (Lower Limb - Priority)

i. Cycling / Walking

Parameter	Detail
Starting Position	Seated on cycle ergometer / standing for walking
Technique	Steady-state cycling or walking at target intensity; use PLB during exercise
Intensity	Borg 4-6/10 OR 60-80% peak VO₂; or 70-85% peak HR
Duration	Start 15-20 min → build to 30-45 min
Frequency	3-5 days/week
Progression	Increase duration first → then increase intensity → add interval training
Precautions	Monitor SpO₂; add supplemental O₂ if SpO₂ < 88%; avoid after large haemoptysis; post-ACT timing preferred

ii. Swimming

Especially recommended in CF - warm humid air reduces bronchospasm; hydrotherapy also helps loosen secretions; full body aerobic + strengthening

B. RESISTANCE / STRENGTH TRAINING

Key because: Peripheral muscle wasting is common in CF due to chronic inflammation, corticosteroid use, malnutrition, and deconditioning. Strength training has independent benefits on lung function and survival in CF.

Parameter	Detail
Muscles targeted	Quadriceps, hamstrings, hip extensors, biceps, shoulder press, lat pulldown
Intensity	60-80% 1-RM
Sets/Reps	3 sets × 8-12 reps
Frequency	2-3 days/week
Progression	Increase load by 5-10% when 3×12 achieved comfortably
Precautions	Avoid Valsalva; monitor SpO₂; coordinate with feeding and ACT schedule; avoid if spontaneous pneumothorax risk is high

C. INSPIRATORY MUSCLE TRAINING (IMT)

Parameter	Detail
Indication	When MIP is reduced (advanced CF); to improve cough force; post-transplantation
Device	Threshold IMT device
Intensity	30-50% MIP
Protocol	3 sets × 30 breaths/day
Frequency	Daily
Progression	Increase by 5% MIP every 2-4 weeks
Precautions	Reassess MIP every 4 weeks; avoid if recent pneumothorax

✅ 14. ELECTROTHERAPY

Note: Electrotherapy is rarely used as primary intervention in CF. Physiotherapy focus is ACT and exercise. However:

TENS for Chest Wall Pain

Parameter	Detail
Indication	Musculoskeletal chest pain from coughing; pleuritic pain; rib fractures (rare with osteoporosis)
Placement	Paravertebral / over affected area; NEVER anteriorly over chest
Frequency	80-150 Hz (Conventional TENS)
Pulse width	50-80 µs
Duration	20-30 minutes
Contraindications	Cardiac pacemaker; over anterior chest/carotid sinus

NMES (Neuromuscular Electrical Stimulation)

Indication	Advanced CF with severe peripheral muscle weakness unable to exercise
Target	Quadriceps primarily
Parameters	35-50 Hz; 200-400 µs; 30-60 min/session; 6-8 weeks
Evidence	Emerging evidence in severe CF and post-transplant muscle rehabilitation

TENS-Assisted Cough (Neuromuscular Stimulation of Expiratory Muscles)

Experimental in CF with neuromuscular weakness impairing cough
Electrodes over abdominal muscles to assist forced expiration
Not standard practice; specialist centres only

✅ 15. FUNCTIONAL AND GAIT TRAINING

Functional Issues in CF:

Barrel chest posture → thoracic kyphosis → impaired respiratory mechanics
Reduced thoracic mobility → reduced chest wall compliance
Fatigue-limited ADLs → energy conservation training essential

Postural Training:

Thoracic extension exercises (over foam roller / gym ball)
Scapular retraction exercises
Core strengthening (improve spinal alignment and respiratory mechanics)
Breathing control during postural exercise

Functional Activities:

Energy conservation techniques (4 Ps: Prioritise, Plan, Pace, Position)
School/work activity scheduling around ACT and exercise sessions
Teaching parents/caregivers of young children ACT techniques (percussion, vibration, postural drainage)

Gait / Exercise Tolerance:

Progressive walking programme (stair climbing, incline walking)
Walking aids NOT typically needed (young patients); if advanced disease - rollator for support
Supplemental oxygen during exercise if SpO₂ falls below 88%

✅ 16. HOME EXERCISE PROGRAMME (HEP)

Daily CF Routine (Stable phase) - Lifelong Commitment:

Morning Session (30-45 minutes):

Bronchodilator nebulisation (Salbutamol) - 10 minutes
Hypertonic saline / DNase nebulisation - 10-15 minutes
ACBT or chosen ACT - 20-30 minutes
Inhaled antibiotic (if prescribed) - after ACT

Exercise (30-60 minutes, most days): 5. Aerobic exercise (walking/cycling/swimming) - 30-45 min; Borg 4-5 6. Resistance training - 20-30 min; 2-3 days/week 7. Postural exercises (thoracic extension, scapular retraction)

Evening Session (30 minutes): 8. Repeat ACT sequence (bronchodilator → saline → ACBT)

Nutritional:

High-calorie, high-protein diet (120-150% of normal energy requirements)
Pancreatic enzyme replacement therapy (PERT) with all meals/snacks
Fat-soluble vitamin supplementation (A, D, E, K)

Patient Education:

Recognise early exacerbation signs: ↑cough, ↑dyspnoea, change in sputum, ↓exercise tolerance, weight loss, fever
Adherence education - non-adherence to ACT is the single biggest barrier to good outcomes
Cross-infection prevention: CF patients must NOT share rooms/equipment with other CF patients (Burkholderia cepacia risk)

✅ 17. CRITERIA FOR RETURN TO ACTIVITY / SPORT

Criteria	Target
Resolution of exacerbation	Afebrile; sputum volume and purulence returned to baseline
SpO₂	≥ 88% on room air during activity
FEV₁	Returned to within 10% of personal best
Dyspnoea	Borg ≤ 4 during moderate activity
Medical clearance	Physician review; rule out pneumothorax; no active haemoptysis
Exercise test	6MWT or exercise test showing safe tolerance
ACT adherence	Patient back on twice-daily ACT routine

Contact sports: Generally permitted unless severe lung disease; avoid with pneumothorax risk

✅ 18. COMPLICATIONS AND PROGNOSIS

Complication	Physiotherapy Relevance
Pneumothorax	Modify/stop ACT; avoid vigorous exercise; refer urgently; restart ACT after treatment
Haemoptysis (minor: <250 mL)	Continue ACT with modification (avoid head-down positions, percussion over bleeding site)
Haemoptysis (massive: >250 mL)	STOP ACT; urgent medical management; embolisation
Respiratory failure	NIV support; adjust ACT; oxygen therapy
Cor pulmonale	Graded exercise; oxygen; restrict exercise in severe cases
Pneumonia / severe exacerbation	Intensive inpatient physiotherapy (3-4× daily ACT)
Rib fractures	Osteoporosis-related; modify ACT (avoid percussion); TENS for pain
Pneumothorax post-exercise	Occurs in advanced disease; monitor during exercise
CFRD	Coordinate ACT and exercise around insulin timing and meals

Prognosis:

Predicted median survival: > 47 years (dramatically improved with CFTR modulators, better antibiotics, intensive ACT)
Historically: median age of death ~30 years; now extending significantly
FEV₁ % predicted is the single most important prognostic marker - decline rate of FEV₁ determines survival
Burkholderia cepacia colonisation: worse prognosis; associated with "cepacia syndrome" (rapid deterioration)
CFTR modulator therapy (Elexacaftor-Tezacaftor-Ivacaftor - Kaftrio/Trikafta): For F508del homozygous and other eligible mutations; dramatically improves lung function, reduces exacerbations, improves nutrition; physiotherapy remains essential alongside

✅ 19. HIGH-YIELD VIVA AND UNIVERSITY EXAM POINTS

⭐ Frequently Asked University Questions:

Define cystic fibrosis. Describe its inheritance and genetic basis.
What is the CFTR protein? Classify its mutations with examples.
Describe the pathophysiology of lung disease in CF.
What is the role of physiotherapy in management of CF?
Describe ACBT in detail. Compare it with Autogenic Drainage.
What are the different airway clearance techniques used in CF?
What is the sequence of inhalation therapy in CF? Why is the sequence important?
Write a note on complications of CF and physiotherapy modifications.
Describe the exercise prescription for a patient with CF.
What is the sweat chloride test? What values are diagnostic?

⭐ Clinically Important Points:

CF is autosomal recessive - both parents must be carriers; 25% risk each pregnancy
F508del mutation accounts for ~70% of all CF alleles - most common worldwide
Sweat chloride ≥ 60 mmol/L is diagnostic; < 40 normal; 40-59 borderline (intermediate)
Pseudomonas aeruginosa colonisation is inevitable in most CF patients and is the major cause of morbidity/mortality - once established, cannot be eradicated (only suppressed)
ACT is lifelong, twice daily, non-negotiable - it is the cornerstone of CF physiotherapy
Inhalation sequence MATTERS: Bronchodilator → Hypertonic Saline/DNase → ACT → Inhaled Antibiotic
CF patients must NEVER share rooms or equipment with other CF patients (cross-infection risk with Burkholderia cepacia and resistant Pseudomonas)
FEV₁ % predicted is the most important single prognostic measurement in CF
Exercise is NOT a substitute for ACT (Cochrane 2022, Heinz et al.); exercise is additive and complementary
In haemoptysis: minor = modify ACT; massive (> 250 mL) = STOP ACT immediately
In pneumothorax: STOP all ACT and vigorous exercise

⭐ Common Examiner Viva Questions:

"What is the difference between ACBT, Autogenic Drainage, and PEP therapy?" → ACBT: three-phase cycle (BC-TEE-FET); no device; therapist or self-performed. AD: three-level lung volume breathing (unstick-collect-evacuate); no device; requires significant patient cooperation and training; very useful for independent adults. PEP: device-based; creates back pressure 10-20 cmH₂O; holds peripheral airways open; mobilises secretions; also has OPEP variants (Flutter, Acapella)
"In what order do you give inhaled medications before ACT?" → Bronchodilator first (opens airways) → Hypertonic saline/DNase (thins secretions) → then ACT → Inhaled antibiotic last (reaches deeper airways after clearance)
"What modifications would you make to ACT if a CF patient has haemoptysis?" → Minor haemoptysis (< 250 mL): continue ACT but avoid head-down positions and direct percussion over bleeding site; use positive pressure techniques (PEP). Massive haemoptysis (> 250 mL): STOP all ACT; refer urgently for medical management (bronchial artery embolisation)
"What is the sweat chloride test? How is it done?" → Pilocarpine iontophoresis method; sweat collected from forearm; chloride measured; ≥ 60 mmol/L = CF diagnostic; two separate tests required for diagnosis
"Why should exercise not replace ACT in CF?" → Exercise improves exercise capacity, QoL, and has some airway clearance benefit through increased tidal volumes and airflow; however, it does not achieve the equivalent systematic peripheral-to-central secretion clearance as dedicated ACT. Cochrane evidence (Heinz et al. 2022) confirms exercise is not equivalent to ACT; they are complementary

⭐ Common Mistakes Students Make:

Saying exercise can replace ACT - WRONG (exercise is complementary, not a substitute)
Omitting the inhalation therapy sequence before ACT - critical clinical omission
Not knowing the sweat chloride diagnostic cut-off (≥ 60 mmol/L)
Not mentioning the cross-infection risk between CF patients
Forgetting haemoptysis modifications to ACT (continues to appear in MCQs and viva)
Not knowing Autogenic Drainage phases (unsticking → collecting → evacuating)
Confusing B. cepacia with P. aeruginosa - B. cepacia is rare but far more dangerous
Not accounting for CFRD in exercise prescription (coordinate with insulin and meals)
Saying CF affects only the lungs - it is a multisystem disease (pancreas, liver, intestine, reproductive)
Not mentioning F508del as the most common mutation (asked directly in many universities)

✅ 20. REFERENCES

Thompson & Thompson Genetics and Genomics in Medicine, 9th Edition - Chapter 13: Cystic Fibrosis genetics, CFTR gene, mutation classes
Robbins, Cotran & Kumar Pathologic Basis of Disease - Diagnostic criteria for CF; pulmonary pathology
Murray & Nadel's Textbook of Respiratory Medicine, 2-Volume - CF and bronchiectasis
Sleisenger & Fordtran's Gastrointestinal and Liver Disease - GI manifestations; Table of GI features in CF
Fishman's Pulmonary Diseases and Disorders, 2-Volume Set - Airway clearance and rehabilitation in CF
Burnham P, et al. Autogenic drainage for airway clearance in cystic fibrosis. Cochrane Database Syst Rev. 2021. PMID: 34910295
Heinz KD, et al. Exercise versus airway clearance techniques for people with cystic fibrosis. Cochrane Database Syst Rev. 2022. PMID: 35731672
Warnock L, Gates A. Airway clearance techniques compared to no airway clearance techniques for cystic fibrosis. Cochrane Database Syst Rev. 2023. PMID: 37042825
Wilson LM, et al. Active cycle of breathing technique for cystic fibrosis. Cochrane Database Syst Rev. 2023. PMID: 36727723
Main E, Rand S. Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis. Cochrane Database Syst Rev. 2023. PMID: 37144842
Cystic Fibrosis Foundation (CFF) Clinical Practice Guidelines - cfcaremodel.org
Farrell PM, et al. Diagnosis of Cystic Fibrosis: Consensus Guidelines from the CFF. J Pediatr. 2017;181:S4-S15.

💡 Exam Tip: For theory - write the CFTR mutation class table with examples (examiners love this). For viva - know the sweat chloride diagnostic values cold (< 40 = normal; 40-59 = borderline; ≥ 60 = CF), and be able to demonstrate/describe ACBT phases in sequence. For practicals - demonstrate correct PEP device technique and the inhalation therapy sequence. The single most commonly asked viva question: "Can exercise replace ACT in CF?" - answer is No, with the Cochrane evidence to back it.

Make me a ppt of what will I write in exame as a final year bpt student not just a 10 - 15 marks ans

I want to make sure the PPT matches exactly what you need.

Asking for Preferences

Which topic should the exam-answer PPT cover? · What type of exam question format should I focus on?

Got it. Creating a PPT that shows exactly how to write exam answers for Cystic Fibrosis - both 10-15 mark structured answers and case-based scenarios, formatted as model answer templates a student can memorize and reproduce in exams.

Reading File

Running Command

mkdir -p /home/daytona/workspace/cf-exam-ppt && ls /home/daytona/workspace/cf-exam-ppt

Writing File

~/cf-exam-ppt/cf_exam_answers.js

const pptxgen = require("pptxgenjs");
const pres = new pptxgen();
pres.layout = "LAYOUT_16x9";
pres.title = "Cystic Fibrosis - Exam Answer Templates BPT Final Year";

// ─── COLOUR PALETTE ───────────────────────────────────────────────
const C = {
  bg:        "0C1A2E",   // main dark bg
  bgLight:   "112240",   // card bg
  bgMid:     "0F1E35",   // alternate row
  teal:      "00BFA6",   // primary accent
  sky:       "4FC3F7",   // secondary accent
  gold:      "FFD166",   // highlights / headings
  coral:     "EF5350",   // warnings / marks box
  green:     "66BB6A",   // positive points
  white:     "FFFFFF",
  light:     "B0BEC5",   // body text
  navy:      "1A2E4A",   // darker card
  purple:    "9C6FDE",   // case study accent
  orange:    "FF9800",   // short note accent
};

function bg(s) {
  s.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:10, h:5.625, fill:{color:C.bg}, line:{type:"none"} });
}
function topBar(s, color=C.teal) {
  s.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:10, h:0.07, fill:{color}, line:{type:"none"} });
}
function sectionHeader(s, title, color=C.teal) {
  s.addShape(pres.shapes.RECTANGLE, { x:0, y:0.07, w:10, h:0.58, fill:{color:C.bgLight}, line:{type:"none"} });
  s.addText(title, { x:0.35, y:0.07, w:9.3, h:0.58, fontSize:17, bold:true, color, valign:"middle", charSpacing:0.8, margin:0 });
}
function card(s, x, y, w, h, fill=C.bgLight, border=C.teal) {
  s.addShape(pres.shapes.RECTANGLE, { x, y, w, h, fill:{color:fill}, line:{color:border, width:1},
    shadow:{type:"outer", color:"000000", blur:6, offset:2, angle:135, opacity:0.2} });
}
function marksTag(s, text, x, y, color=C.coral) {
  s.addShape(pres.shapes.ROUNDED_RECTANGLE, { x, y, w:1.5, h:0.3, rectRadius:0.12, fill:{color}, line:{type:"none"} });
  s.addText(text, { x, y, w:1.5, h:0.3, fontSize:9, bold:true, color:C.white, align:"center", valign:"middle", margin:0 });
}
function stepNum(s, n, x, y, color=C.teal) {
  s.addShape(pres.shapes.OVAL, { x:x-0.18, y:y-0.04, w:0.34, h:0.34, fill:{color}, line:{type:"none"} });
  s.addText(String(n), { x:x-0.18, y:y-0.04, w:0.34, h:0.34, fontSize:9, bold:true, color:C.bg, align:"center", valign:"middle", margin:0 });
}
function pill(s, text, x, y, w=1.8, color=C.teal) {
  s.addShape(pres.shapes.ROUNDED_RECTANGLE, { x, y, w, h:0.28, rectRadius:0.12, fill:{color}, line:{type:"none"} });
  s.addText(text, { x, y, w, h:0.28, fontSize:8, bold:true, color:C.bg, align:"center", valign:"middle", margin:0 });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 1 – COVER
// ═══════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  bg(s);
  s.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:0.15, h:5.625, fill:{color:C.teal}, line:{type:"none"} });
  s.addShape(pres.shapes.RECTANGLE, { x:0.15, y:3.8, w:9.85, h:1.825, fill:{color:C.bgLight}, line:{type:"none"} });

  s.addText("🫁", { x:0.5, y:0.55, w:1.5, h:1.5, fontSize:60, align:"center" });

  s.addText("CYSTIC FIBROSIS", { x:2.0, y:0.55, w:7.5, h:0.8, fontSize:40, bold:true, color:C.white, charSpacing:3 });
  s.addText("EXAM ANSWER TEMPLATES", { x:2.0, y:1.38, w:7.5, h:0.65, fontSize:28, bold:true, color:C.teal, charSpacing:2 });
  s.addShape(pres.shapes.RECTANGLE, { x:2.0, y:2.1, w:6, h:0.05, fill:{color:C.gold}, line:{type:"none"} });
  s.addText("BPT Final Year  •  How to Write the Perfect Exam Answer", {
    x:2.0, y:2.2, w:7.5, h:0.38, fontSize:13, color:C.light, italic:true
  });

  pill(s, "10–15 Marks Answer", 2.0, 2.72, 2.3, C.coral);
  pill(s, "Case-Based Answer", 4.4, 2.72, 2.1, C.purple);
  pill(s, "Short Notes (5 marks)", 6.6, 2.72, 2.2, C.orange);

  s.addText("What to write  •  How much to write  •  What examiners look for", {
    x:0.25, y:4.0, w:9.5, h:0.35, fontSize:11, color:C.gold, bold:true, align:"center"
  });
  s.addText("Final Year BPT  |  Cardiopulmonary Physiotherapy  |  Examination Preparation Guide", {
    x:0.25, y:5.2, w:9.5, h:0.28, fontSize:8, color:C.light, align:"center"
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 2 – HOW TO STRUCTURE ANY CF ANSWER
// ═══════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  bg(s); topBar(s, C.gold);
  sectionHeader(s, "HOW TO STRUCTURE YOUR CF ANSWER — The Examiner's Checklist", C.gold);

  // Left: Marks breakdown
  card(s, 0.2, 0.78, 4.4, 4.56, C.bgLight, C.gold);
  s.addShape(pres.shapes.RECTANGLE, { x:0.2, y:0.78, w:4.4, h:0.4, fill:{color:C.gold}, line:{type:"none"} });
  s.addText("MARKS ALLOCATION (15-mark answer)", { x:0.3, y:0.78, w:4.2, h:0.4, fontSize:10, bold:true, color:C.bg, valign:"middle", margin:0 });

  const marks = [
    ["Definition + Genetics + Classification", "2 marks"],
    ["Pathophysiology (CFTR mechanism)", "2 marks"],
    ["Clinical Features (systemic)", "2 marks"],
    ["Diagnosis (Sweat Chloride + PFTs)", "1 mark"],
    ["Physiotherapy Assessment", "2 marks"],
    ["Airway Clearance Techniques (ACT)", "3 marks"],
    ["Exercise Training", "1 mark"],
    ["Complications + Prognosis", "1 mark"],
    ["Diagram / Table (bonus)", "+1 mark"],
  ];
  marks.forEach(([topic, mark], i) => {
    const y = 1.28 + i * 0.43;
    s.addShape(pres.shapes.RECTANGLE, { x:0.3, y, w:4.1, h:0.38, fill:{color: i%2===0 ? C.bgMid : C.bgLight}, line:{type:"none"} });
    s.addText(topic, { x:0.4, y, w:2.9, h:0.38, fontSize:8.5, color:C.white, valign:"middle", margin:0 });
    s.addText(mark, { x:3.5, y, w:0.85, h:0.38, fontSize:8.5, bold:true, color:C.gold, align:"right", valign:"middle", margin:0 });
  });

  // Right: Sequence to follow
  card(s, 4.8, 0.78, 5.0, 4.56, C.bgLight, C.teal);
  s.addShape(pres.shapes.RECTANGLE, { x:4.8, y:0.78, w:5.0, h:0.4, fill:{color:C.teal}, line:{type:"none"} });
  s.addText("SEQUENCE TO WRITE IN EXAM", { x:4.9, y:0.78, w:4.8, h:0.4, fontSize:10, bold:true, color:C.bg, valign:"middle", margin:0 });

  const seq = [
    ["STEP 1", "Definition (1–2 sentences max)", C.teal],
    ["STEP 2", "Inheritance + Gene + Most common mutation (F508del)", C.sky],
    ["STEP 3", "Pathophysiology: CFTR → mucus → infection diagram", C.gold],
    ["STEP 4", "Multi-system clinical features (lung + pancreas + liver + reproductive)", C.teal],
    ["STEP 5", "Diagnosis: Sweat chloride ≥60 + Spirometry + CFTR genotyping", C.sky],
    ["STEP 6", "Physiotherapy Assessment (inspection, palpation, auscultation, 6MWT)", C.green],
    ["STEP 7", "ACT techniques in DETAIL (ACBT phases, PEP, AD)", C.gold],
    ["STEP 8", "Exercise prescription + Inhalation therapy sequence", C.teal],
    ["STEP 9", "Complications (pneumothorax, haemoptysis) + modifications", C.coral],
  ];
  seq.forEach(([step, text, color], i) => {
    stepNum(s, i+1, 5.08, 1.38 + i * 0.43, color);
    s.addText(text, { x:5.2, y:1.24 + i * 0.43, w:4.4, h:0.38, fontSize:8.5, color:C.white, valign:"middle", margin:0 });
  });

  s.addText("⭐ TIP: Always write a short intro paragraph, then use HEADINGS + SUB-HEADINGS for each section. Examiners scan for keywords.", {
    x:0.2, y:5.28, w:9.6, h:0.24, fontSize:7.5, color:C.gold, bold:true, align:"center"
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 3 – MODEL 15-MARK ANSWER: PART 1 (Definition → Pathophysiology)
// ═══════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  bg(s); topBar(s, C.coral);
  sectionHeader(s, "MODEL ANSWER: 15-Mark Question — Part 1 of 3", C.coral);
  marksTag(s, "Q: Write on CF", 8.3, 0.15);

  // --- Definition box ---
  card(s, 0.2, 0.78, 9.6, 0.88, C.navy, C.gold);
  s.addShape(pres.shapes.RECTANGLE, { x:0.2, y:0.78, w:1.8, h:0.88, fill:{color:C.gold}, line:{type:"none"} });
  s.addText("DEFINITION\n(2 marks)", { x:0.2, y:0.78, w:1.8, h:0.88, fontSize:10, bold:true, color:C.bg, align:"center", valign:"middle", margin:0 });
  s.addText(
    "Cystic fibrosis (CF) is the most common lethal autosomal recessive genetic disorder in people of European descent, caused by mutations in the CFTR gene (chromosome 7q31), leading to defective chloride ion transport across epithelial membranes, resulting in thick viscous secretions affecting the lungs, pancreas, liver, intestines, and reproductive tract.",
    { x:2.1, y:0.82, w:7.5, h:0.8, fontSize:9, color:C.white, italic:true }
  );

  // --- Genetics box ---
  card(s, 0.2, 1.78, 9.6, 0.98, C.navy, C.sky);
  s.addShape(pres.shapes.RECTANGLE, { x:0.2, y:1.78, w:1.8, h:0.98, fill:{color:C.sky}, line:{type:"none"} });
  s.addText("GENETICS\n(1 mark)", { x:0.2, y:1.78, w:1.8, h:0.98, fontSize:10, bold:true, color:C.bg, align:"center", valign:"middle", margin:0 });
  s.addText([
    { text: "Gene: ", options:{bold:true, color:C.sky} }, { text:"CFTR (chromosome 7q31), 27 exons, 190 kb  |  ", options:{color:C.white} },
    { text:"Inheritance: ", options:{bold:true, color:C.sky} }, { text:"Autosomal Recessive  |  ", options:{color:C.white} },
    { text:"Most common mutation: ", options:{bold:true, color:C.gold} }, { text:"F508del (Phe508del) — ~70% of all CF alleles in European populations\n", options:{color:C.gold} },
    { text:"Incidence: ", options:{bold:true, color:C.sky} }, { text:"1 in 2500 (European)  |  Carrier frequency: 1 in 25  |  6 classes of CFTR mutations", options:{color:C.white} },
  ], { x:2.1, y:1.82, w:7.5, h:0.9, fontSize:9 });

  // --- Pathophysiology box ---
  card(s, 0.2, 2.88, 9.6, 2.5, C.navy, C.teal);
  s.addShape(pres.shapes.RECTANGLE, { x:0.2, y:2.88, w:1.8, h:2.5, fill:{color:C.teal}, line:{type:"none"} });
  s.addText("PATHO-\nPHYSIO-\nLOGY\n(2 marks)", { x:0.2, y:2.88, w:1.8, h:2.5, fontSize:10, bold:true, color:C.bg, align:"center", valign:"middle", margin:0 });

  // Flow diagram in text form
  const flow = [
    "CFTR gene mutation (F508del most common)",
    "Defective / absent CFTR Cl⁻ channel at apical epithelial membrane",
    "↓ Cl⁻ secretion + ↑ Na⁺ absorption (ENaC overactive) → Airway surface liquid (ASL) depleted",
    "Thick, viscous mucus → Mucociliary clearance impaired → Mucus plugging",
    "Bacterial colonisation: S. aureus (early) → Pseudomonas aeruginosa (chronic by age 18)",
    "Neutrophilic inflammation → Protease release → Bronchiectasis → Respiratory failure",
  ];
  flow.forEach((text, i) => {
    const y = 3.0 + i * 0.37;
    s.addShape(pres.shapes.OVAL, { x:2.05, y:y+0.04, w:0.26, h:0.26, fill:{color:C.teal}, line:{type:"none"} });
    s.addText(String(i+1), { x:2.05, y:y+0.04, w:0.26, h:0.26, fontSize:8, bold:true, color:C.bg, align:"center", valign:"middle", margin:0 });
    s.addText(text, { x:2.4, y, w:7.1, h:0.34, fontSize:8.5, color: i===0||i===5 ? C.gold : C.white, valign:"middle", margin:0 });
    if (i < 5) s.addText("▼", { x:2.12, y:y+0.28, w:0.18, h:0.14, fontSize:7, color:C.teal, align:"center" });
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 4 – MODEL 15-MARK ANSWER: PART 2 (Clinical + Diagnosis)
// ═══════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  bg(s); topBar(s, C.sky);
  sectionHeader(s, "MODEL ANSWER: 15-Mark Question — Part 2 of 3", C.sky);
  marksTag(s, "Q: Write on CF", 8.3, 0.15);

  // Clinical features table
  card(s, 0.2, 0.78, 9.6, 2.32, C.navy, C.sky);
  s.addShape(pres.shapes.RECTANGLE, { x:0.2, y:0.78, w:9.6, h:0.38, fill:{color:C.sky}, line:{type:"none"} });
  s.addText("CLINICAL FEATURES — Write as a table for maximum marks (2 marks)", { x:0.35, y:0.78, w:9.2, h:0.38, fontSize:10.5, bold:true, color:C.bg, valign:"middle", margin:0 });

  const systems = [
    ["System", "Clinical Feature", "Examiner Keyword"],
    ["Respiratory", "Chronic productive cough, Bronchiectasis, Digital clubbing, Hyperinflation, P. aeruginosa colonisation", "Barrel chest, Coarse crackles"],
    ["Pancreas", "Pancreatic insufficiency (85–90%), Steatorrhoea, CFRD (50% adults), Pancreatitis", "Fat-soluble vitamin deficiency"],
    ["GI / Intestine", "Meconium ileus (10–25% neonates), DIOS in adults (18%), Rectal prolapse", "Distal intestinal obstruction"],
    ["Liver", "Focal biliary cirrhosis, Portal hypertension (28% adults), Prolonged neonatal jaundice", "Multilobular cirrhosis"],
    ["Reproductive", "CBAVD → Azoospermia → Male infertility (98%), Reduced female fertility", "Congenital bilateral absence of vas deferens"],
    ["Sweat glands", "Salty sweat — DIAGNOSTIC FEATURE; parents kiss infant and notice salty taste", "Sweat Na⁺ + Cl⁻ elevated"],
  ];
  systems.forEach(([sys, feat, key], i) => {
    const y = 1.2 + i * 0.27;
    const fill = i===0 ? "1A3A5A" : i%2===0 ? C.bgMid : C.bgLight;
    s.addShape(pres.shapes.RECTANGLE, { x:0.25, y, w:9.5, h:0.26, fill:{color:fill}, line:{type:"none"} });
    s.addText(sys, { x:0.35, y, w:1.4, h:0.26, fontSize: i===0?8:8, bold: i===0, color: i===0?C.gold:C.sky, valign:"middle", margin:0 });
    s.addText(feat, { x:1.8, y, w:5.4, h:0.26, fontSize:7.8, color: i===0?C.white:C.white, valign:"middle", margin:0 });
    s.addText(key, { x:7.3, y, w:2.3, h:0.26, fontSize:7.5, color: i===0?C.white:C.gold, italic: i!==0, valign:"middle", margin:0 });
  });

  // Diagnosis
  card(s, 0.2, 3.25, 9.6, 2.1, C.navy, C.green);
  s.addShape(pres.shapes.RECTANGLE, { x:0.2, y:3.25, w:9.6, h:0.38, fill:{color:C.green}, line:{type:"none"} });
  s.addText("DIAGNOSIS — (1 mark) — MUST Know These Values", { x:0.35, y:3.25, w:9.2, h:0.38, fontSize:10.5, bold:true, color:C.bg, valign:"middle", margin:0 });

  const diag = [
    { test:"Sweat Chloride Test (GOLD STANDARD)", val:"< 40 = Normal | 40–59 = Borderline | ≥ 60 mmol/L = DIAGNOSTIC (two tests required)", color:C.gold },
    { test:"Newborn Screening (IRT test)", val:"Immunoreactive trypsinogen — elevated in CF; triggers sweat test confirmation", color:C.sky },
    { test:"CFTR Genotyping", val:"Identifies specific mutation class; required for CFTR modulator therapy eligibility", color:C.green },
    { test:"Spirometry (PFTs)", val:"FEV₁/FVC < 70% (obstructive) | ↑TLC and ↑RV (air trapping) | FEV₁% predicted = PRIMARY PROGNOSTIC MARKER", color:C.gold },
  ];
  diag.forEach(({test, val, color}, i) => {
    s.addText("■  " + test + ":", { x:0.35, y:3.72 + i*0.37, w:3.4, h:0.34, fontSize:8.5, bold:true, color, valign:"middle", margin:0 });
    s.addText(val, { x:3.8, y:3.72 + i*0.37, w:5.8, h:0.34, fontSize:8, color:C.white, valign:"middle", margin:0 });
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 5 – MODEL 15-MARK ANSWER: PART 3 (PT Assessment + ACT)
// ═══════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  bg(s); topBar(s, C.teal);
  sectionHeader(s, "MODEL ANSWER: 15-Mark Question — Part 3 of 3", C.teal);
  marksTag(s, "Q: Write on CF", 8.3, 0.15);

  // Assessment
  card(s, 0.2, 0.78, 4.5, 2.0, C.navy, C.sky);
  s.addShape(pres.shapes.RECTANGLE, { x:0.2, y:0.78, w:4.5, h:0.36, fill:{color:C.sky}, line:{type:"none"} });
  s.addText("PHYSIOTHERAPY ASSESSMENT (2 marks)", { x:0.3, y:0.78, w:4.3, h:0.36, fontSize:9.5, bold:true, color:C.bg, valign:"middle", margin:0 });
  const assess = [
    ["Inspection", "Barrel chest, Digital clubbing, Cyanosis, Accessory muscle use, Harrison's sulcus, Low BMI"],
    ["Palpation", "Reduced chest expansion (bilateral), Tactile fremitus changes"],
    ["Percussion", "Hyperresonance (emphysema); Dullness (consolidation/plugging)"],
    ["Auscultation", "Coarse crackles (secretions), Wheeze, Reduced air entry"],
    ["Sputum", "Volume, colour (yellow-green=infected), consistency, organisms"],
  ];
  assess.forEach(([head, body], i) => {
    s.addText(head + ":", { x:0.35, y:1.22 + i*0.3, w:1.1, h:0.26, fontSize:8.5, bold:true, color:C.sky, valign:"middle", margin:0 });
    s.addText(body, { x:1.5, y:1.22 + i*0.3, w:2.95, h:0.26, fontSize:8, color:C.white, valign:"middle", margin:0 });
  });

  // Outcome measures
  card(s, 4.85, 0.78, 4.95, 2.0, C.navy, C.green);
  s.addShape(pres.shapes.RECTANGLE, { x:4.85, y:0.78, w:4.95, h:0.36, fill:{color:C.green}, line:{type:"none"} });
  s.addText("OUTCOME MEASURES", { x:4.95, y:0.78, w:4.7, h:0.36, fontSize:9.5, bold:true, color:C.bg, valign:"middle", margin:0 });
  const om = [
    ["Lung function", "FEV₁% predicted (PRIMARY PROGNOSTIC MARKER)"],
    ["Exercise capacity", "6MWT; Cycle ergometry; VO₂peak"],
    ["QoL", "CFQ-R (CF Questionnaire – Revised) — CF-specific"],
    ["Dyspnoea", "Modified Borg (0–10); MRC Dyspnoea Scale"],
    ["Nutritional", "BMI, z-score (children), FFMI"],
  ];
  om.forEach(([k, v], i) => {
    s.addText(k + ":", { x:5.0, y:1.22 + i*0.3, w:1.4, h:0.26, fontSize:8.5, bold:true, color:C.green, valign:"middle", margin:0 });
    s.addText(v, { x:6.45, y:1.22 + i*0.3, w:3.1, h:0.26, fontSize:8, color:C.white, valign:"middle", margin:0 });
  });

  // ACT Section — the BIG section
  card(s, 0.2, 2.93, 9.6, 2.42, C.navy, C.gold);
  s.addShape(pres.shapes.RECTANGLE, { x:0.2, y:2.93, w:9.6, h:0.38, fill:{color:C.gold}, line:{type:"none"} });
  s.addText("AIRWAY CLEARANCE TECHNIQUES (ACT) — MOST IMPORTANT SECTION (3 marks)", { x:0.35, y:2.93, w:9.2, h:0.38, fontSize:10.5, bold:true, color:C.bg, valign:"middle", margin:0 });

  // Inhalation sequence banner
  s.addShape(pres.shapes.RECTANGLE, { x:0.25, y:3.37, w:9.5, h:0.32, fill:{color:"1A3A2A"}, line:{type:"none"} });
  s.addText([
    { text:"Sequence BEFORE ACT:  ", options:{bold:true, color:C.gold} },
    { text:"(1) Bronchodilator  →  (2) Hypertonic Saline / DNase  →  (3) ACT  →  (4) Inhaled Antibiotic  (LAST — reaches deeper airways post-clearance)", options:{color:C.white} },
  ], { x:0.35, y:3.37, w:9.2, h:0.3, fontSize:8.5, valign:"middle" });

  const acts = [
    { name:"ACBT", phases:"(1) Breathing Control (3–5 tidal breaths) → (2) Thoracic Expansion Exercises (3–5 deep breaths + 3-sec hold) → (3) Forced Expiration / Huff (open glottis)", note:"Repeat 2–4 cycles; No device needed; Most commonly taught", color:C.teal },
    { name:"Autogenic\nDrainage (AD)", phases:"(1) Unsticking: low lung volume breathing → (2) Collecting: mid lung volume → (3) Evacuating: high lung volume + huff", note:"No device; independent; requires cooperation and training", color:C.sky },
    { name:"PEP Therapy", phases:"Breathe in (larger than tidal) → exhale against resistance (10–20 cmH₂O back pressure) → 2–3 huffs  |  I:E = 1:3  |  15 breaths × 3–4 cycles", note:"PEP mask / Acapella / Flutter / Aerobika", color:C.green },
  ];
  acts.forEach(({name, phases, note, color}, i) => {
    const x = 0.25 + i * 3.22;
    card(s, x, 3.77, 3.12, 1.45, "0A1A2E", color);
    s.addText(name, { x:x+0.1, y:3.8, w:2.9, h:0.32, fontSize:9.5, bold:true, color, valign:"middle", margin:0 });
    s.addText(phases, { x:x+0.1, y:4.15, w:2.9, h:0.7, fontSize:7.5, color:C.white });
    s.addText("→ " + note, { x:x+0.1, y:4.9, w:2.9, h:0.25, fontSize:7, color:C.light, italic:true });
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 6 – CASE-BASED ANSWER TEMPLATE
// ═══════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  bg(s); topBar(s, C.purple);
  sectionHeader(s, "CASE-BASED QUESTION — MODEL ANSWER TEMPLATE", C.purple);
  marksTag(s, "Case Study", 8.4, 0.15, C.purple);

  // Case vignette
  card(s, 0.2, 0.78, 9.6, 0.95, "1A0A2E", C.purple);
  s.addText("📋  CASE:", { x:0.35, y:0.82, w:0.85, h:0.32, fontSize:9, bold:true, color:C.purple, valign:"middle", margin:0 });
  s.addText(
    "A 10-year-old boy presents with chronic productive cough since infancy, failure to thrive, recurrent chest infections, and foul-smelling bulky stools. On examination: barrel chest, digital clubbing, bilateral coarse crackles, SpO₂ 92%. Parents state he has a 'salty' taste when kissed. FEV₁ = 55% predicted.",
    { x:1.15, y:0.82, w:8.5, h:0.88, fontSize:9, color:C.white }
  );

  // Answer structure in 5 steps
  const steps = [
    {
      num:"1", head:"DIAGNOSIS (with justification)", color:C.purple,
      body:[
        "Diagnosis: Cystic Fibrosis",
        "Justification: Chronic productive cough + failure to thrive + steatorrhoea + digital clubbing + salty taste (elevated sweat NaCl) + obstructive pattern on PFTs (FEV₁ 55% predicted)",
        "Confirm with: Sweat chloride test (≥60 mmol/L = diagnostic) + CFTR genotyping (F508del mutation most likely)"
      ]
    },
    {
      num:"2", head:"PROBLEM LIST (from case)", color:C.sky,
      body:[
        "Impairments: Obstructive lung disease (FEV₁ 55%), chronic sputum retention, digital clubbing/hypoxaemia (SpO₂ 92%), malnutrition (failure to thrive), pancreatic insufficiency",
        "Activity limitations: Reduced exercise tolerance, inability to keep up with peers, impaired school attendance",
        "Participation: Restricted physical play, social isolation, psychological impact of chronic illness"
      ]
    },
    {
      num:"3", head:"SMART GOALS", color:C.green,
      body:[
        "Short-term (2–4 wk): Child will clear sputum independently with ACBT within 1 week; maintain SpO₂ ≥88% during play activities",
        "Long-term (3–6 months): FEV₁ maintained above current baseline; independent twice-daily ACT routine without prompting; weight gain ≥0.5 kg/month"
      ]
    },
    {
      num:"4", head:"PHYSIOTHERAPY MANAGEMENT", color:C.gold,
      body:[
        "Inhalation sequence: Salbutamol → Hypertonic saline (7%) → ACT → Inhaled antibiotic (if prescribed)",
        "ACT: Teach ACBT to child + parents; twice daily (30 min each session); increase to 3–4×/day during exacerbations; consider OPEP device (Acapella) for independence and adherence",
        "Exercise: 30 min aerobic (swimming, cycling) 3–5×/week; strength training 2–3×/week; swimming especially beneficial in CF (warm humid air)",
        "Education: Parents taught percussion/PD; recognise exacerbation signs; cross-infection prevention (NO contact with other CF patients)"
      ]
    },
    {
      num:"5", head:"COMPLICATIONS TO WATCH", color:C.coral,
      body:[
        "Pneumothorax: Stop ACT; urgent referral; restart only after medical clearance",
        "Haemoptysis (minor <250 mL): Modify ACT — avoid head-down positions and percussion over bleeding site",
        "Haemoptysis (massive >250 mL): STOP ALL ACT immediately; medical emergency",
        "CFRD: Coordinate exercise and ACT around insulin/meals; annual OGTT screening from age 10"
      ]
    },
  ];

  steps.forEach(({num, head, color, body}, i) => {
    const col = i < 3 ? 0 : 1;
    const row = i < 3 ? i : i - 3;
    const x = col === 0 ? 0.2 : 5.1;
    const y = 1.85 + row * 1.22;
    const h = i === 4 ? 1.25 : 1.15;
    const w = col === 0 ? 4.7 : 4.7;
    card(s, x, y, w, h, "0A0E1E", color);
    s.addShape(pres.shapes.OVAL, { x:x+0.08, y:y+0.1, w:0.32, h:0.32, fill:{color}, line:{type:"none"} });
    s.addText(num, { x:x+0.08, y:y+0.1, w:0.32, h:0.32, fontSize:10, bold:true, color:C.bg, align:"center", valign:"middle", margin:0 });
    s.addText(head, { x:x+0.5, y:y+0.08, w:w-0.6, h:0.33, fontSize:9, bold:true, color, valign:"middle", margin:0 });
    body.forEach((line, j) => {
      s.addText("• " + line, { x:x+0.15, y:y+0.45+j*0.22, w:w-0.25, h:0.22, fontSize:7.8, color:C.white });
    });
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 7 – SHORT NOTE (5-10 marks): ACBT + ACT
// ═══════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  bg(s); topBar(s, C.orange);
  sectionHeader(s, "SHORT NOTE MODEL ANSWER — Airway Clearance Techniques in CF  (5–10 marks)", C.orange);
  marksTag(s, "5–10 marks", 8.3, 0.15, C.orange);

  // How to start short note box
  card(s, 0.2, 0.78, 9.6, 0.55, "1A1A00", C.gold);
  s.addText([
    { text:"How to start: ", options:{bold:true, color:C.gold} },
    { text:'"CF patients require lifelong, twice-daily airway clearance therapy (ACT) to compensate for defective mucociliary clearance. The goal is to mobilise secretions from peripheral to central airways for expectoration. The inhalation therapy sequence before ACT is: ', options:{color:C.white} },
    { text:"Bronchodilator → Hypertonic Saline / DNase → ACT → Inhaled Antibiotic.", options:{bold:true, color:C.gold} },
    { text:'"', options:{color:C.white} },
  ], { x:0.35, y:0.8, w:9.2, h:0.5, fontSize:9, italic:true });

  const techniques = [
    {
      name:"ACBT\n(Active Cycle of Breathing)", color:C.teal,
      phases:[
        ["Phase 1: Breathing Control", "3–5 relaxed tidal breaths (diaphragmatic). Purpose: Rest airways, reduce bronchospasm"],
        ["Phase 2: Thoracic Expansion (TEE)", "3–5 deep slow breaths with 3-second inspiratory hold. Purpose: Collateral ventilation, mobilise secretions peripherally"],
        ["Phase 3: Forced Expiration / Huff", "Medium or low lung volume huff — open glottis (not cough). Purpose: Move secretions centrally"],
        ["Cycle", "Repeat 2–4 cycles until no more secretions. No device needed. Evidence: Cochrane 2023 (Wilson et al.)"],
      ]
    },
    {
      name:"PEP Therapy\n(Positive Expiratory Pressure)", color:C.green,
      phases:[
        ["Mechanism", "Breathe in slightly larger than tidal → exhale against resistance → 10–20 cmH₂O back pressure → prevents premature airway collapse → secretions mobilised"],
        ["Technique", "I:E ratio = 1:3 | 15 breaths per cycle | 3–4 cycles | followed by 2–3 huffs each cycle"],
        ["Devices", "PEP mask (standard) | Flutter (oscillating PEP + vibration) | Acapella (position-independent OPEP) | Aerobika (can nebulise simultaneously)"],
        ["Preferred when", "Child/patient who prefers device; independence; adherence in teenagers"],
      ]
    },
    {
      name:"Autogenic Drainage\n(AD)", color:C.sky,
      phases:[
        ["Phase 1: Unsticking", "Low lung volume (ERV) tidal breathing × 4–8 breaths + suppress cough. Loosens secretions in PERIPHERAL airways"],
        ["Phase 2: Collecting", "Mid lung volume (tidal) breathing × 4–8 breaths. Moves secretions to INTERMEDIATE airways"],
        ["Phase 3: Evacuating", "High lung volume (IRV) breathing → huff/cough. Clears secretions from CENTRAL airways"],
        ["Advantage", "No device; completely independent; patient-preferred in adults. Requires good cooperation and training. Evidence: Cochrane 2021 (Burnham et al.)"],
      ]
    },
  ];

  techniques.forEach(({name, color, phases}, i) => {
    const x = 0.2 + i * 3.28;
    s.addShape(pres.shapes.RECTANGLE, { x, y:1.45, w:3.1, h:0.36, fill:{color}, line:{type:"none"} });
    s.addText(name, { x, y:1.45, w:3.1, h:0.36, fontSize:9, bold:true, color:C.bg, align:"center", valign:"middle", margin:0 });
    card(s, x, 1.81, 3.1, 3.55, "0A0E1E", color);
    phases.forEach(([label, body], j) => {
      s.addText(label + ":", { x:x+0.1, y:1.9 + j*0.84, w:2.9, h:0.25, fontSize:8.5, bold:true, color, valign:"middle", margin:0 });
      s.addText(body, { x:x+0.1, y:2.17 + j*0.84, w:2.9, h:0.5, fontSize:8, color:C.white });
    });
  });

  s.addText("⭐ REMEMBER: In exams, always compare the three techniques in a table OR describe their phases sequentially. State the Cochrane evidence briefly.", {
    x:0.2, y:5.28, w:9.6, h:0.24, fontSize:7.5, color:C.gold, bold:true, align:"center"
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 8 – SHORT NOTE: Exercise in CF + Complications
// ═══════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  bg(s); topBar(s, C.green);
  sectionHeader(s, "SHORT NOTES — Exercise in CF  +  Complications & Modifications  (5 marks each)", C.green);

  // Left: Exercise
  card(s, 0.2, 0.78, 4.6, 4.57, C.navy, C.green);
  s.addShape(pres.shapes.RECTANGLE, { x:0.2, y:0.78, w:4.6, h:0.38, fill:{color:C.green}, line:{type:"none"} });
  s.addText("EXERCISE IN CF — Short Note", { x:0.3, y:0.78, w:4.4, h:0.38, fontSize:10.5, bold:true, color:C.bg, valign:"middle", margin:0 });

  s.addText([
    { text:"Key Principle: ", options:{bold:true, color:C.gold} },
    { text:"Exercise is COMPLEMENTARY to ACT, NOT a substitute (Cochrane 2022 — Heinz et al.).\n\n", options:{color:C.white} },
    { text:"Aerobic Exercise:\n", options:{bold:true, color:C.green} },
    { text:"• Mode: Walking, cycling, swimming (swimming preferred — warm humid air ↓ bronchospasm)\n• Intensity: Borg 4–6 / 60–80% VO₂peak\n• Duration: 30–45 min\n• Frequency: 3–5 days/week\n• Progress: Duration first → then intensity\n\n", options:{color:C.white} },
    { text:"Resistance Training:\n", options:{bold:true, color:C.green} },
    { text:"• Muscles: Quadriceps (primary), shoulder girdle, core\n• Load: 60–80% 1-RM | 3 × 8–12 reps | 2–3 days/week\n• Why: Peripheral muscle wasting from chronic inflammation, corticosteroids, malnutrition\n\n", options:{color:C.white} },
    { text:"IMT (Inspiratory Muscle Training):\n", options:{bold:true, color:C.sky} },
    { text:"• When: Reduced MIP; advanced CF; post-transplant\n• Device: Threshold IMT; 30–50% MIP → Daily × 30 breaths", options:{color:C.white} },
  ], { x:0.35, y:1.25, w:4.2, h:3.95, fontSize:8.5 });

  // Right: Complications
  card(s, 5.0, 0.78, 4.8, 4.57, C.navy, C.coral);
  s.addShape(pres.shapes.RECTANGLE, { x:5.0, y:0.78, w:4.8, h:0.38, fill:{color:C.coral}, line:{type:"none"} });
  s.addText("COMPLICATIONS + PT MODIFICATIONS", { x:5.1, y:0.78, w:4.6, h:0.38, fontSize:10.5, bold:true, color:C.white, valign:"middle", margin:0 });

  const comps = [
    {
      c:"PNEUMOTHORAX", icon:"⚡",
      pt:"STOP all ACT and vigorous exercise immediately\nRefer for urgent medical management\nRestart ACT and exercise only after chest drain removal + medical clearance",
      col:C.coral
    },
    {
      c:"HAEMOPTYSIS (Minor < 250 mL)", icon:"🩸",
      pt:"CONTINUE ACT with modifications:\n→ Avoid head-down (postural drainage) positions\n→ Avoid percussion over bleeding lung segment\n→ Use PEP / ACBT in upright sitting only",
      col:C.gold
    },
    {
      c:"HAEMOPTYSIS (Massive > 250 mL)", icon:"🚨",
      pt:"STOP ALL ACT IMMEDIATELY\nMedical emergency → Bronchial artery embolisation\nResume ACT only after haemostasis confirmed by physician",
      col:C.coral
    },
    {
      c:"CFRD (CF-Related Diabetes)", icon:"💉",
      pt:"Coordinate exercise and ACT around insulin timing\nMonitor blood glucose before/after exercise\nAnnual OGTT screening from age 10",
      col:C.sky
    },
    {
      c:"RESPIRATORY FAILURE / NIV", icon:"😷",
      pt:"Adapt ACT: use NIV-assisted techniques\nSupplemental O₂ during exercise (SpO₂ ≥88%)\nModify exercise intensity; frequent rest periods",
      col:C.purple
    },
  ];
  comps.forEach(({c, icon, pt, col}, i) => {
    card(s, 5.1, 1.25 + i*0.85, 4.6, 0.78, "0A0A1E", col);
    s.addText(icon + "  " + c, { x:5.2, y:1.3 + i*0.85, w:4.35, h:0.28, fontSize:8.5, bold:true, color:col, valign:"middle", margin:0 });
    s.addText(pt, { x:5.2, y:1.6 + i*0.85, w:4.35, h:0.4, fontSize:7.8, color:C.white });
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 9 – KEY NUMBERS + VIVA BOMBS
// ═══════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  bg(s); topBar(s, C.gold);
  sectionHeader(s, "KEY NUMBERS + VIVA BOMBS — Memorise These Before Your Exam", C.gold);

  const numbers = [
    ["Sweat Chloride DIAGNOSTIC", "≥ 60 mmol/L (TWO separate tests required)"],
    ["Sweat Chloride BORDERLINE", "40–59 mmol/L"],
    ["Sweat Chloride NORMAL", "< 40 mmol/L"],
    ["Most common mutation", "F508del (Phe508del) — ~70% of CF alleles (European)"],
    ["Incidence (European)", "1 in 2,500 births | Carrier: 1 in 25"],
    ["P. aeruginosa colonisation", "80% of CF patients by age 18 years"],
    ["CFRD (CF-Related Diabetes)", "Up to 50% of adult CF patients"],
    ["Male infertility (CBAVD)", "98% of CF males — congenital bilateral absence of vas deferens"],
    ["Meconium ileus", "10–25% of CF neonates"],
    ["FEV₁% predicted", "PRIMARY prognostic marker in CF"],
    ["ACT frequency (stable)", "Twice daily | 30 min each session"],
    ["ACT frequency (exacerbation)", "3–4 times per day"],
    ["Median survival", "Now extending beyond 47 years (with modern therapy)"],
    ["PEP pressure target", "10–20 cmH₂O during expiration (I:E ratio 1:3)"],
    ["Haemoptysis threshold", "Minor < 250 mL (modify) | Massive > 250 mL (STOP ACT)"],
  ];

  numbers.forEach(([label, val], i) => {
    const col = i < 8 ? 0 : 1;
    const row = i < 8 ? i : i - 8;
    const x = col === 0 ? 0.2 : 5.1;
    const y = 0.85 + row * 0.58;
    const fillColor = i % 2 === 0 ? C.bgMid : C.bgLight;
    s.addShape(pres.shapes.RECTANGLE, { x, y, w:4.7, h:0.5, fill:{color:fillColor}, line:{color: col===0?C.teal:C.gold, width:1} });
    s.addText(label, { x:x+0.1, y:y+0.03, w:4.4, h:0.22, fontSize:8.5, bold:true, color: col===0?C.sky:C.gold, valign:"middle", margin:0 });
    s.addText(val, { x:x+0.1, y:y+0.26, w:4.4, h:0.2, fontSize:8, color:C.white, valign:"middle", margin:0 });
  });

  s.addText("⭐ These numbers come up in EVERY MCQ, viva, and practical exam. Write them on a card and review daily.", {
    x:0.2, y:5.28, w:9.6, h:0.24, fontSize:8, color:C.gold, bold:true, align:"center"
  });
}

// ═══════════════════════════════════════════════════════════════════
// SLIDE 10 – COMMON MISTAKES + EXAMINER TIPS
// ═══════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  bg(s); topBar(s, C.coral);
  sectionHeader(s, "COMMON EXAM MISTAKES  +  Examiner Tips for CF", C.coral);

  // Left: Mistakes
  card(s, 0.2, 0.78, 4.55, 4.58, C.navy, C.coral);
  s.addShape(pres.shapes.RECTANGLE, { x:0.2, y:0.78, w:4.55, h:0.4, fill:{color:C.coral}, line:{type:"none"} });
  s.addText("❌  MISTAKES STUDENTS MAKE", { x:0.3, y:0.78, w:4.3, h:0.4, fontSize:11, bold:true, color:C.white, valign:"middle", margin:0 });

  const mistakes = [
    ["Saying exercise can REPLACE ACT", "Exercise is COMPLEMENTARY — never a substitute (Cochrane 2022)"],
    ["Wrong sweat chloride cut-off", "≥ 60 mmol/L diagnostic — NOT 40 or 50"],
    ["Forgetting inhalation sequence", "Bronchodilator FIRST → Saline/DNase → ACT → Antibiotic LAST"],
    ["Saying CF affects only lungs", "CF is MULTISYSTEM: lung + pancreas + liver + intestine + reproductive"],
    ["Missing cross-infection rule", "CF patients must NOT share rooms or equipment with other CF patients"],
    ["Wrong ACT for haemoptysis", "Massive haemoptysis → STOP ACT; Minor → Modify (no head-down, no percussion over that site)"],
    ["Not knowing AD phases", "Unsticking (low vol) → Collecting (mid vol) → Evacuating (high vol) — all 3 required"],
    ["Confusing organisms", "S. aureus = EARLY coloniser; P. aeruginosa = CHRONIC/LATE — 80% by age 18; B. cepacia = RARE but WORST prognosis"],
  ];
  mistakes.forEach(([wrong, correct], i) => {
    card(s, 0.3, 1.27 + i*0.47, 4.3, 0.42, "1A050A", i%2===0?C.coral:C.orange);
    s.addText("✗  " + wrong, { x:0.4, y:1.3 + i*0.47, w:4.1, h:0.2, fontSize:8, bold:true, color:C.coral, valign:"middle", margin:0 });
    s.addText("✓  " + correct, { x:0.4, y:1.52 + i*0.47, w:4.1, h:0.18, fontSize:7.8, color:C.white, valign:"middle", margin:0 });
  });

  // Right: Examiner tips
  card(s, 5.0, 0.78, 4.8, 4.58, C.navy, C.gold);
  s.addShape(pres.shapes.RECTANGLE, { x:5.0, y:0.78, w:4.8, h:0.4, fill:{color:C.gold}, line:{type:"none"} });
  s.addText("⭐  EXAMINER TIPS — Score FULL MARKS", { x:5.1, y:0.78, w:4.6, h:0.4, fontSize:11, bold:true, color:C.bg, valign:"middle", margin:0 });

  const tips = [
    ["Start with the ATS definition", "For any CF/PR question — shows you know evidence base"],
    ["Draw the CFTR mutation table", "6 classes with 1 example each — easy 2 marks"],
    ["Write Sweat Chloride values early", "< 40 / 40–59 / ≥ 60 — examiners scan for this"],
    ["Use headings + sub-headings", "Examiners scan answers — bold headings get you marks even if body is incomplete"],
    ["State Cochrane evidence for ACT", "ACBT (Wilson 2023), AD (Burnham 2021), Exercise vs ACT (Heinz 2022)"],
    ["Draw the ACT inhalation sequence", "Arrow diagram: Bronchodilator → Saline → ACT → Antibiotic gets visual marks"],
    ["Always include complication modifications", "Pneumothorax + haemoptysis with exact thresholds shows clinical thinking"],
    ["Mention CFQ-R for QoL", "CF-specific quality of life tool — shows domain knowledge"],
    ["SMART goals in case-based", "Write one short-term and one long-term goal — shows clinical reasoning"],
    ["End with prognosis", "FEV₁% predicted as primary prognostic marker — concluding sentence rounds off the answer"],
  ];
  tips.forEach(([tip, why], i) => {
    s.addText("⭐  " + tip, { x:5.1, y:1.27 + i*0.42, w:4.55, h:0.2, fontSize:8.5, bold:true, color:C.gold, valign:"middle", margin:0 });
    s.addText("→  " + why, { x:5.1, y:1.49 + i*0.42, w:4.55, h:0.17, fontSize:7.8, color:C.light, valign:"middle", margin:0 });
  });
}

// ─── WRITE FILE ───────────────────────────────────────────────────
pres.writeFile({ fileName: "/home/daytona/workspace/cf-exam-ppt/CF_Exam_Answer_Templates_BPT.pptx" })
  .then(() => console.log("✅ Done!"))
  .catch(e => console.error("❌", e));

Running Command

cd /home/daytona/workspace/cf-exam-ppt && node cf_exam_answers.js 2>&1

Running Command

ls -lh /home/daytona/workspace/cf-exam-ppt/CF_Exam_Answer_Templates_BPT.pptx

Your exam PPT is ready! ✅

CF Exam Answer Templates BPT

Presentation · PPTX

10 slides — dark navy theme — designed specifically for exam writing:

Slide	What It Shows
1	Cover + what this deck covers
2	How to structure a CF answer — marks allocation + step-by-step sequence
3	Model 15-mark answer Part 1 — Definition, Genetics, Pathophysiology (with flow diagram)
4	Model 15-mark answer Part 2 — Clinical Features table + Diagnosis values
5	Model 15-mark answer Part 3 — PT Assessment + ACT techniques + inhalation sequence
6	Full Case-Based Model Answer — Diagnosis, Problem List, SMART Goals, Management, Complications
7	Short Note (5-10 marks) — ACBT vs Autogenic Drainage vs PEP — all 3 side-by-side
8	Short Note — Exercise in CF + Complications with exact modifications
9	Key Numbers to memorise — 15 values examiners test (sweat chloride, mutation frequency, etc.)
10	Common exam mistakes + Examiner tips for full marks

Bronchitis

Finding Sources

Searching PubMed

chronic bronchitis COPD physiotherapy management exercise

Finding Sources

Reading File

Searching PubMed

acute bronchitis treatment antibiotic

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

BRONCHITIS (Acute and Chronic)

BPT / MPT Final Year - Clinical, Evidence-Based Format

✅ 1. DEFINITION AND CLASSIFICATION

A. Acute Bronchitis

Definition: Acute bronchitis is an acute, self-limited inflammation of the large airways (trachea and bronchi) without evidence of pneumonia or underlying lung disease, most commonly caused by viral respiratory infections, characterised by cough with or without sputum production lasting 10-20 days.

Fishman's Pulmonary Diseases and Disorders, 2-Volume Set

B. Chronic Bronchitis

Definition (Clinical - WHO/ATS):

Chronic bronchitis is defined as persistent productive cough for at least 3 consecutive months in at least 2 consecutive years, in the absence of any other identifiable cause.

Robbins, Cotran & Kumar Pathologic Basis of Disease; Robbins & Kumar Basic Pathology

⭐ Key exam point: Chronic bronchitis is defined clinically (by symptoms). Emphysema is defined anatomically/pathologically. This distinction is commonly asked in viva.

Classification:

Type	Duration	Mechanism	Reversibility
Acute Bronchitis	< 3 weeks	Viral (90%) / Bacterial	Self-limiting; complete recovery
Chronic Bronchitis	≥ 3 months/year × 2 consecutive years	Smoking, pollutants, recurrent infection	Partially reversible; component of COPD
Acute-on-Chronic Bronchitis (AECB)	Acute exacerbation on chronic background	Viral / Bacterial	Treat acute; return to chronic baseline
Asthmatic Bronchitis	Variable	Hyperresponsive airways + bronchitis	Partially reversible with bronchodilators

✅ 2. DETAILED ANATOMY AND BIOMECHANICS

Relevant Anatomy:

Airways involved: Trachea + Main bronchi + Lobar bronchi + Segmental bronchi (large airways); in advanced chronic bronchitis - also small bronchi and bronchioles (< 2-3 mm diameter)
Mucous glands: Submucosal glands in trachea and large bronchi - secrete mucus; enlarged in chronic bronchitis (Reid Index increases)
Goblet cells: Line the airway epithelium; hypersecrete mucus - increased in number in chronic bronchitis especially in small airways
Cilia: Beat frequency 10-15 Hz; clear mucus toward larynx; damaged and paralysed by tobacco smoke → mucociliary dysfunction
Smooth muscle: In airway walls; hypertrophies in chronic bronchitis → contributes to airway narrowing
Reid Index:
- = Thickness of mucous gland layer / Thickness of bronchial wall between epithelium and cartilage
- Normal: 0.4
- Increased in chronic bronchitis (> 0.4), proportional to severity
- ⭐ Classically asked in exams and viva

Biomechanics of Airway Obstruction in Chronic Bronchitis:

Mucus hypersecretion → airway lumen narrowing
Mucosal oedema and inflammation → further narrowing
Smooth muscle hypertrophy + peribronchial fibrosis → fixed obstruction
Air trapping → hyperinflation → increased FRC and RV
V/Q mismatch → hypoxaemia → compensatory polycythaemia → hyperviscosity

✅ 3. PATHOPHYSIOLOGY

Acute Bronchitis:

Viral / Bacterial infection (90% viral)
        ↓
Mucosal inflammation of trachea + large bronchi
        ↓
Mucosal oedema + increased mucus secretion
        ↓
Cough (with/without sputum) + Wheeze (if bronchospasm)
        ↓
Self-limiting: Resolution in 10-20 days

Chronic Bronchitis:

Primary initiating factors: Cigarette smoke (90%), air pollutants (SO₂, NO₂, dust)

Chronic inhalation of noxious substances (tobacco smoke)
        ↓
Mucosal damage + Release of cytokines (IL-13, histamine)
        ↓
(1) Hypertrophy of submucosal mucous glands (↑ Reid Index)
(2) ↑ Goblet cells in small bronchi/bronchioles
(3) Chronic inflammation: Neutrophils + Lymphocytes + Macrophages
(No eosinophils — contrast with asthma)
        ↓
Mucus hypersecretion → Impaired mucociliary clearance (cilia damaged by smoke)
        ↓
Mucus plugging → Small airway obstruction (< 2-3 mm airways)
        ↓
Chronic bronchiolitis + Peribronchial fibrosis
        ↓
Airflow obstruction (obstructive pattern on spirometry)
        ↓
Air trapping → Hyperinflation → V/Q mismatch
        ↓
Hypoxaemia → Pulmonary hypertension → Cor pulmonale

Additional mechanisms:

Acquired CFTR dysfunction from smoking → abnormal dehydrated mucus (worsens mucus clearance)
Infection: Does not initiate chronic bronchitis but maintains and exacerbates it; bacteria colonise (S. pneumoniae, H. influenzae, M. catarrhalis)
Cigarette smoke: damages cilia + interferes with mucociliary clearance + induces oxidative stress

✅ 4. CLINICAL PRESENTATION

Acute Bronchitis:

Feature	Details
Onset	Acute, follows URTI by a few days
Cough	Hallmark; with or without sputum; lasts 10-20 days (can persist > 1 month)
Sputum	Initially clear/white; may become yellow-green (does NOT reliably indicate bacterial infection)
Wheeze	May be present if bronchospasm
Low-grade fever	Common; high fever suggests pneumonia
Headache, rhinorrhoea, sore throat	Associated URTI symptoms
Constitutional symptoms	Mild fatigue, malaise
Dyspnoea	Absent or mild (if present - consider pneumonia/asthma)

Chronic Bronchitis - "Blue Bloater" (classic type B COPD patient):

Feature	Details
Chronic productive cough	Diagnostic; morning cough with mucoid sputum (early) → purulent during exacerbations
Dyspnoea	Initially only on exertion; progressive
Cyanosis	Central (blue/dusky) - hypoxaemia
Oedema	Ankle and leg oedema (cor pulmonale)
Appearance	Overweight/obese, plethoric, cyanosed - "Blue Bloater"
Wheeze	Expiratory wheeze (airflow obstruction)
Barrel chest	Late finding (when emphysema coexists)
Polycythaemia	Secondary to chronic hypoxaemia
Recurrent exacerbations	Triggered by infections; progressive decline in FEV₁

"Blue Bloater" vs "Pink Puffer" (Exam Favourite):

Feature	Blue Bloater (Chronic Bronchitis)	Pink Puffer (Emphysema)
Body habitus	Obese / overweight	Thin, cachexic
Colour	Cyanosed (blue)	Pink (normal colour)
Oedema	Present (cor pulmonale)	Absent
Breathlessness	Mild-moderate	Severe (predominant symptom)
Cough	Productive, copious sputum	Minimal / dry
PaO₂	Low (hypoxaemia)	Near normal
PaCO₂	High (hypercapnia)	Normal or low
Polycythaemia	Present	Absent
Cor pulmonale	Common	Late
Mechanism	V/Q mismatch + ↓ ventilatory drive	↑ WOB; maintains PaO₂ by hyperventilation

⭐ Note: Most COPD patients have a mixed picture of both chronic bronchitis and emphysema. "Blue Bloater" and "Pink Puffer" are clinical extremes, not mutually exclusive.

✅ 5. MUSCLE-WISE ASSESSMENT

Respiratory Muscles:

Muscle	Assessment	Finding
Diaphragm	Diaphragmatic excursion; ultrasound; sniff nasal pressure	Flattened (hyperinflation in chronic); reduced excursion
Accessory muscles (SCM, Scalenes)	Inspection at rest	Hypertrophied; active at rest in severe disease
Abdominals	Active expiration observed	Recruited in forced expiration
Inspiratory muscles	MIP (Max Inspiratory Pressure)	Reduced in moderate-severe chronic bronchitis
Expiratory muscles	MEP (Max Expiratory Pressure)	Reduced; important for effective cough

Peripheral Muscles:

Muscle	Finding	Cause
Quadriceps	Weakness (most common)	Deconditioning + systemic inflammation
Upper limb muscles	Reduced grip strength	General deconditioning
Respiratory muscles	Weakness in advanced disease	Hyperinflation disadvantage + malnutrition

✅ 6. EXPECTED POSITIVE FINDINGS

Inspection:

Acute Bronchitis:

No significant findings; mild respiratory distress at most
Rhinorrhoea, mild throat redness

Chronic Bronchitis:

Barrel chest (AP diameter increased, if emphysema coexists)
Central cyanosis (tongue, lips)
Pursed lip breathing (if significant obstruction)
Use of accessory muscles
Ankle oedema (cor pulmonale)
Plethora (polycythaemia)
Nicotine staining of fingers

Palpation:

Reduced chest expansion (bilateral, chronic)
Reduced tactile fremitus in areas of mucus plugging

Percussion:

Hyperresonance (air trapping in chronic)
Cardiac dullness reduced (hyperinflation)

Auscultation:

Finding	Acute Bronchitis	Chronic Bronchitis
Air entry	Normal or mildly reduced	Reduced bilaterally
Added sounds	Coarse crackles, wheeze	Coarse crackles (clear partially on coughing), expiratory wheeze
Bronchial sounds	Absent (differentiates from pneumonia)	May be present in consolidated areas

⭐ Key diagnostic clue: In acute bronchitis, there should be no bronchial breathing and no dullness on percussion - these suggest pneumonia.

Spirometry / PFTs:

Test	Acute Bronchitis	Chronic Bronchitis
FEV₁	Normal (transient reduction if bronchospasm)	Reduced
FVC	Normal	Reduced
FEV₁/FVC	Normal	< 0.70 (post-bronchodilator)
TLC	Normal	Increased (air trapping)
RV	Normal	Increased
DLCO	Normal	Reduced (if emphysema coexists)

✅ 7. DIFFERENTIAL DIAGNOSIS

Condition	Key Differentiating Feature
Pneumonia	Fever > 38°C; bronchial breath sounds; lobar dullness; CXR consolidation
Asthma	Episodic; reversible bronchospasm; atopy; eosinophilia; normal between episodes
COPD Exacerbation (AECB)	Known COPD; baseline FEV₁ reduced; older patient, smoker
Pulmonary Tuberculosis	Haemoptysis; night sweats; weight loss; AFB on sputum; apical lesion on CXR
Bronchiectasis	Copious purulent sputum; digital clubbing; tram-track signs on HRCT
Cystic Fibrosis	Young patient; elevated sweat chloride; CFTR mutation
Lung Cancer	Haemoptysis; weight loss; clubbing; hilar mass on CXR
Congestive Heart Failure	Bilateral basal crackles; raised JVP; cardiomegaly; responds to diuretics
GERD-related cough	Cough worsens lying flat; heartburn; no sputum; upper GI symptoms

✅ 8. INVESTIGATIONS

Acute Bronchitis:

Investigation	Finding / Purpose
Clinical diagnosis	Usually sufficient in young healthy adults
Chest X-Ray	Normal (to exclude pneumonia); indicated in elderly/comorbid patients
SpO₂	Usually normal; if reduced - consider pneumonia
Sputum culture	Not routinely indicated (viral in 90%); if > 10-14 days or immunocompromised
FBC	WBC may be mildly elevated

Chronic Bronchitis:

Investigation	Finding
Spirometry (PFTs)	FEV₁/FVC < 0.70 (post-bronchodilator) = COPD diagnosis; GOLD staging by FEV₁% predicted
Chest X-Ray (CXR)	Hyperinflation (> 6 anterior ribs); peribronchial thickening ("dirty chest"); increased lung markings; enlarged right ventricle (cor pulmonale)
HRCT Chest	Airway wall thickening; mucus plugging; "signet ring" sign (bronchus wider than adjacent artery); coexisting emphysema (centrilobular)
ABG (Arterial Blood Gas)	↓PaO₂ (hypoxaemia); ↑PaCO₂ (hypercapnia); compensated respiratory acidosis
Sputum culture	During exacerbation: S. pneumoniae, H. influenzae, M. catarrhalis; P. aeruginosa in advanced disease
FBC	Polycythaemia (elevated Hb, RBC) - secondary to chronic hypoxaemia
ECG / Echocardiogram	P pulmonale, Right ventricular hypertrophy (cor pulmonale)
6MWT	Functional exercise capacity assessment

GOLD Classification for COPD (relevant to chronic bronchitis as COPD component):

GOLD Grade	FEV₁ % Predicted	Severity
I	≥ 80%	Mild
II	50–79%	Moderate
III	30–49%	Severe
IV	< 30%	Very Severe

✅ 9. PROBLEM LIST

Acute Bronchitis:

Productive cough (disturbing sleep, social interactions)
Mild dyspnoea / wheeze (if bronchospasm)
Low-grade fever and malaise
Activity limitations (reduced work/school attendance)

Chronic Bronchitis:

Impairments:

Chronic productive cough (morning cough + throughout day)
Obstructive ventilatory defect (reduced FEV₁, ↑RV)
Sputum retention / impaired mucociliary clearance
Dyspnoea on exertion (progressive)
Peripheral muscle weakness
Hypoxaemia + Hypercapnia (advanced)
Cor pulmonale (right heart failure - ankle oedema, raised JVP)

Activity Limitations:

Reduced exercise tolerance for ADLs
Difficulty climbing stairs, walking distances
Impaired sleep (nocturnal cough)

Participation Restrictions:

Reduced social participation
Unable to work (occupational exposure may continue)
Dependency for ADLs (severe disease)

✅ 10. SMART GOALS

Acute Bronchitis:

Cough frequency will reduce from >10 episodes/hr to <3 episodes/hr within 1 week of symptomatic management
Patient will demonstrate effective huff/cough technique for sputum clearance within 1 session
Patient will return to full daily activities within 2-3 weeks

Chronic Bronchitis (Short-Term - 4-6 weeks):

Patient will demonstrate independent ACBT technique within 1 week
Patient will report reduction in dyspnoea from Borg 6 to ≤ 3 during ADLs within 4 weeks
Sputum clearance time will reduce by 50% with twice-daily ACBT within 2 weeks

Chronic Bronchitis (Long-Term - 3-6 months):

Patient will complete 6MWT ≥ MCID (25-33 m) improvement within 3 months of PR programme
Patient will perform 30 minutes continuous aerobic exercise within 3 months
Patient will demonstrate smoking cessation (confirmed at 3-month review) - referral to cessation programme
Patient will maintain FEV₁ decline ≤ 2% per year with optimal management

✅ 11. PHASE-WISE PHYSIOTHERAPY MANAGEMENT

ACUTE BRONCHITIS:

Phase 1: Acute Symptomatic (Days 1-7)

Rest; adequate hydration (thins secretions)
Steam inhalation / humidification (loosens mucus)
Positioning: semi-upright (30-45°) to reduce dyspnoea
Breathing exercises: diaphragmatic breathing; PLB if dyspnoeic
Effective cough technique: Huffing (FET) to expectorate sputum
Patient education: not to suppress cough; steam inhalation technique; avoid cold air
Physiotherapy ONLY if: significant sputum retention; elderly; immunocompromised; underlying lung disease

Phase 2: Recovery (Days 7-21)

Graduated return to activity
Breathing control exercises
Postural advice (avoid prolonged sitting/lying)
Education: smoking cessation referral

CHRONIC BRONCHITIS (COPD Component):

Phase 1: Acute Exacerbation (Inpatient/Acute)

Positioning: High-Fowler's (60-90°) or forward-lean sitting
Controlled oxygen therapy: maintain SpO₂ 88-92% (avoid high-flow O₂ - blunts hypoxic drive)
NIV (BIPAP): if acute hypercapnic respiratory failure (pH < 7.35, PaCO₂ > 45)
Airway clearance: ACBT; active FET; postural drainage with percussion/vibration
Bronchodilators (nebulised): Salbutamol + Ipratropium
Antibiotics: if purulent sputum + ≥ 2 of: ↑ dyspnoea, ↑ sputum volume, ↑ sputum purulence (Anthonisen criteria)
Early mobilisation: sitting → standing → walking (as tolerated)
Monitor: SpO₂, HR, RR, ABG, sputum character

Phase 2: Stable Chronic Bronchitis - Outpatient PR Programme (6-12 weeks)

Aerobic training: walking / cycling (Borg 4-6; 30-45 min; 3-5 days/week)
Resistance training: quadriceps, UL, core
Airway clearance: ACBT twice daily; PEP device; postural drainage
Breathing re-education: PLB, diaphragmatic breathing
Patient education: inhaler technique, smoking cessation, nutrition

Phase 3: Maintenance (Long-term)

Community walking programme; home exercise programme
Annual review; monitor FEV₁ decline
Tele-rehabilitation option for homebound patients

✅ 12. MUSCLE-SPECIFIC EXERCISES WITH FULL DETAILS

A. Pursed Lip Breathing (PLB)

Parameter	Detail
Starting Position	Sitting upright, shoulders relaxed
Technique	Inhale slowly through nose (2 counts); purse lips (whistle position); exhale slowly through pursed lips (4 counts); maintain I:E ratio of 1:2 minimum
Sets/Reps	During all activity; especially during exertion
Frequency	Every time dyspnoea occurs during activity
Mechanism	Creates back-pressure → prevents premature small airway collapse (intrinsic PEEP) → reduces air trapping → reduces dynamic hyperinflation → reduces dyspnoea
Precautions	Do not force expiration; avoid breathlessness

B. Diaphragmatic Breathing

Parameter	Detail
Starting Position	Supine → Sitting → Standing (progress)
Technique	One hand on chest, one on abdomen; inhale - abdomen rises (chest stays still); exhale slowly
Ratio	Inhale 2 sec : Hold 1 sec : Exhale 4 sec
Sets/Reps	3 sets × 10 breaths; 3× daily
Frequency	3-4 times per day; during activity as tolerated
Precautions	Assess individual response (less effective if diaphragm severely flattened in advanced hyperinflation)

C. ACBT (for Sputum Clearance)

Phase	Technique	Purpose
Breathing Control	3-5 tidal breaths, relaxed	Rest; prevent bronchospasm
Thoracic Expansion (TEE)	3-5 deep breaths + 3-sec hold	Collateral ventilation; loosen secretions
FET / Huff	Medium or low volume huff; open glottis	Move secretions centrally

Twice daily (stable); 3-4× per day (exacerbation)
2-4 cycles per session until sputum cleared

D. Aerobic Exercise - Walking Programme

Parameter	Detail
Starting Position	Standing; comfortable footwear; rollator if needed
Technique	Walk at target pace; use PLB on exertion; breathe rhythmically
Intensity	Borg dyspnoea 4-6/10; or 60-80% peak HR
Duration	Start 10-15 min → build to 30-45 min
Sets	1 continuous session; or interval (3:2 min) if severe
Frequency	5 days/week
Progression	Increase duration → increase speed → add incline / stairs
Precautions	SpO₂ > 88%; supplement O₂ if prescribed; stop if Borg > 7 or chest pain

E. Quadriceps Strengthening - Seated Knee Extension

Parameter	Detail
Starting Position	Seated on chair, feet hanging
Technique	Extend knee fully; hold 2 sec; lower slowly (4 sec eccentric)
Sets/Reps	3 × 10-12 repetitions
Intensity	60-70% 1-RM; progress to ankle weight
Frequency	2-3 times/week
Progression	Add ankle weights → resistance band → functional squats
Precautions	Breathe out on exertion (avoid Valsalva); no exercise during acute exacerbation with O₂ requirements

F. Effective Cough Technique / Huffing (FET)

Parameter	Detail
Starting Position	Sitting upright, slightly leaning forward
Technique	Take medium-sized breath → open mouth and glottis (say "haaaa" not "kaaah") → expel air forcefully but smoothly; this is a HUff, not a cough
When to cough	Only when secretions reach central airways (felt in throat) → single effective cough to expectorate
Frequency	During ACBT sessions; as needed throughout day
Why huff > cough	Coughing with closed glottis → high intrathoracic pressure → dynamic airway compression → less effective; Huff (open glottis) maintains airway patency → more efficient

✅ 13. ELECTROTHERAPY

A. TENS (Transcutaneous Electrical Nerve Stimulation)

Parameter	Detail
Indication	Chest wall pain; pleuritic pain; musculoskeletal pain from coughing
Electrode placement	Paravertebral T1-T8; or over painful site; NEVER over anterior chest/carotid
Frequency	80-150 Hz
Pulse width	50-80 µs
Duration	20-30 minutes
Contraindications	Pacemaker; anterior chest; pregnancy; over implanted metal

B. Chest Percussion and Mechanical Vibrator

Indication	Excess sputum retention; elderly / debilitated patients unable to self-clear
Manual percussion	Cupped hands; rhythmic clapping over affected segment during postural drainage
Vibration	Fine manual vibration during expiration
Mechanical vibrator	Electric vibration pad / HFCWO vest (high-frequency chest wall oscillation)

C. NMES (Neuromuscular Electrical Stimulation)

Indication	Severe COPD/chronic bronchitis with peripheral muscle weakness unable to exercise
Target	Quadriceps
Frequency	35-50 Hz; 200-400 µs; 30-60 min/session
Duration	6-8 weeks

✅ 14. FUNCTIONAL AND GAIT TRAINING

Acute Bronchitis:

Encourage ambulation as soon as fever resolves
Avoid prolonged bed rest (increases secretion pooling)
Teach coughing in optimal position (sitting forward, supporting chest with arms)

Chronic Bronchitis:

Stair climbing training with handrail + PLB
Sit-to-stand training (3 sets × 10 reps)
Functional walking with rollator walker (reduces dyspnoea - offloads thoracic accessory muscles, allows forward lean)
Energy conservation: 4 Ps (Prioritise, Plan, Pace, Position)
Pacing training: activity - rest - activity pattern
Balance training (fall risk increased in COPD patients due to muscle weakness + medications)

Posture Correction:

Thoracic kyphosis correction (foam roller extension)
Scapular retraction exercises
Forward lean sitting (tripod position) - reduces dyspnoea by fixing shoulder girdle to allow accessory muscle action

✅ 15. AIRWAY CLEARANCE TECHNIQUES

(Detailed in exercise section - summary table)

Technique	Best For	Position
ACBT	All patients; self-management	Sitting
Postural Drainage	Specific lung segments; copious secretions	Segment-specific (12 positions)
PEP Device	Independence; adherence	Sitting
Humidification / Steam Inhalation	Thick tenacious secretions	Any
Saline nebulisation	Mucus hydration	Sitting
Vibration + Percussion	Debilitated / elderly / post-surgical	Postural drainage position

✅ 16. HOME EXERCISE PROGRAMME (HEP)

Acute Bronchitis:

Steam inhalation - 10-15 min, 2-3× daily (bowl of hot water with towel over head, or steam inhaler)
Effective huffing technique - 3-4 cycles whenever sputum present
Adequate hydration - ≥ 2 litres water/day (thins secretions)
Warm saline gargles - for throat irritation
Positioning - semi-upright sleeping; avoid cold/dry air
Graduated activity - rest acutely; walk 10-15 min/day from day 4-5

Chronic Bronchitis (Stable):

ACBT - twice daily (morning + evening); 20-30 min each
PLB - during all physical activities; habitual practice
Diaphragmatic breathing - 3 sets × 10 breaths, 3× daily
Walking programme - 30 min × 5 days/week; target Borg 4-5
Seated quadriceps exercises - 3 × 12 reps × 2-3 days/week
Postural exercises - thoracic extension over foam roller; scapular retraction × daily
Inhaler technique - practice correct MDI/DPI technique (pMDI + spacer preferred)
Smoking cessation - refer to programme if still smoking

Education:

Recognise exacerbation: ↑ cough, ↑ dyspnoea, colour change in sputum, fever
When to seek medical help: increased SpO₂ fall; confusion; unable to speak full sentences
Flu vaccination annually; Pneumococcal vaccination
Avoid smoky/dusty environments; wear mask in polluted air

✅ 17. CRITERIA FOR RETURN TO ACTIVITY / SPORT

Acute Bronchitis:

Afebrile for ≥ 48 hours
Cough frequency reducing (not necessarily absent)
SpO₂ ≥ 96% on room air at rest
No significant dyspnoea at rest
Can complete 10-minute walk without significant symptoms
Gradual return: walking → jogging → sport (over 1-2 weeks)

Chronic Bronchitis (Post-Exacerbation):

Returned to baseline FEV₁ (within 10% of personal best)
SpO₂ ≥ 88% on room air during activity
Sputum returned to baseline colour/volume
Independent on ACBT routine
Physician clearance

✅ 18. COMPLICATIONS AND PROGNOSIS

Acute Bronchitis:

Complication	Notes
Pneumonia	Most important complication; risk in elderly, immunocompromised, smokers
Exacerbation of asthma/COPD	In those with underlying lung disease
Chronic bronchitis development	Recurrent episodes in smokers
Pertussis (Bordetella)	Cough > 3 weeks; whoop; lymphocytosis - must rule out

Prognosis of Acute Bronchitis: Excellent in healthy adults; self-limiting; recovery in 10-20 days. Antibiotics provide minimal benefit and are NOT routinely recommended (CDC, IDSA guidelines).

Chronic Bronchitis:

Complication	Notes
Cor pulmonale	Right heart failure secondary to pulmonary hypertension; most serious
Acute-on-Chronic Exacerbation (AECB)	Each exacerbation accelerates FEV₁ decline
Secondary polycythaemia	Chronic hypoxaemia → erythropoietin → ↑ RBC; hyperviscosity, thrombosis risk
Respiratory failure	Type II (hypercapnic) - PaO₂ < 60, PaCO₂ > 45
Bronchiectasis	Repeated infections → airway wall destruction
Lung cancer	Smoking is the common aetiological factor
Osteoporosis	Steroid use + inactivity + smoking
Pneumothorax	Rupture of bullae (if coexisting emphysema)

Prognosis of Chronic Bronchitis:

Progressive; rate of FEV₁ decline is the key prognostic indicator (normal: 25-30 mL/year; smokers: up to 60 mL/year)
Smoking cessation is the SINGLE MOST EFFECTIVE intervention to slow FEV₁ decline
Pulmonary rehabilitation significantly improves symptoms and QoL but does NOT alter FEV₁ decline or mortality
LTOT (Long-Term Oxygen Therapy): If resting PaO₂ < 55 mmHg or < 60 mmHg with cor pulmonale - improves survival

✅ 19. HIGH-YIELD VIVA AND UNIVERSITY EXAM POINTS

⭐ Frequently Asked University Questions:

Define acute bronchitis. How does it differ from chronic bronchitis and pneumonia?
Define chronic bronchitis. What is the Reid index?
Compare "Blue Bloater" and "Pink Puffer" with a table.
Describe the pathophysiology of chronic bronchitis.
What is the role of physiotherapy in chronic bronchitis?
Describe the ACBT technique in detail.
What are the principles of oxygen therapy in chronic bronchitis?
Write about airway clearance techniques in COPD/chronic bronchitis.
What are the complications of chronic bronchitis?
How do you manage an acute exacerbation of chronic bronchitis physiotherapeutically?

⭐ Clinically Important Points:

Chronic bronchitis = CLINICAL definition (3 months × 2 consecutive years); not based on PFTs or histology
Reid Index = normally 0.4; increased (> 0.4) in chronic bronchitis - proportional to severity
Antibiotics are NOT recommended for uncomplicated acute bronchitis (CDC/IDSA Choosing Wisely)
Sputum purulence does NOT reliably indicate bacterial infection in acute bronchitis
Chronic bronchitis = chronic airway disease component of COPD; alone does NOT cause obstruction until bronchioles involved
Smoking cessation is the single most impactful intervention in chronic bronchitis - slows FEV₁ decline
Controlled O₂ therapy in chronic bronchitis: maintain SpO₂ 88-92% (NOT > 94%) - risk of hypercapnic drive suppression
Do NOT give high-flow O₂ to a chronic bronchitic with acute exacerbation - can worsen hypercapnia
Postural drainage positions for lower lobes: head-down tilt (Trendelenburg) - requires patient to be haemodynamically stable
Rollator walker significantly reduces dyspnoea in COPD/chronic bronchitis (allows forward lean + arm support)

⭐ Common Examiner Viva Questions:

"What is the Reid Index? What is its significance?" → Ratio of mucous gland layer thickness to bronchial wall thickness; normally 0.4; increased (> 0.4) in chronic bronchitis proportional to disease severity; assessed histologically on bronchial biopsy
"Why do we give controlled oxygen in chronic bronchitis and not high-flow oxygen?" → Chronic bronchitics are "CO₂ retainers" (Blue Bloaters); their respiratory drive depends on hypoxic drive (not CO₂ drive as in normal); high-flow O₂ removes the hypoxic stimulus → worsening hypoventilation → worsening hypercapnia → CO₂ narcosis → respiratory arrest
"What is the difference between a huff and a cough?" → Huff (FET): open glottis; medium flow; prevents dynamic airway collapse; more effective at clearing peripheral secretions. Cough: closed glottis → explosive open; high intrathoracic pressure → dynamic airway compression → less effective for peripheral secretions; can cause bronchospasm in reactive airways
"What are Anthonisen criteria for antibiotic therapy in AECB?" → Type I AECB (all 3): ↑dyspnoea + ↑sputum volume + ↑sputum purulence → antibiotics indicated. Type II (2 of 3) → antibiotics appropriate. Type III (1 of 3) → antibiotics usually NOT indicated

⭐ Common Mistakes Students Make:

Defining chronic bronchitis by pathology instead of clinically (3 months × 2 years)
Not knowing the Reid Index value (0.4) - frequently asked in viva
Recommending antibiotics for uncomplicated acute bronchitis
Giving high-flow O₂ to a chronic bronchitic (dangerous - suppresses hypoxic drive)
Confusing Blue Bloater (Chronic Bronchitis) with Pink Puffer (Emphysema) in tables
Not knowing Anthonisen criteria for antibiotic use in AECB
Forgetting to include smoking cessation as the primary intervention in chronic bronchitis
Omitting the comparative table of Chronic Bronchitis vs Emphysema in exams (easy marks)

✅ 20. REFERENCES

Robbins, Cotran & Kumar Pathologic Basis of Disease - Chapter 15: Chronic Bronchitis; Reid Index; Pathogenesis
Robbins & Kumar Basic Pathology - Chapter 11: Chronic Bronchitis; Morphology
Fishman's Pulmonary Diseases and Disorders, 2-Volume Set - Chapter on Acute Bronchitis
Murray & Nadel's Textbook of Respiratory Medicine - Chronic Bronchitis; COPD
Textbook of Family Medicine, 9th Edition - Acute Bronchitis management
GOLD (Global Initiative for Chronic Obstructive Lung Disease) Guidelines 2024 - COPD management including chronic bronchitis
CDC/IDSA Choosing Wisely - Avoid antibiotics for acute uncomplicated bronchitis (2024)
Baillie EJ, et al. Early-career GPs' antibiotic prescribing for acute infections. J Antimicrob Chemother. 2024. PMID: 38252922

💡 Exam Tip: In theory exams - the examiner expects: (1) Clinical definition verbatim (3 months × 2 years), (2) Reid index = 0.4, (3) Blue Bloater vs Pink Puffer table, (4) Controlled O₂ therapy rationale (88-92%), (5) ACBT phases in sequence. In viva - most commonly asked: "Why do we give controlled O₂ in chronic bronchitis?" - this alone can earn 3-4 marks in viva if answered confidently with the hypoxic drive mechanism.

Make me nice ppt for this exame oriented

Reading File

Good, I have enough to build the PPT. Let me create a comprehensive, visually rich exam-oriented presentation on Bronchitis now.

Running Command

ls /home/daytona/workspace/

Running Command

mkdir -p /home/daytona/workspace/bronchitis-ppt

Writing File

~/bronchitis-ppt/bronchitis_ppt.js

const pptxgen = require("pptxgenjs");
let pres = new pptxgen();
pres.layout = 'LAYOUT_16x9';
pres.title = 'Bronchitis - BPT Exam Preparation';
pres.author = 'BPT Final Year';

// ─── COLOUR PALETTE ───────────────────────────────────────────────────────────
const C = {
  darkBg:    "0D1B2A",  // deep navy
  midBg:     "1B2E45",  // dark blue
  accent:    "E63946",  // vivid red (respiratory theme)
  accentAlt: "F4A261",  // warm amber / highlight
  teal:      "2EC4B6",  // teal accent
  white:     "FFFFFF",
  lightGray: "D1D9E6",
  textDark:  "1A1A2E",
  cardBg:    "1E3A52",  // card panels
  gold:      "FFD700",  // star items
  green:     "4CAF50",  // clinical pearl
  lightBlue: "56CCF2",
};

// ─── HELPERS ──────────────────────────────────────────────────────────────────
function addSectionBand(slide, title) {
  // Full-width colored band at top
  slide.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:10, h:0.75, fill:{color: C.accent}, line:{color: C.accent} });
  slide.addText(title, { x:0.3, y:0, w:9.4, h:0.75, fontSize:20, bold:true, color:C.white, valign:"middle" });
}

function addFooter(slide) {
  slide.addShape(pres.shapes.RECTANGLE, { x:0, y:5.3, w:10, h:0.325, fill:{color: C.midBg}, line:{color: C.midBg} });
  slide.addText([
    { text:"BPT Final Year  |  ", options:{color: C.lightGray, fontSize:9} },
    { text:"BRONCHITIS", options:{color: C.accentAlt, fontSize:9, bold:true} },
    { text:"  |  Robbins Pathology · Fishman's · Murray & Nadel", options:{color: C.lightGray, fontSize:9} }
  ], { x:0.2, y:5.3, w:9.6, h:0.32, valign:"middle", align:"center" });
}

function addCard(slide, x, y, w, h, titleText, titleColor, bodyLines, opts = {}) {
  slide.addShape(pres.shapes.ROUNDED_RECTANGLE, {
    x, y, w, h,
    fill:{color: opts.bg || C.cardBg},
    line:{color: opts.border || C.teal, pt:1.5},
    rectRadius: 0.1
  });
  if (titleText) {
    slide.addShape(pres.shapes.RECTANGLE, { x, y, w, h:0.34, fill:{color: opts.titleBg || C.teal}, line:{color: opts.titleBg || C.teal} });
    slide.addText(titleText, { x:x+0.08, y:y+0.01, w:w-0.16, h:0.32, fontSize:opts.titleFs||11, bold:true, color: titleColor||C.white, valign:"middle" });
  }
  if (bodyLines && bodyLines.length) {
    slide.addText(bodyLines, { x:x+0.12, y:y+0.38, w:w-0.24, h:h-0.48, fontSize:opts.bodyFs||9.5, color:C.lightGray, valign:"top" });
  }
}

// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
// SLIDE 1 — COVER
// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
{
  let s = pres.addSlide();
  s.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:10, h:5.625, fill:{color:C.darkBg}, line:{color:C.darkBg} });
  // left accent bar
  s.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:0.15, h:5.625, fill:{color:C.accent}, line:{color:C.accent} });
  // main circles (decorative)
  s.addShape(pres.shapes.OVAL, { x:7.0, y:-0.6, w:4.5, h:4.5, fill:{color:"1A2E44"}, line:{color:"1A2E44"} });
  s.addShape(pres.shapes.OVAL, { x:7.8, y:2.8, w:3.0, h:3.0, fill:{color:"172840"}, line:{color:"172840"} });
  // lung icon area (symbolic text)
  s.addText("🫁", { x:7.5, y:1.0, w:2, h:2, fontSize:70, align:"center", valign:"middle" });

  // Tag
  s.addShape(pres.shapes.RECTANGLE, { x:0.35, y:0.55, w:2.5, h:0.35, fill:{color:C.accent}, line:{color:C.accent} });
  s.addText("BPT FINAL YEAR", { x:0.35, y:0.55, w:2.5, h:0.35, fontSize:10, bold:true, color:C.white, align:"center", valign:"middle" });

  s.addText("BRONCHITIS", { x:0.3, y:1.1, w:7, h:1.4, fontSize:62, bold:true, color:C.white, charSpacing:3 });
  s.addText("Acute  •  Chronic  •  COPD Spectrum", { x:0.3, y:2.45, w:7, h:0.5, fontSize:16, color:C.teal, charSpacing:1 });

  // horizontal line
  s.addShape(pres.shapes.RECTANGLE, { x:0.3, y:3.05, w:6.5, h:0.04, fill:{color:C.accentAlt}, line:{color:C.accentAlt} });

  s.addText([
    { text:"Pathophysiology  •  Clinical Features  •  Physiotherapy Management\n", options:{color:C.lightGray, fontSize:12} },
    { text:"Exercises  •  Airway Clearance  •  Viva Points  •  Exam Templates", options:{color:C.lightGray, fontSize:12} }
  ], { x:0.3, y:3.15, w:7, h:0.9 });

  // pills
  const pills = ["Robbins Pathology","Fishman's Pulmonary","Murray & Nadel"];
  pills.forEach((p,i) => {
    s.addShape(pres.shapes.ROUNDED_RECTANGLE, { x:0.3 + i*2.3, y:4.25, w:2.15, h:0.35, fill:{color:C.midBg}, line:{color:C.teal, pt:1}, rectRadius:0.15 });
    s.addText(p, { x:0.3 + i*2.3, y:4.25, w:2.15, h:0.35, fontSize:8.5, color:C.teal, align:"center", valign:"middle" });
  });

  s.addText("Exam-Oriented | Evidence-Based | BPT University Format", { x:0.3, y:4.75, w:7.5, h:0.35, fontSize:10, color:"4A6580", align:"left" });
}

// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
// SLIDE 2 — DEFINITION & CLASSIFICATION
// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
{
  let s = pres.addSlide();
  s.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:10, h:5.625, fill:{color:C.darkBg}, line:{color:C.darkBg} });
  addSectionBand(s, "01  |  DEFINITION & CLASSIFICATION");

  // Acute Def box
  s.addShape(pres.shapes.RECTANGLE, { x:0.25, y:0.88, w:4.6, h:0.34, fill:{color:C.teal}, line:{color:C.teal} });
  s.addText("ACUTE BRONCHITIS", { x:0.25, y:0.88, w:4.6, h:0.34, fontSize:11, bold:true, color:C.white, align:"center", valign:"middle" });
  s.addShape(pres.shapes.RECTANGLE, { x:0.25, y:1.22, w:4.6, h:1.35, fill:{color:C.cardBg}, line:{color:C.teal, pt:1} });
  s.addText([
    { text:"Acute, self-limited inflammation of the large airways\n(trachea + bronchi) without pneumonia\n", options:{bold:false, breakLine:false} },
    { text:"\n• Cough ± sputum (hallmark)\n• Duration: 10–20 days (may persist >1 month)\n• 90% VIRAL aetiology", options:{} }
  ], { x:0.35, y:1.24, w:4.4, h:1.3, fontSize:10, color:C.lightGray, valign:"top" });

  // Chronic Def box (★ starred)
  s.addShape(pres.shapes.RECTANGLE, { x:5.15, y:0.88, w:4.6, h:0.34, fill:{color:C.accent}, line:{color:C.accent} });
  s.addText("CHRONIC BRONCHITIS  ⭐ EXAM FAVOURITE", { x:5.15, y:0.88, w:4.6, h:0.34, fontSize:10.5, bold:true, color:C.white, align:"center", valign:"middle" });
  s.addShape(pres.shapes.RECTANGLE, { x:5.15, y:1.22, w:4.6, h:1.35, fill:{color:C.cardBg}, line:{color:C.accent, pt:1.5} });
  s.addText([
    { text:"PRODUCTIVE COUGH for ≥ 3 consecutive months\nin ≥ 2 consecutive years\n", options:{bold:true, color:C.gold} },
    { text:"in absence of any other identifiable cause\n\n", options:{bold:false, color:C.lightGray} },
    { text:"⚠ CLINICAL definition (not pathological/spirometric)", options:{bold:true, color:C.accentAlt} }
  ], { x:5.25, y:1.24, w:4.4, h:1.3, fontSize:10, valign:"top" });

  // Classification table
  s.addShape(pres.shapes.RECTANGLE, { x:0.25, y:2.72, w:9.5, h:0.3, fill:{color:C.midBg}, line:{color:C.midBg} });
  s.addText("CLASSIFICATION TABLE", { x:0.25, y:2.72, w:9.5, h:0.3, fontSize:10, bold:true, color:C.accentAlt, align:"center", valign:"middle" });

  const cols = [1.8, 1.8, 1.8, 2.0, 2.0];
  const headers = ["TYPE","DURATION","AETIOLOGY","REVERSIBILITY","EXAMPLE"];
  const rows = [
    ["Acute Bronchitis","< 3 weeks","90% Viral","Complete (self-limiting)","Post-URTI cough"],
    ["Chronic Bronchitis","≥3m/yr × 2yr","Smoking / Pollutants","Partial","COPD Type B"],
    ["Asthmatic Bronchitis","Variable","Hyperreactive airways","Good (bronchodilators)","Smoker + asthma"],
    ["AECB","Acute episode","Viral / Bacterial","Returns to baseline","COPD exacerbation"],
  ];

  let xPos = 0.25;
  headers.forEach((h, i) => {
    s.addShape(pres.shapes.RECTANGLE, { x:xPos, y:3.04, w:cols[i], h:0.3, fill:{color:C.teal}, line:{color:C.teal} });
    s.addText(h, { x:xPos, y:3.04, w:cols[i], h:0.3, fontSize:9, bold:true, color:C.white, align:"center", valign:"middle" });
    xPos += cols[i];
  });

  rows.forEach((row, ri) => {
    let xp = 0.25;
    row.forEach((cell, ci) => {
      const bg = ri % 2 === 0 ? "162537" : C.cardBg;
      s.addShape(pres.shapes.RECTANGLE, { x:xp, y:3.35+ri*0.38, w:cols[ci], h:0.37, fill:{color:bg}, line:{color:"274560", pt:0.5} });
      s.addText(cell, { x:xp+0.05, y:3.35+ri*0.38, w:cols[ci]-0.1, h:0.37, fontSize:8.5, color:C.lightGray, align:"center", valign:"middle" });
      xp += cols[ci];
    });
  });

  addFooter(s);
}

// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
// SLIDE 3 — PATHOPHYSIOLOGY (CHRONIC BRONCHITIS)
// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
{
  let s = pres.addSlide();
  s.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:10, h:5.625, fill:{color:C.darkBg}, line:{color:C.darkBg} });
  addSectionBand(s, "02  |  PATHOPHYSIOLOGY — CHRONIC BRONCHITIS");

  // Flow chain boxes
  const steps = [
    { t:"NOXIOUS INHALANTS", sub:"Tobacco smoke (90%) • SO₂ • NO₂ • Dust", col:C.accent },
    { t:"MUCOSAL DAMAGE", sub:"↑ Cytokines: IL-13, Histamine\nNeutrophils • Lymphocytes • Macrophages\n(NO eosinophils — contrast with asthma)", col:"C0392B" },
    { t:"MUCUS HYPERSECRETION", sub:"⭐ Hypertrophy of submucosal glands (↑ Reid Index > 0.4)\n↑ Goblet cells in small bronchi/bronchioles\nAcquired CFTR dysfunction (abnormal mucus)", col:C.accentAlt },
    { t:"MUCOCILIARY FAILURE", sub:"Cilia damaged by smoke → impaired clearance\nMucus plugging → small airway obstruction (<2-3mm)", col:"E67E22" },
    { t:"AIRWAY OBSTRUCTION", sub:"Chronic bronchiolitis + Peribronchial fibrosis\nAir trapping → Hyperinflation → V/Q mismatch", col:"8E44AD" },
    { t:"HYPOXAEMIA + COR PULMONALE", sub:"↓PaO₂ → Polycythaemia → Pulm. HTN → Right HF\nBlue Bloater phenotype", col:C.teal },
  ];

  steps.forEach((step, i) => {
    const col = i < 3 ? 0 : 1;
    const row = i < 3 ? i : i - 3;
    const x = col === 0 ? 0.2 : 5.15;
    const y = 0.95 + row * 1.38;

    s.addShape(pres.shapes.RECTANGLE, { x, y, w:4.7, h:0.3, fill:{color:step.col}, line:{color:step.col} });
    s.addText(step.t, { x:x+0.08, y, w:4.54, h:0.3, fontSize:10.5, bold:true, color:C.white, valign:"middle" });
    s.addShape(pres.shapes.RECTANGLE, { x, y:y+0.3, w:4.7, h:0.88, fill:{color:C.cardBg}, line:{color:step.col, pt:1} });
    s.addText(step.sub, { x:x+0.1, y:y+0.32, w:4.5, h:0.84, fontSize:9, color:C.lightGray, valign:"top" });

    // Arrow down (within column)
    if (row < 2) {
      s.addShape(pres.shapes.RECTANGLE, { x:x+2.25, y:y+1.2, w:0.12, h:0.18, fill:{color:C.accentAlt}, line:{color:C.accentAlt} });
    }
  });

  // Reid Index callout
  s.addShape(pres.shapes.ROUNDED_RECTANGLE, { x:3.6, y:2.0, w:2.75, h:1.1, fill:{color:"2C1810"}, line:{color:C.gold, pt:2}, rectRadius:0.1 });
  s.addText([
    { text:"⭐ REID INDEX\n", options:{bold:true, color:C.gold, fontSize:12} },
    { text:"Normal = 0.4\n", options:{color:C.white, fontSize:11, bold:true} },
    { text:"Chronic Bronchitis = > 0.4\n", options:{color:C.accentAlt, fontSize:10} },
    { text:"Proportional to disease severity", options:{color:C.lightGray, fontSize:9} }
  ], { x:3.65, y:2.05, w:2.65, h:1.0, valign:"top" });

  addFooter(s);
}

// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
// SLIDE 4 — BLUE BLOATER vs PINK PUFFER (★★★ most asked)
// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
{
  let s = pres.addSlide();
  s.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:10, h:5.625, fill:{color:C.darkBg}, line:{color:C.darkBg} });
  addSectionBand(s, "03  |  BLUE BLOATER vs PINK PUFFER  ⭐⭐⭐ Most Asked in Viva & Theory");

  // left header
  s.addShape(pres.shapes.RECTANGLE, { x:0.2, y:0.85, w:4.5, h:0.42, fill:{color:"1A5276"}, line:{color:"3498DB", pt:2} });
  s.addText("🔵 BLUE BLOATER\n(Chronic Bronchitis — Type B)", { x:0.2, y:0.85, w:4.5, h:0.42, fontSize:11, bold:true, color:"56CCF2", align:"center", valign:"middle" });

  // right header
  s.addShape(pres.shapes.RECTANGLE, { x:5.3, y:0.85, w:4.5, h:0.42, fill:{color:"4A1520"}, line:{color:C.accent, pt:2} });
  s.addText("🩷 PINK PUFFER\n(Emphysema — Type A)", { x:5.3, y:0.85, w:4.5, h:0.42, fontSize:11, bold:true, color:"FF8A80", align:"center", valign:"middle" });

  const features = [
    ["Body Habitus", "Obese / Overweight", "Thin, Cachexic"],
    ["Colour", "Cyanosed (BLUE)", "Pink (well-oxygenated)"],
    ["Oedema", "Present (Cor Pulmonale)", "ABSENT"],
    ["Breathlessness", "Mild-Moderate", "SEVERE (dominant symptom)"],
    ["Cough/Sputum", "Productive, copious sputum", "Minimal / Dry"],
    ["PaO₂", "LOW (Hypoxaemia)", "Near normal"],
    ["PaCO₂", "HIGH (Hypercapnia)", "Normal or LOW"],
    ["Polycythaemia", "PRESENT", "Absent"],
    ["Cor Pulmonale", "COMMON", "Late feature only"],
    ["Mechanism", "V/Q mismatch + ↓ ventilatory drive", "↑WOB; hyperventilates to maintain PaO₂"],
  ];

  features.forEach((row, i) => {
    const y = 1.38 + i * 0.37;
    const bg = i % 2 === 0 ? "0F2233" : "132B40";
    // Feature label
    s.addShape(pres.shapes.RECTANGLE, { x:0.2, y, w:1.5, h:0.36, fill:{color:C.midBg}, line:{color:"274560", pt:0.5} });
    s.addText(row[0], { x:0.2, y, w:1.5, h:0.36, fontSize:8.5, bold:true, color:C.teal, align:"center", valign:"middle" });
    // Blue Bloater
    s.addShape(pres.shapes.RECTANGLE, { x:1.72, y, w:3.36, h:0.36, fill:{color:bg}, line:{color:"274560", pt:0.5} });
    s.addText(row[1], { x:1.77, y, w:3.26, h:0.36, fontSize:8.5, color:"56CCF2", align:"center", valign:"middle" });
    // Pink Puffer
    s.addShape(pres.shapes.RECTANGLE, { x:5.1, y, w:4.7, h:0.36, fill:{color:bg}, line:{color:"274560", pt:0.5} });
    s.addText(row[2], { x:5.15, y, w:4.6, h:0.36, fontSize:8.5, color:"FF8A80", align:"center", valign:"middle" });
  });

  // warning note
  s.addShape(pres.shapes.ROUNDED_RECTANGLE, { x:0.2, y:5.08, w:9.6, h:0.25, fill:{color:"2C2005"}, line:{color:C.gold, pt:1}, rectRadius:0.05 });
  s.addText("⚠ Most COPD patients = MIXED picture. Blue Bloater & Pink Puffer are clinical extremes, not mutually exclusive.", { x:0.25, y:5.08, w:9.5, h:0.25, fontSize:8.5, bold:true, color:C.gold, align:"center", valign:"middle" });
}

// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
// SLIDE 5 — CLINICAL FEATURES (BOTH TYPES)
// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
{
  let s = pres.addSlide();
  s.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:10, h:5.625, fill:{color:C.darkBg}, line:{color:C.darkBg} });
  addSectionBand(s, "04  |  CLINICAL FEATURES & KEY INVESTIGATIONS");

  // --- Acute Bronchitis (left)
  s.addShape(pres.shapes.RECTANGLE, { x:0.2, y:0.85, w:4.5, h:0.3, fill:{color:C.teal}, line:{color:C.teal} });
  s.addText("ACUTE BRONCHITIS — Key Features", { x:0.2, y:0.85, w:4.5, h:0.3, fontSize:10.5, bold:true, color:C.white, align:"center", valign:"middle" });
  const acuteFeats = [
    "Cough (hallmark) ± sputum — lasts 10-20 days",
    "Sputum: clear → yellow/green (NOT reliable for bacteria)",
    "Low-grade fever (high fever → suspect pneumonia)",
    "Rhinorrhoea, sore throat (preceding URTI)",
    "Wheeze if bronchospasm (transient)",
    "NO bronchial breathing, NO lobar dullness",
    "Normal CXR (differentiates from pneumonia)",
  ];
  s.addShape(pres.shapes.RECTANGLE, { x:0.2, y:1.16, w:4.5, h:2.2, fill:{color:C.cardBg}, line:{color:C.teal, pt:1} });
  s.addText(acuteFeats.map((t,i) => ({ text:(i<acuteFeats.length-1 ? t+"\n" : t), options:{bullet:{type:"bullet"}, color:C.lightGray} })),
    { x:0.3, y:1.19, w:4.3, h:2.15, fontSize:9, valign:"top" });

  // --- Chronic Bronchitis (right)
  s.addShape(pres.shapes.RECTANGLE, { x:5.3, y:0.85, w:4.5, h:0.3, fill:{color:C.accent}, line:{color:C.accent} });
  s.addText("CHRONIC BRONCHITIS — Key Features", { x:5.3, y:0.85, w:4.5, h:0.3, fontSize:10.5, bold:true, color:C.white, align:"center", valign:"middle" });
  const chronFeats = [
    "Chronic productive morning cough (diagnostic)",
    "Progressive dyspnoea (exertion → rest)",
    "Central cyanosis (tongue/lips — Blue Bloater)",
    "Ankle oedema (cor pulmonale)",
    "Expiratory wheeze (airflow obstruction)",
    "Coarse crackles (↓ on coughing)",
    "Barrel chest if emphysema coexists",
    "Polycythaemia, plethora",
  ];
  s.addShape(pres.shapes.RECTANGLE, { x:5.3, y:1.16, w:4.5, h:2.2, fill:{color:C.cardBg}, line:{color:C.accent, pt:1} });
  s.addText(chronFeats.map((t,i) => ({ text:(i<chronFeats.length-1 ? t+"\n" : t), options:{bullet:{type:"bullet"}, color:C.lightGray} })),
    { x:5.4, y:1.19, w:4.3, h:2.15, fontSize:9, valign:"top" });

  // --- Investigations strip
  s.addShape(pres.shapes.RECTANGLE, { x:0.2, y:3.48, w:9.6, h:0.3, fill:{color:C.midBg}, line:{color:C.midBg} });
  s.addText("KEY INVESTIGATIONS", { x:0.2, y:3.48, w:9.6, h:0.3, fontSize:10, bold:true, color:C.accentAlt, align:"center", valign:"middle" });

  const invCols = [
    { title:"Spirometry", body:"FEV₁/FVC < 0.70\n(post-bronchodilator)\nGOLD staging by FEV₁%", col:C.teal },
    { title:"CXR", body:"Hyperinflation\n>6 ant. ribs on CXR\nPeribronchial thickening", col:"3498DB" },
    { title:"ABG", body:"↓PaO₂ (hypoxaemia)\n↑PaCO₂ (hypercapnia)\nRespiratory acidosis", col:C.accent },
    { title:"FBC", body:"Polycythaemia\n↑ Hb, ↑ RBC\n(secondary to ↓PaO₂)", col:"8E44AD" },
  ];
  invCols.forEach((inv, i) => {
    const x = 0.2 + i*2.4;
    s.addShape(pres.shapes.RECTANGLE, { x, y:3.8, w:2.32, h:0.28, fill:{color:inv.col}, line:{color:inv.col} });
    s.addText(inv.title, { x, y:3.8, w:2.32, h:0.28, fontSize:10, bold:true, color:C.white, align:"center", valign:"middle" });
    s.addShape(pres.shapes.RECTANGLE, { x, y:4.09, w:2.32, h:0.95, fill:{color:C.cardBg}, line:{color:inv.col, pt:1} });
    s.addText(inv.body, { x:x+0.08, y:4.11, w:2.16, h:0.91, fontSize:9, color:C.lightGray, valign:"top", align:"center" });
  });

  addFooter(s);
}

// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
// SLIDE 6 — DIFFERENTIAL DIAGNOSIS + PROBLEM LIST
// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
{
  let s = pres.addSlide();
  s.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:10, h:5.625, fill:{color:C.darkBg}, line:{color:C.darkBg} });
  addSectionBand(s, "05  |  DIFFERENTIAL DIAGNOSIS & PROBLEM LIST");

  // DD table
  s.addShape(pres.shapes.RECTANGLE, { x:0.2, y:0.86, w:5.5, h:0.28, fill:{color:C.teal}, line:{color:C.teal} });
  s.addText("DIFFERENTIAL DIAGNOSIS", { x:0.2, y:0.86, w:5.5, h:0.28, fontSize:10.5, bold:true, color:C.white, align:"center", valign:"middle" });

  const dds = [
    ["Pneumonia","Fever >38°C, bronchial breathing, lobar dullness, ↑WBC, CXR consolidation"],
    ["Asthma","Episodic, reversible, atopy, eosinophilia, responds to BD, normal between attacks"],
    ["TB","Haemoptysis, night sweats, weight loss, AFB+, apical CXR lesion"],
    ["Bronchiectasis","Copious purulent sputum, clubbing, tram-tracks on HRCT"],
    ["Lung Cancer","Haemoptysis, weight loss, clubbing, hilar mass CXR"],
    ["CCF","Bilateral basal crackles, raised JVP, cardiomegaly, responds to diuretics"],
    ["GERD Cough","Cough worsens lying flat, heartburn, no sputum, upper GI symptoms"],
  ];

  dds.forEach((dd, i) => {
    const y = 1.16 + i * 0.41;
    const bg = i % 2 === 0 ? C.cardBg : "132B40";
    s.addShape(pres.shapes.RECTANGLE, { x:0.2, y, w:1.6, h:0.4, fill:{color:bg}, line:{color:"274560", pt:0.5} });
    s.addText(dd[0], { x:0.2, y, w:1.6, h:0.4, fontSize:9, bold:true, color:C.accentAlt, align:"center", valign:"middle" });
    s.addShape(pres.shapes.RECTANGLE, { x:1.82, y, w:3.88, h:0.4, fill:{color:bg}, line:{color:"274560", pt:0.5} });
    s.addText(dd[1], { x:1.87, y, w:3.78, h:0.4, fontSize:8.5, color:C.lightGray, valign:"middle" });
  });

  // Problem list (right side)
  s.addShape(pres.shapes.RECTANGLE, { x:5.9, y:0.86, w:3.9, h:0.28, fill:{color:C.accent}, line:{color:C.accent} });
  s.addText("PHYSIOTHERAPY PROBLEM LIST", { x:5.9, y:0.86, w:3.9, h:0.28, fontSize:10, bold:true, color:C.white, align:"center", valign:"middle" });

  s.addShape(pres.shapes.RECTANGLE, { x:5.9, y:1.16, w:3.9, h:0.22, fill:{color:"1A2E45"}, line:{color:C.teal} });
  s.addText("IMPAIRMENTS", { x:5.9, y:1.16, w:3.9, h:0.22, fontSize:9, bold:true, color:C.teal, align:"center", valign:"middle" });

  const probs1 = [
    "Chronic productive cough",
    "Obstructive ventilatory defect (↓FEV₁)",
    "Sputum retention / impaired clearance",
    "Progressive dyspnoea on exertion",
    "Peripheral muscle weakness (quads)",
    "Hypoxaemia + Hypercapnia (advanced)",
    "Cor pulmonale (ankle oedema)",
  ];
  s.addShape(pres.shapes.RECTANGLE, { x:5.9, y:1.38, w:3.9, h:2.05, fill:{color:C.cardBg}, line:{color:C.accent, pt:1} });
  s.addText(probs1.map((t,i) => ({ text:(i<probs1.length-1 ? t+"\n" : t), options:{bullet:{type:"bullet"}, color:C.lightGray} })),
    { x:6.0, y:1.4, w:3.7, h:2.0, fontSize:9, valign:"top" });

  s.addShape(pres.shapes.RECTANGLE, { x:5.9, y:3.45, w:3.9, h:0.22, fill:{color:"1A2E45"}, line:{color:C.teal} });
  s.addText("ACTIVITY / PARTICIPATION LIMITS", { x:5.9, y:3.45, w:3.9, h:0.22, fontSize:9, bold:true, color:C.teal, align:"center", valign:"middle" });

  const probs2 = [
    "Reduced exercise tolerance (6MWT ↓)",
    "Difficulty climbing stairs/walking",
    "Impaired ADL performance",
    "Dependency for basic activities (severe)",
  ];
  s.addShape(pres.shapes.RECTANGLE, { x:5.9, y:3.68, w:3.9, h:1.4, fill:{color:C.cardBg}, line:{color:C.accentAlt, pt:1} });
  s.addText(probs2.map((t,i) => ({ text:(i<probs2.length-1 ? t+"\n" : t), options:{bullet:{type:"bullet"}, color:C.lightGray} })),
    { x:6.0, y:3.7, w:3.7, h:1.35, fontSize:9, valign:"top" });

  addFooter(s);
}

// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
// SLIDE 7 — PHASE-WISE PT MANAGEMENT
// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
{
  let s = pres.addSlide();
  s.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:10, h:5.625, fill:{color:C.darkBg}, line:{color:C.darkBg} });
  addSectionBand(s, "06  |  PHASE-WISE PHYSIOTHERAPY MANAGEMENT");

  const phases = [
    {
      phase:"PHASE 1", sub:"Acute Exacerbation (Inpatient)",
      col:C.accent,
      items:[
        "High-Fowler's position (60-90°)",
        "Controlled O₂: SpO₂ 88-92% (NOT >94%)",
        "NIV/BiPAP if acute hypercapnic RF",
        "ACBT + FET for airway clearance",
        "Nebulised Salbutamol + Ipratropium",
        "Early mobilisation: sit → stand → walk",
        "Monitor: SpO₂, HR, RR, ABG",
      ]
    },
    {
      phase:"PHASE 2", sub:"Stable Outpatient PR (6-12 weeks)",
      col:"8E44AD",
      items:[
        "Aerobic training: walk/cycle, Borg 4-6",
        "30-45 min × 3-5 days/week",
        "Resistance: quadriceps + UL + core",
        "Twice-daily ACBT + PEP device",
        "Breathing re-education: PLB + diaphragmatic",
        "Inhaler technique education",
        "Smoking cessation referral (MANDATORY)",
      ]
    },
    {
      phase:"PHASE 3", sub:"Maintenance & Long-Term",
      col:C.teal,
      items:[
        "Community walking programme",
        "Home exercise programme (HEP)",
        "Annual spirometry review",
        "Tele-rehabilitation (homebound patients)",
        "Flu + Pneumococcal vaccination",
        "Monitor FEV₁ decline annually",
        "LTOT if resting PaO₂ < 55 mmHg",
      ]
    },
  ];

  phases.forEach((ph, i) => {
    const x = 0.2 + i * 3.28;
    s.addShape(pres.shapes.RECTANGLE, { x, y:0.85, w:3.15, h:0.48, fill:{color:ph.col}, line:{color:ph.col} });
    s.addText([
      { text:ph.phase+"\n", options:{bold:true, fontSize:13, color:C.white} },
      { text:ph.sub, options:{fontSize:9, color:"rgba(255,255,255,0.85)"} }
    ], { x:x+0.05, y:0.87, w:3.05, h:0.44, align:"center", valign:"middle" });

    s.addShape(pres.shapes.RECTANGLE, { x, y:1.35, w:3.15, h:3.82, fill:{color:C.cardBg}, line:{color:ph.col, pt:1.5} });
    s.addText(ph.items.map((t,j) => ({ text:(j<ph.items.length-1 ? t+"\n" : t), options:{bullet:{type:"bullet"}, color:C.lightGray} })),
      { x:x+0.12, y:1.38, w:2.91, h:3.75, fontSize:9.5, valign:"top" });
  });

  // O2 callout
  s.addShape(pres.shapes.ROUNDED_RECTANGLE, { x:0.25, y:5.06, w:9.5, h:0.3, fill:{color:"2C0505"}, line:{color:C.accent, pt:1.5}, rectRadius:0.05 });
  s.addText("⭐ CRITICAL: Controlled O₂ = 88-92% SpO₂ in chronic bronchitis. HIGH-FLOW O₂ → removes hypoxic drive → CO₂ narcosis → RESPIRATORY ARREST", { x:0.3, y:5.06, w:9.4, h:0.3, fontSize:9, bold:true, color:"FF6B6B", align:"center", valign:"middle" });
}

// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
// SLIDE 8 — ACBT + HUFFING (AIRWAY CLEARANCE)
// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
{
  let s = pres.addSlide();
  s.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:10, h:5.625, fill:{color:C.darkBg}, line:{color:C.darkBg} });
  addSectionBand(s, "07  |  AIRWAY CLEARANCE TECHNIQUES  ⭐ Must Know for Viva");

  // ACBT cycle
  s.addShape(pres.shapes.RECTANGLE, { x:0.2, y:0.86, w:5.5, h:0.28, fill:{color:C.teal}, line:{color:C.teal} });
  s.addText("ACBT — Active Cycle of Breathing Technique", { x:0.2, y:0.86, w:5.5, h:0.28, fontSize:10.5, bold:true, color:C.white, align:"center", valign:"middle" });

  const acbtPhases = [
    { name:"1. BREATHING CONTROL", col:"1A5276", body:"3-5 tidal breaths\nRelaxed, low effort\nPrevents bronchospasm\nHands on abdomen" },
    { name:"2. THORACIC EXPANSION", col:"1A6B3A", body:"3-5 DEEP slow breaths\n3-second inspiratory hold\nCollateral ventilation\nLoosens secretions" },
    { name:"3. FET / HUFF", col:"7D3C1E", body:"Medium/low volume\nOpen glottis (\"haaa\")\nMoves secretions centrally\nThen effective cough" },
  ];

  acbtPhases.forEach((ph, i) => {
    const x = 0.22 + i * 1.85;
    s.addShape(pres.shapes.RECTANGLE, { x, y:1.16, w:1.76, h:0.26, fill:{color:ph.col}, line:{color:ph.col} });
    s.addText(ph.name, { x, y:1.16, w:1.76, h:0.26, fontSize:8.5, bold:true, color:C.white, align:"center", valign:"middle" });
    s.addShape(pres.shapes.RECTANGLE, { x, y:1.43, w:1.76, h:1.15, fill:{color:C.cardBg}, line:{color:ph.col, pt:1} });
    s.addText(ph.body, { x:x+0.07, y:1.45, w:1.62, h:1.1, fontSize:9, color:C.lightGray, valign:"top", align:"center" });

    if (i < 2) {
      s.addShape(pres.shapes.RECTANGLE, { x:x+1.78, y:1.97, w:0.04, h:0.06, fill:{color:C.accentAlt}, line:{color:C.accentAlt} });
      s.addText("→", { x:x+1.78, y:1.88, w:0.07, h:0.2, fontSize:14, bold:true, color:C.accentAlt, align:"center" });
    }
  });

  s.addShape(pres.shapes.ROUNDED_RECTANGLE, { x:0.22, y:2.62, w:5.5, h:0.32, fill:{color:"1A2E45"}, line:{color:C.teal, pt:1}, rectRadius:0.05 });
  s.addText("Cycle: BC → TEE → FET → (COUGH if needed) → BC  |  2-4 cycles per session  |  Twice daily (stable); 3-4×/day (exacerbation)", { x:0.27, y:2.62, w:5.4, h:0.32, fontSize:8.5, color:C.lightGray, align:"center", valign:"middle" });

  // Huff vs Cough
  s.addShape(pres.shapes.RECTANGLE, { x:0.2, y:3.02, w:5.5, h:0.26, fill:{color:C.accent}, line:{color:C.accent} });
  s.addText("HUFF (FET) vs COUGH — Why Huff is BETTER  ⭐ Viva", { x:0.2, y:3.02, w:5.5, h:0.26, fontSize:10.5, bold:true, color:C.white, align:"center", valign:"middle" });

  const hcCols = [
    ["HUFF (FET)","Open glottis\nMedium flow\nNo Valsalva effect\nMaintains airway patency\nEffective for peripheral secretions\nLess bronchospasm", C.teal],
    ["COUGH","Closed glottis → explosive\nHigh intrathoracic pressure\nDynamic airway compression\nLess effective peripherally\nCan trigger bronchospasm\nExhausting for patient", C.accent],
  ];
  hcCols.forEach((col, i) => {
    const x = 0.22 + i * 2.8;
    s.addShape(pres.shapes.RECTANGLE, { x, y:3.3, w:2.65, h:0.24, fill:{color:col[2]}, line:{color:col[2]} });
    s.addText(col[0], { x, y:3.3, w:2.65, h:0.24, fontSize:10, bold:true, color:C.white, align:"center", valign:"middle" });
    s.addShape(pres.shapes.RECTANGLE, { x, y:3.55, w:2.65, h:1.58, fill:{color:C.cardBg}, line:{color:col[2], pt:1} });
    s.addText(col[1], { x:x+0.1, y:3.57, w:2.45, h:1.53, fontSize:9, color:C.lightGray, valign:"top" });
  });

  // Other ACTs (right panel)
  s.addShape(pres.shapes.RECTANGLE, { x:5.9, y:0.86, w:3.9, h:0.28, fill:{color:"8E44AD"}, line:{color:"8E44AD"} });
  s.addText("OTHER AIRWAY CLEARANCE TECHNIQUES", { x:5.9, y:0.86, w:3.9, h:0.28, fontSize:9.5, bold:true, color:C.white, align:"center", valign:"middle" });

  const otherACTs = [
    { t:"Postural Drainage", b:"12 segment positions\nHead-down (Trendelenburg)\nGravity-assisted" },
    { t:"PEP Device", b:"Positive Expiratory Pressure\nMaintains airway patency\nBetter adherence (independent)" },
    { t:"Flutter / Acapella / Aerobika", b:"OPEP devices\nOscillating PEP\nLoosens thick secretions" },
    { t:"Humidification / Saline Nebulisation", b:"Thins tenacious secretions\nPre-ACT therapy\nHypertonic saline 3-7%" },
  ];
  otherACTs.forEach((act, i) => {
    const y = 1.16 + i * 1.06;
    s.addShape(pres.shapes.RECTANGLE, { x:5.9, y, w:3.9, h:0.24, fill:{color:"5B2C6F"}, line:{color:"8E44AD", pt:0.5} });
    s.addText(act.t, { x:5.9, y, w:3.9, h:0.24, fontSize:9.5, bold:true, color:C.lightGray, align:"center", valign:"middle" });
    s.addShape(pres.shapes.RECTANGLE, { x:5.9, y:y+0.24, w:3.9, h:0.8, fill:{color:C.cardBg}, line:{color:"8E44AD", pt:0.5} });
    s.addText(act.b, { x:6.0, y:y+0.26, w:3.7, h:0.75, fontSize:8.8, color:C.lightGray, valign:"top" });
  });

  addFooter(s);
}

// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
// SLIDE 9 — EXERCISES (DETAILED)
// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
{
  let s = pres.addSlide();
  s.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:10, h:5.625, fill:{color:C.darkBg}, line:{color:C.darkBg} });
  addSectionBand(s, "08  |  MUSCLE-SPECIFIC EXERCISES WITH PARAMETERS");

  const exRows = [
    { name:"Pursed Lip Breathing", pos:"Sitting upright", tech:"Inhale thru nose (2 counts); purse lips (whistle); exhale 4 counts. I:E = 1:2", reps:"All activity; every time dyspnoeic", freq:"Continuous habit", mech:"Creates back-pressure → prevents premature small airway collapse → ↓ air trapping → ↓ dyspnoea", warn:"Do not force expiration" },
    { name:"Diaphragmatic Breathing", pos:"Supine → Sitting → Standing (progress)", tech:"One hand chest, one abdomen. Inhale: abdomen rises (chest still). Exhale slowly", reps:"3×10 breaths per session", freq:"3-4 times/day", mech:"Re-trains diaphragm; reduces accessory muscle use; ↓ WOB", warn:"Less effective if severe hyperinflation/flat diaphragm" },
    { name:"Aerobic Walking Programme", pos:"Standing; use rollator if needed", tech:"Walk at target pace; use PLB on exertion; breathe rhythmically", reps:"Start 10-15 min → build to 30-45 min; Borg 4-6", freq:"5 days/week", mech:"Peripheral muscle conditioning; ↓ ventilatory demand at same workload", warn:"SpO₂ > 88%; stop if chest pain or Borg >7" },
    { name:"Quadriceps (Seated Knee Extension)", pos:"Seated on chair, feet hanging", tech:"Extend knee fully; hold 2 sec; lower slowly (4 sec eccentric)", reps:"3 × 10-12 reps; progress to ankle weight", freq:"2-3 days/week", mech:"Largest peripheral muscle; most affected in COPD; ↑ exercise capacity", warn:"Breathe out on exertion (avoid Valsalva)" },
    { name:"Sit-to-Stand (Functional)", pos:"Standard chair; feet hip-width", tech:"Lean forward, stand; use arms if needed; breathe out on standing", reps:"3 × 10 reps", freq:"Daily (functional training)", mech:"Quadriceps + gluteals; simulates stair-climbing; ADL training", warn:"Supervise initially; no handrails to increase challenge progressively" },
  ];

  const colWidths = [1.7, 1.2, 2.2, 1.55, 1.25, 1.4];
  const colHeads = ["EXERCISE","POSITION","TECHNIQUE / REPS","FREQUENCY","MECHANISM","PRECAUTION"];
  const colX = [0.2, 1.92, 3.14, 5.36, 6.93, 8.2];

  // Header
  colHeads.forEach((h, i) => {
    s.addShape(pres.shapes.RECTANGLE, { x:colX[i], y:0.85, w:colWidths[i], h:0.28, fill:{color:C.teal}, line:{color:"274560", pt:0.5} });
    s.addText(h, { x:colX[i], y:0.85, w:colWidths[i], h:0.28, fontSize:8.5, bold:true, color:C.white, align:"center", valign:"middle" });
  });

  exRows.forEach((ex, ri) => {
    const y = 1.14 + ri * 0.86;
    const bg = ri % 2 === 0 ? C.cardBg : "132B40";
    const rowData = [ex.name, ex.pos, ex.tech + " | " + ex.reps, ex.freq, ex.mech, ex.warn];
    const rowColors = [C.accentAlt, C.lightGray, C.lightGray, C.lightGray, C.teal, "FF8A80"];
    rowData.forEach((cell, ci) => {
      s.addShape(pres.shapes.RECTANGLE, { x:colX[ci], y, w:colWidths[ci], h:0.85, fill:{color:bg}, line:{color:"274560", pt:0.5} });
      s.addText(cell, { x:colX[ci]+0.04, y:y+0.02, w:colWidths[ci]-0.08, h:0.81, fontSize:7.8, color:rowColors[ci], valign:"top" });
    });
  });

  addFooter(s);
}

// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
// SLIDE 10 — COMPLICATIONS + PROGNOSIS + OXYGEN THERAPY
// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
{
  let s = pres.addSlide();
  s.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:10, h:5.625, fill:{color:C.darkBg}, line:{color:C.darkBg} });
  addSectionBand(s, "09  |  COMPLICATIONS, PROGNOSIS & OXYGEN THERAPY");

  // complications
  s.addShape(pres.shapes.RECTANGLE, { x:0.2, y:0.86, w:5.5, h:0.26, fill:{color:C.accent}, line:{color:C.accent} });
  s.addText("COMPLICATIONS OF CHRONIC BRONCHITIS", { x:0.2, y:0.86, w:5.5, h:0.26, fontSize:10.5, bold:true, color:C.white, align:"center", valign:"middle" });

  const comps = [
    { c:"Cor Pulmonale", d:"Pulm HTN → RV failure; most serious complication; ankle oedema, ↑JVP, P-pulmonale on ECG" },
    { c:"Respiratory Failure", d:"Type II: PaO₂ <60 + PaCO₂ >45; requires NIV/BiPAP" },
    { c:"Polycythaemia", d:"Secondary to chronic ↓PaO₂; hyperviscosity → thrombosis risk" },
    { c:"Acute-on-Chronic Exacerbation", d:"Each AECB accelerates FEV₁ decline; Anthonisen criteria for antibiotics" },
    { c:"Bronchiectasis", d:"Repeated infection → airway wall destruction → copious purulent sputum" },
    { c:"Osteoporosis", d:"Steroid use + inactivity + smoking; fragility fractures" },
    { c:"Lung Cancer", d:"Common aetiological factor (smoking); monitor for haemoptysis, weight loss" },
  ];

  comps.forEach((comp, i) => {
    const y = 1.14 + i * 0.42;
    const bg = i % 2 === 0 ? C.cardBg : "132B40";
    s.addShape(pres.shapes.RECTANGLE, { x:0.2, y, w:1.6, h:0.41, fill:{color:bg}, line:{color:"274560", pt:0.5} });
    s.addText(comp.c, { x:0.2, y, w:1.6, h:0.41, fontSize:8.5, bold:true, color:C.accentAlt, align:"center", valign:"middle" });
    s.addShape(pres.shapes.RECTANGLE, { x:1.82, y, w:3.88, h:0.41, fill:{color:bg}, line:{color:"274560", pt:0.5} });
    s.addText(comp.d, { x:1.87, y, w:3.78, h:0.41, fontSize:8.5, color:C.lightGray, valign:"middle" });
  });

  // Prognosis strip
  s.addShape(pres.shapes.RECTANGLE, { x:0.2, y:4.24, w:5.5, h:0.28, fill:{color:C.teal}, line:{color:C.teal} });
  s.addText("PROGNOSIS — Key Points", { x:0.2, y:4.24, w:5.5, h:0.28, fontSize:10.5, bold:true, color:C.white, align:"center", valign:"middle" });
  s.addShape(pres.shapes.RECTANGLE, { x:0.2, y:4.53, w:5.5, h:0.78, fill:{color:C.cardBg}, line:{color:C.teal, pt:1} });
  s.addText([
    { text:"• FEV₁ % predicted = PRIMARY prognostic marker\n", options:{color:C.lightGray} },
    { text:"• Normal FEV₁ decline: 25-30 mL/yr  |  Smoker: up to 60 mL/yr\n", options:{color:C.lightGray} },
    { text:"• SMOKING CESSATION = single most effective intervention to slow FEV₁ decline\n", options:{color:C.gold, bold:true} },
    { text:"• PR improves QoL + exercise capacity — does NOT alter FEV₁ or mortality", options:{color:C.lightGray} }
  ], { x:0.3, y:4.55, w:5.3, h:0.74, fontSize:9, valign:"top" });

  // O2 therapy panel (right)
  s.addShape(pres.shapes.RECTANGLE, { x:5.9, y:0.86, w:3.9, h:0.26, fill:{color:"E67E22"}, line:{color:"E67E22"} });
  s.addText("OXYGEN THERAPY  ⭐ Viva Must-Know", { x:5.9, y:0.86, w:3.9, h:0.26, fontSize:10.5, bold:true, color:C.white, align:"center", valign:"middle" });

  s.addShape(pres.shapes.ROUNDED_RECTANGLE, { x:5.9, y:1.14, w:3.9, h:2.3, fill:{color:C.cardBg}, line:{color:"E67E22", pt:2}, rectRadius:0.08 });
  s.addText([
    { text:"TARGET SpO₂: 88 – 92%  (NOT >94%)\n\n", options:{bold:true, color:C.gold, fontSize:13} },
    { text:"WHY controlled O₂?\n", options:{bold:true, color:C.accentAlt, fontSize:10} },
    { text:"Chronic bronchitics are CO₂ retainers.\nTheir ONLY respiratory drive = HYPOXIC DRIVE.\n\n", options:{color:C.lightGray, fontSize:9.5} },
    { text:"High-flow O₂ removes the hypoxic stimulus\n→ Hypoventilation\n→ ↑↑ PaCO₂\n→ CO₂ narcosis\n→ RESPIRATORY ARREST\n\n", options:{color:"FF8A80", fontSize:9.5} },
    { text:"Give 24-28% Venturi mask / 1-2 L/min nasal prongs", options:{color:C.lightGray, fontSize:9} }
  ], { x:5.98, y:1.16, w:3.74, h:2.25, fontSize:10, valign:"top" });

  // LTOT
  s.addShape(pres.shapes.ROUNDED_RECTANGLE, { x:5.9, y:3.48, w:3.9, h:0.85, fill:{color:"1A2E45"}, line:{color:C.teal, pt:1.5}, rectRadius:0.08 });
  s.addText([
    { text:"LTOT Criteria:\n", options:{bold:true, color:C.teal, fontSize:10.5} },
    { text:"• Resting PaO₂ < 55 mmHg  OR\n", options:{color:C.lightGray, fontSize:9.5} },
    { text:"• PaO₂ < 60 mmHg WITH cor pulmonale\n", options:{color:C.lightGray, fontSize:9.5} },
    { text:"• Minimum 15-16 hrs/day  →  improves survival", options:{color:C.gold, fontSize:9, bold:true} }
  ], { x:5.98, y:3.50, w:3.74, h:0.8, valign:"top" });

  addFooter(s);
}

// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
// SLIDE 11 — HEP + RETURN TO ACTIVITY
// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
{
  let s = pres.addSlide();
  s.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:10, h:5.625, fill:{color:C.darkBg}, line:{color:C.darkBg} });
  addSectionBand(s, "10  |  HOME EXERCISE PROGRAMME (HEP) & RETURN TO ACTIVITY");

  // HEP Acute
  s.addShape(pres.shapes.RECTANGLE, { x:0.2, y:0.86, w:4.5, h:0.26, fill:{color:C.teal}, line:{color:C.teal} });
  s.addText("HEP — ACUTE BRONCHITIS", { x:0.2, y:0.86, w:4.5, h:0.26, fontSize:11, bold:true, color:C.white, align:"center", valign:"middle" });
  const hepAcute = [
    "Steam inhalation: 10-15 min × 2-3×/day",
    "Effective huffing (FET): 3-4 cycles when sputum present",
    "Adequate hydration: ≥ 2 litres water/day (thins secretions)",
    "Semi-upright sleeping position (30-45°)",
    "Warm saline gargles for throat irritation",
    "Graduated activity from day 4-5: 10-15 min walk",
    "Avoid cold/dry air; warm moist environment"
  ];
  s.addShape(pres.shapes.RECTANGLE, { x:0.2, y:1.13, w:4.5, h:2.25, fill:{color:C.cardBg}, line:{color:C.teal, pt:1} });
  s.addText(hepAcute.map((t,i) => ({ text:(i<hepAcute.length-1 ? t+"\n" : t), options:{bullet:{type:"bullet"}} })),
    { x:0.3, y:1.16, w:4.3, h:2.2, fontSize:9.5, color:C.lightGray, valign:"top" });

  // HEP Chronic
  s.addShape(pres.shapes.RECTANGLE, { x:5.3, y:0.86, w:4.5, h:0.26, fill:{color:C.accent}, line:{color:C.accent} });
  s.addText("HEP — CHRONIC BRONCHITIS (STABLE)", { x:5.3, y:0.86, w:4.5, h:0.26, fontSize:11, bold:true, color:C.white, align:"center", valign:"middle" });
  const hepChronic = [
    "ACBT twice daily (morning + evening; 20-30 min each)",
    "PLB during all physical activities (habitual)",
    "Diaphragmatic breathing: 3×10 breaths × 3 daily",
    "Walking: 30 min × 5 days/week; Borg 4-5",
    "Seated quadriceps: 3×12 reps × 2-3 days/week",
    "Thoracic extension (foam roller) + scapular retraction daily",
    "Correct inhaler technique (MDI + spacer)"
  ];
  s.addShape(pres.shapes.RECTANGLE, { x:5.3, y:1.13, w:4.5, h:2.25, fill:{color:C.cardBg}, line:{color:C.accent, pt:1} });
  s.addText(hepChronic.map((t,i) => ({ text:(i<hepChronic.length-1 ? t+"\n" : t), options:{bullet:{type:"bullet"}} })),
    { x:5.4, y:1.16, w:4.3, h:2.2, fontSize:9.5, color:C.lightGray, valign:"top" });

  // Return to activity
  s.addShape(pres.shapes.RECTANGLE, { x:0.2, y:3.45, w:9.6, h:0.26, fill:{color:"8E44AD"}, line:{color:"8E44AD"} });
  s.addText("RETURN TO ACTIVITY CRITERIA", { x:0.2, y:3.45, w:9.6, h:0.26, fontSize:10.5, bold:true, color:C.white, align:"center", valign:"middle" });

  const rta = [
    { h:"Acute Bronchitis", items:["Afebrile ≥ 48 hours","SpO₂ ≥ 96% on room air","Cough frequency reducing","10-min walk without significant symptoms","Gradual: walk → jog → sport (1-2 weeks)"], col:C.teal },
    { h:"Chronic Bronchitis (Post-Exacerbation)", items:["Returned to baseline FEV₁ (±10%)","SpO₂ ≥ 88% during activity","Sputum baseline colour/volume","Independent on ACBT routine","Physician clearance obtained"], col:C.accent },
  ];
  rta.forEach((r, i) => {
    const x = 0.2 + i * 5.0;
    s.addShape(pres.shapes.RECTANGLE, { x, y:3.73, w:4.75, h:0.22, fill:{color:r.col}, line:{color:r.col} });
    s.addText(r.h, { x, y:3.73, w:4.75, h:0.22, fontSize:9.5, bold:true, color:C.white, align:"center", valign:"middle" });
    s.addShape(pres.shapes.RECTANGLE, { x, y:3.96, w:4.75, h:1.37, fill:{color:C.cardBg}, line:{color:r.col, pt:1} });
    s.addText(r.items.map((t,j) => ({ text:(j<r.items.length-1 ? t+"\n" : t), options:{bullet:{type:"bullet"}} })),
      { x:x+0.1, y:3.98, w:4.55, h:1.32, fontSize:9, color:C.lightGray, valign:"top" });
  });

  addFooter(s);
}

// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
// SLIDE 12 — EXAM VIVA GOLD CARD
// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
{
  let s = pres.addSlide();
  s.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:10, h:5.625, fill:{color:C.darkBg}, line:{color:C.darkBg} });
  addSectionBand(s, "11  |  HIGH-YIELD VIVA & EXAM POINTS  ⭐ GOLD CARD");

  // Key numbers box
  s.addShape(pres.shapes.ROUNDED_RECTANGLE, { x:0.2, y:0.85, w:4.5, h:3.65, fill:{color:"1C1208"}, line:{color:C.gold, pt:2}, rectRadius:0.1 });
  s.addText("⭐ KEY NUMBERS — MUST MEMORISE", { x:0.2, y:0.88, w:4.5, h:0.3, fontSize:11, bold:true, color:C.gold, align:"center", valign:"middle" });

  const numbers = [
    ["CLINICAL DEFINITION","Productive cough ≥ 3 months × 2 consecutive years"],
    ["REID INDEX (normal)","0.4  (increased >0.4 in chronic bronchitis)"],
    ["VIRAL AETIOLOGY (acute)","90% viral (rhinovirus, coronavirus, RSV)"],
    ["COUGH DURATION (acute)","10–20 days (can persist >1 month)"],
    ["TARGET SpO₂ (chronic)","88–92% (controlled O₂, Venturi mask 24-28%)"],
    ["LTOT SpO₂ criterion","PaO₂ < 55 mmHg  OR  <60 mmHg with cor pulmonale"],
    ["LTOT hours/day","≥ 15–16 hours/day"],
    ["FEV₁ decline (smoker)","Up to 60 mL/year  (normal: 25-30 mL/yr)"],
    ["6MWT MCID","25–33 metres (COPD)"],
    ["GOLD I criterion","FEV₁ ≥ 80% predicted"],
  ];

  numbers.forEach((n, i) => {
    const y = 1.2 + i * 0.33;
    const bg = i % 2 === 0 ? "1A1208" : "221710";
    s.addShape(pres.shapes.RECTANGLE, { x:0.22, y, w:4.46, h:0.32, fill:{color:bg}, line:{color:"2C2010", pt:0.5} });
    s.addText([
      { text:n[0]+" — ", options:{bold:true, color:C.accentAlt} },
      { text:n[1], options:{color:C.lightGray} }
    ], { x:0.28, y:y+0.01, w:4.34, h:0.3, fontSize:8.8, valign:"middle" });
  });

  // Viva Q&A
  s.addShape(pres.shapes.RECTANGLE, { x:5.0, y:0.85, w:4.8, h:0.28, fill:{color:C.accent}, line:{color:C.accent} });
  s.addText("VIVA QUESTIONS — Model Answers", { x:5.0, y:0.85, w:4.8, h:0.28, fontSize:10.5, bold:true, color:C.white, align:"center", valign:"middle" });

  const qas = [
    {
      q:"Q: What is the Reid Index?",
      a:"Ratio of mucous gland layer thickness to bronchial wall thickness (epithelium to cartilage). Normal = 0.4. Increased (>0.4) in chronic bronchitis, proportional to severity."
    },
    {
      q:"Q: Why controlled O₂ in chronic bronchitis?",
      a:"Chronic bronchitics are CO₂ retainers; respiratory drive depends on hypoxic drive. High-flow O₂ removes hypoxic stimulus → hypoventilation → ↑PaCO₂ → CO₂ narcosis → respiratory arrest. Maintain SpO₂ 88-92%."
    },
    {
      q:"Q: Why huff instead of cough?",
      a:"Huff (FET) = open glottis → no dynamic airway collapse → effective peripheral secretion clearance. Cough = closed glottis → high intrathoracic pressure → dynamic airway compression → less effective + can cause bronchospasm."
    },
    {
      q:"Q: What are Anthonisen criteria?",
      a:"Type I AECB (all 3 criteria): ↑dyspnoea + ↑sputum volume + ↑sputum purulence → antibiotics indicated. Type II (2/3) → appropriate. Type III (1/3) → usually NOT indicated."
    },
  ];

  qas.forEach((qa, i) => {
    const y = 1.15 + i * 1.08;
    s.addShape(pres.shapes.RECTANGLE, { x:5.0, y, w:4.8, h:0.24, fill:{color:"2C0505"}, line:{color:C.accent, pt:0.5} });
    s.addText(qa.q, { x:5.05, y, w:4.7, h:0.24, fontSize:9.5, bold:true, color:"FF8A80", valign:"middle" });
    s.addShape(pres.shapes.RECTANGLE, { x:5.0, y:y+0.25, w:4.8, h:0.82, fill:{color:C.cardBg}, line:{color:C.accent, pt:0.5} });
    s.addText(qa.a, { x:5.07, y:y+0.27, w:4.66, h:0.78, fontSize:8.8, color:C.lightGray, valign:"top" });
  });

  // Common mistakes
  s.addShape(pres.shapes.ROUNDED_RECTANGLE, { x:0.2, y:4.54, w:9.6, h:0.78, fill:{color:"0D1F12"}, line:{color:C.green, pt:1.5}, rectRadius:0.08 });
  s.addText("✅  COMMON MISTAKES TO AVOID:", { x:0.28, y:4.56, w:3, h:0.2, fontSize:9.5, bold:true, color:C.green });
  s.addText([
    { text:"1. Define chronic bronchitis clinically (3m×2yrs), NOT by PFTs  ", options:{color:C.lightGray, fontSize:9} },
    { text:"| ", options:{color:"4A6580"} },
    { text:"2. Reid Index = 0.4 (know this cold!)  ", options:{color:C.lightGray, fontSize:9} },
    { text:"| ", options:{color:"4A6580"} },
    { text:"3. Never give HIGH-FLOW O₂ to a Blue Bloater  ", options:{color:"FF8A80", bold:true, fontSize:9} },
    { text:"| ", options:{color:"4A6580"} },
    { text:"4. No antibiotics for uncomplicated acute bronchitis  ", options:{color:C.lightGray, fontSize:9} },
    { text:"| ", options:{color:"4A6580"} },
    { text:"5. Include smoking cessation in every answer", options:{color:C.accentAlt, fontSize:9} }
  ], { x:0.25, y:4.74, w:9.5, h:0.55, valign:"top" });
}

// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
// SLIDE 13 — CLOSING / REFERENCES
// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
{
  let s = pres.addSlide();
  s.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:10, h:5.625, fill:{color:C.darkBg}, line:{color:C.darkBg} });
  s.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:0.15, h:5.625, fill:{color:C.teal}, line:{color:C.teal} });
  s.addShape(pres.shapes.OVAL, { x:6.5, y:-1, w:5, h:5, fill:{color:"172840"}, line:{color:"172840"} });
  s.addShape(pres.shapes.OVAL, { x:7.2, y:3, w:4, h:4, fill:{color:"1A2E45"}, line:{color:"1A2E45"} });

  s.addText("🫁", { x:7.3, y:1.0, w:2.0, h:2.0, fontSize:70, align:"center", valign:"middle" });

  s.addText("KEY TAKEAWAYS", { x:0.3, y:0.5, w:6, h:0.42, fontSize:14, bold:true, color:C.teal, charSpacing:3 });
  s.addShape(pres.shapes.RECTANGLE, { x:0.3, y:0.95, w:5.5, h:0.04, fill:{color:C.accentAlt}, line:{color:C.accentAlt} });

  const takeaways = [
    "Chronic bronchitis = CLINICAL definition: 3 months × 2 consecutive years",
    "Reid Index = 0.4 (normally) — proportional increase in chronic bronchitis",
    "Blue Bloater (chronic bronchitis) vs Pink Puffer (emphysema) — master this table",
    "Pathophysiology: mucus hypersecretion → mucociliary failure → obstruction → V/Q mismatch",
    "Controlled O₂ 88-92% — NEVER give high-flow O₂ to Blue Bloater",
    "ACBT = gold standard airway clearance; 3 phases: BC → TEE → FET/Huff",
    "Huff > Cough: open glottis → no dynamic airway collapse",
    "Smoking cessation = single most effective intervention (slows FEV₁ decline)",
    "Antibiotics NOT recommended for uncomplicated acute bronchitis (CDC/IDSA)",
    "Pulmonary Rehabilitation: improves QoL + exercise capacity; does NOT change FEV₁",
  ];

  takeaways.forEach((t, i) => {
    s.addText([
      { text:"→  ", options:{color:C.teal, bold:true} },
      { text:t, options:{color:C.lightGray} }
    ], { x:0.3, y:1.05 + i*0.41, w:6, h:0.4, fontSize:9.8, valign:"middle" });
  });

  s.addShape(pres.shapes.RECTANGLE, { x:0.3, y:5.2, w:6, h:0.28, fill:{color:C.midBg}, line:{color:C.midBg} });
  s.addText("References: Robbins & Cotran Pathologic Basis of Disease • Robbins Basic Pathology • Fishman's Pulmonary Diseases • Murray & Nadel's Respiratory Medicine • GOLD 2024 • CDC/IDSA Guidelines", { x:0.3, y:5.21, w:6, h:0.27, fontSize:7.5, color:"4A6580", valign:"middle" });
}

// ─── WRITE FILE ────────────────────────────────────────────────────────────────
pres.writeFile({ fileName: "/home/daytona/workspace/bronchitis-ppt/Bronchitis_BPT_Exam.pptx" })
  .then(() => console.log("✅ Done: Bronchitis_BPT_Exam.pptx"))
  .catch(err => { console.error("ERROR:", err); process.exit(1); });

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.

When credits reset tomorrow, ask for TB (Tuberculosis) in BPT format

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.

This is a shared conversation. Sign in to Orris to start your own chat.